{
  "responseHeader":{
    "status":0,
    "QTime":1,
    "params":{
      "q":"(Background: melanoma OR Doc_title: melanoma) AND (Background: lymphocytes without tumor infiltrating OR no tumor infiltrating lymphocytes)"}},
  "response":{"numFound":2970,"start":0,"docs":[
      {
        "Meeting_name":" A randomized, prospective evaluation comparing intensity of lymphodepletion prior to adoptive transfer of tumor infiltrating lymphocytes for patients with metastatic melanoma.",
        "Background":"['Background', ' Adoptive cell transfer (ACT), the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52/93, 56%). The addition and intensification of total body irradiation (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objective partial and complete response rates. Here, we evaluated the importance of adding TBI to the adoptive transfer of tumor-infiltrating lymphocytes (TIL) in a randomized fashion. Methods', ' 101 patients with metastatic melanoma, including 76 with M1c disease, were randomly assigned to receive nonmyeloablative chemotherapy with or without 1200 cGy TBI prior to transfer of TIL. The primary endpoints were complete response rate (as defined by Response Evaluation Criteria in Solid Tumors 1.0) and overall survival. Clinical and laboratory data were analyzed for correlates of response. Results', ' Complete response rates were 24% in both groups (12/50 v 12/51) and overall survival was also similar (median OS, 38.2 v 36.6 months; hazard ratio [HR], 1.11; 95% CI, 0.65 to 1.91, P= .71). Thrombotic microangiopathy was an adverse event unique to the TBI arm and occurred in 13/48 treated patients. With a median potential follow-up of 40.9 months, only one of the 24 complete responders recurred. Conclusions', ' Adoptive cell transfer with tumor-infiltrating lymphocytes can mediate durable complete regressions in 24% of patients with metastatic melanoma and a median survival greater than three years. Results were similar using chemotherapy preparative regimens with or without the addition of TBI . Clinical trial information', ' NCT01319565']",
        "Doc_id":"ASCO_162743-176",
        "Doc_title":" A randomized, prospective evaluation comparing intensity of lymphodepletion prior to adoptive transfer of tumor infiltrating lymphocytes for patients with metastatic melanoma.",
        "_version_":1606189022530502656},
      {
        "Meeting_name":" Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.",
        "Background":"['Background', '  Matrix metalloproteinase-23 (MMP-23) can inhibit T cell activation by selectively blocking the voltage-gated potassium channel Kv1.3, and may also alter T cell activity and phenotype through cleavage of proteins affecting cytokine and chemokine signaling.  We therefore tested the hypothesis that MMP-23 can negatively regulate the anti-tumor T cell response in human melanoma.  Methods', '  We characterized MMP-23 expression in primary melanoma patients who received adjuvant immunotherapy. We examined the association of MMP-23 with the intrinsic anti-tumor immune response - as assessed by the prevalence of tumor-infiltrating lymphocytes and Foxp3+ regulatory T-cells. Further, we examined the association between MMP-23 expression and response to immunotherapy. Considering also an in trans mechanism, we examined the association of melanoma MMP-23 and melanoma Kv1.3 expression.  Results', '  Our data revealed an inverse association between primary melanoma MMP-23 expression and the anti-tumor T-cell response, as demonstrated by decreased tumor-infiltrating lymphocytes (TIL) (P=0.05), in particular brisk TILs (P=0.04), and a trend towards an increased proportion of immunosuppressive Foxp3+ regulatory T-cells (P=0.07). High melanoma MMP-23 expression is also associated with recurrence in patients treated with immune biologics (P=0.037) but not in those treated with vaccines (P=0.64). Further, high melanoma MMP-23 expression is associated with shorter periods of progression-free survival for patients receiving immune biologics (P=0.025). On the other hand, there is no relationship between melanoma MMP-23 and melanoma Kv1.3 expression (P=0.27).  Conclusions', '  Our data support a role for MMP-23 as a potential immune checkpoint blockade target in melanoma, as well as a possible biomarker for informing melanoma immunotherapies.']",
        "Doc_id":"ASCO_126962-144",
        "Doc_title":" Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma.",
        "_version_":1606188973878673408},
      {
        "Meeting_name":" The biology and prognostic value of lymphatic vessel density (LD) and lymphatic invasion (LI) in regression in melanoma.",
        "Background":"['Background', ' Regression in melanoma is characterized by increased vascularity, lymphocytic infiltrate and fibroplasia in the papillary dermis, accompanied by the absence (complete regression, CoR) or presence (partial regression, PaR) of melanoma cells in the epidermis. The prognostic value of regression is controversial. We noticed that LD and LI were increased in the areas of regression (AR) or areas with brisk lymphocytic infiltration (AB). Our goal was to clarify the prognostic value of regression in melanoma. Methods', ' Dual immunohistochemical staining was done using antibodies to podoplanin (lymphatic vessels) and S100 (melanoma cells) on paraffin tissues from 321 patients with vertical growth phase (VGP) primary melanomas who had 10 years or more of follow-up. LD in AR (both CoR and PaR) was compared with that of normal dermis adjacent and distant, as well as LD in the AB. LI in these areas was also scored. Unadjusted and adjusted hazard rates were obtained from univariate and multivariate Cox models for time to melanoma-specific death using established melanoma prognostic factors. Results', ' 116 patients (36%) had regression', ' 75 CoR (23%) and 41 PaR (13%). LD significantly decreased stepwise from CoR (mean  se, 23.7  2.7) to PaR (15.5  1.1), adjacent normal dermis (7.3  0.28) and distant normal dermis (5.40.31) and it was significantly elevated in the AB (18.50.78). Melanomas with CoR had the highest percentage of LI in both AR and AB. In addition, the percentage of LI in AB was highest for men and for those with VGP tumor infiltrating lymphocytes (TILs). Both high LD in AR and more LI in AB were associated with poor prognosis (p=0.004 and p=0.002, respectively). Six factors were significant in the final multivariate model', ' LI in AB (HR=2.3), LD in AR (HR=1.04), thickness (HR=1.44), axial (HR=7.7), ulceration (HR=2.5) and no VGP TILs (HR=2.8). Conclusions', ' AR and AB were associated with increased LD and higher incidence of LI in primary melanomas. LD and LI in AR or AB are independent prognostic factors. Our data suggest that the effects of regression on prognosis are mediated at least in part through lymphangiogenesis and LI.']",
        "Doc_id":"ASCO_35368-65",
        "Doc_title":" The biology and prognostic value of lymphatic vessel density (LD) and lymphatic invasion (LI) in regression in melanoma.",
        "_version_":1606189020380921856},
      {
        "Meeting_name":" Differential cellular localization of programmed death ligand 1 (PD-L1) and enhanced expression of programmed death-1 (PD-1) in melanoma progression.",
        "Background":"['Melanoma is an aggressive malignancy with a relatively high metastatic rate, responsible for almost 60% of lethal skin tumors. Although many human cancers such as melanoma express tumor antigens recognized by T cells, host immune responses often fail to control tumor growth for mostly unexplained reasons. Escaping immune destruction is one of the tenets of tumorigenesis; there have been several studies suggesting an important role of PD-1/PD-L1 (B7-H1) interactions in inhibiting the effector functions of cytotoxic T-lymphocyte in tumor. Ghebeh et al., reported that doxorubicin treatment caused decrease in cytosolic B7-H1 and increased nuclear translocalization in breast carcinoma (Breast Cancer Res. 2010;12(4)', 'R48). It is unknown whether differential cellular expression of PD-L1 contributes to the pathogenesis of melanoma. To address the role of PD-L1 and its receptor PD-1 in different stages of malignant melanoma, we have performed semiquantitative immunohistochemical analysis of PD-L1 and PD-1 in benign nevi (n=59), primary melanomas without metastasis (n=22) or with metastasis (n=17), and melanoma metastases (n=32 cases). Benign nevi had significantly higher levels of nuclear PD-L1 immunopositivity (p=0.004) and low levels of PD-1 protein expression (p=0.002). With progression from benign nevi to primary melanoma there was an increase in cytoplasmic positivity for PD-L1 (p=0.03). Also, a significant positive correlation was observed between the percentage of positive cells (p=0.0007) and intensity (p=0.0009) for PD-1 in primary melanomas. Although there was no significant difference in PD-1 levels in between primaries with or without metastasis, a trend was observed for PD-L1 expression', ' primaries with metastasis having a larger number of tumor cells with cytosolic localization than primaries without metastasis (p=0.07). Interestingly, primary melanomas without metastasis showed significantly larger number of tumor infiltrating lymphocytes (TILs) cells having intense immunoreactivity for PD-L1 protein than did metastatic melanomas (p=0.03). In conclusion, differential cellular localization of PD-L1 protein and high levels of PD-1 protein correlates with disease progression and high-risk histologic features in melanoma and might partially explain the resistance of melanoma cells against the immune system.']",
        "Doc_id":"AACR_2013-463",
        "Doc_title":" Differential cellular localization of programmed death ligand 1 (PD-L1) and enhanced expression of programmed death-1 (PD-1) in melanoma progression.",
        "_version_":1606189004923863040},
      {
        "Meeting_name":" Acral lentiginous melanoma and infiltrating lymphocytes in a Latin American population.",
        "Background":"['Background', ' Acral lentiginous melanoma (ALM) is unusual in Caucasian but is the most common subtype in Hispanic populations, and has been associated to poor prognosis. Herein we compare clinicopathological features associated to ALM in a Latin-American population and prospectively evaluate its association with tumor infiltrating lymphocytes (TIL).']",
        "Doc_id":"AACR_2017-4003",
        "Doc_title":" Acral lentiginous melanoma and infiltrating lymphocytes in a Latin American population.",
        "_version_":1606189005571883009},
      {
        "Meeting_name":" Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.",
        "Background":"['Background', '  Matrix metalloproteinase-23 (MMP-23) can inhibit T cell activation by selectively blocking the voltage-gated potassium channel Kv1.3, and may also alter T cell activity and phenotype through cleavage of proteins affecting cytokine and chemokine signaling. We therefore tested the hypothesis that MMP-23 can negatively regulate the anti-tumor T cell response in human melanoma.  Methods', '  We characterized MMP-23 expression in primary melanoma patients who received adjuvant immunotherapy. We examined the association of MMP-23 with the intrinsic anti-tumor immune response - as assessed by the prevalence of tumor-infiltrating lymphocytes and Foxp3+ regulatory T-cells. Further, we examined the association between MMP-23 expression and response to immunotherapy. We used in vitro 3D culture assays to assess T cell lysis of tumor cells expressing MMP-23, and mutagenesis of MMP-23 functional domains to identify the molecular mechanism of MMP-23 inhibition of T cell responses.  Results', '  Our data revealed an inverse association between primary melanoma MMP-23 expression and the anti-tumor T-cell response, as demonstrated by decreased tumor-infiltrating lymphocytes (TIL) (P= 0.05), in particular brisk TILs (P= 0.04), and a trend towards an increased proportion of immunosuppressive Foxp3+ regulatory T-cells (P= 0.07). High melanoma MMP-23 expression is also associated with recurrence in patients treated with immune biologics (P= 0.037). Further, high melanoma MMP-23 expression is associated with shorter periods of progression-free survival for patients receiving immune biologics. In vitro data supports a role for MMP-23 in blocking Kv1.3 channels on activated effector memory T cells.  Conclusions', '  Our data suggest that MMP-23 may affect Kv1.3-dependent effector memory T cells. This support a potential role for MMP-23 as a biomarker and immunotherapeutic target in melanoma.']",
        "Doc_id":"ASCO_150371-156",
        "Doc_title":" Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy.",
        "_version_":1606189007684763648},
      {
        "Meeting_name":" Immune cell profile of sentinel lymph nodes in melanoma patients .",
        "Background":"['Besides being a preferential site of early metastasis, the sentinel lymph node (SLN) is also a privileged site of T-cell priming, and may thus be an appropriate target for investigating cell types involved in antitumor immune reactions. We determined the prevalence of OX40+ activated T lymphocytes, FOXP3+ regulatory T cells, DC-LAMP+ mature dendritic cells (DCs) and CD123+ plasmacytoid DCs by immunohistochemistry in 100 SLNs from 60 melanoma patients. Density values of each cell type in SLNs were compared to those in non-sentinel nodes obtained from block dissections (n=37), and analyzed with regard to associations with clinicopathological parameters and disease outcome. Sentinel nodes showed elevated amount of all cell types studied in comparison to non-sentinel nodes. Metastatic SLNs had higher density of OX40+ lymphocytes compared to tumor-negative nodes, while no significant difference was observed in the case of the other cell types studied. Within the sentinel-positive group, FOXP3+ cell density was higher in patients showing disease progression and >5 years survival than in those without progression and <5 years survival, respectively, or in sentinel-negative cases. High amount of FOXP3+ cells in SLNs was associated with shorter progression-free (P=0.0203) and overall survival (P=0.0238), while no significant correlation was found in the case of the other immune cell types. In multivariate analysis, SLN status, ulceration, Breslow index and patient gender, but not the density values of the immune cell types, proved significant independent predictors of survival. Taken together, our results are compatible with the hypothesis of functional competence of sentinel lymph nodes based on the prevalence of the studied immune cells. The density of FOXP3+ lymphocytes showed association with progression and survival, but none of the immune markers emerged as independent prognostic factor. These results, together with our previous findings on the prognostic value of activated T cells and mature DCs infiltrating primary melanomas, suggest that immune cells residing in the primary tumor, rather than those in sentinel lymph nodes, may be crucial in the development of antitumor immune response reflected in influencing the outcome of the disease. This work was supported by the National Scientific Research Fund OTKA 72836. *The first two authors contributed equally to the work.']",
        "Doc_id":"AACR_2013-453",
        "Doc_title":" Immune cell profile of sentinel lymph nodes in melanoma patients .",
        "_version_":1606189006004944896},
      {
        "Meeting_name":" Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.",
        "Background":"['Background', '  Therapeutic efficacy of agents targeting immune checkpoints has been limited to a subset of patients and cancer types.  Preexisting lymphocytic infiltration of tumors has emerged as an important biomarker predictive of clinical benefit, suggesting that therapeutic effect could be enhanced through strategies that induce tumor inflammation. Here we explored whether the inflammatory responses generated by oncolytic viruses could be harnessed to improve systemic therapeutic efficacy of agents targeting immunologic checkpoints.  Methods', '  For our studies we utilized Newcastle Disease Virus (NDV), an avian virus with robust type I IFN-inducing properties. Metastatic disease was modeled by using bilateral flank B16 mouse melanoma model, with NDV administered unilaterally, allowing us to characterize the immune responses in both virus-injected and distant tumors. Therapeutic efficacy and immune responses utilizing intratumoral NDV with systemic immune checkpoint blocking antibodies were further characterized in several mouse models.  Results', '  Localized intratumoral therapy of B16 melanoma with NDV induced CD4+ and CD8+ lymphocytic infiltrates and anti-tumor effect in distant (non-virally infected) tumors without viral spread to these sites. Combination therapy with localized NDV and systemic immune checkpoint blockade led to distant tumor rejection in both NDV-susceptible and resistant tumor models and protected the animals from tumor re-challenge. This effect was associated with marked tumor infiltration with activated effector, but not regulatory T cells, and was dependent on CD8 and NK cells, and type I and II interferons. To further enhance the T cell effector function in tumors, we genetically-engineered NDVs expressing co-stimulatory ligands and demonstrated further increase in therapeutic efficacy of the combination therapy in several tumor models.  Conclusions', '  In summary, in mouse tumor models, localized therapy with NDV induces inflammatory infiltrates in distant tumors, making them susceptible to systemic therapy with immunomodulatory antibodies.  This provides a strong rationale for investigation of combination therapies utilizing NDV and immune checkpoint blockade in clinic.']",
        "Doc_id":"ASCO_128080-144",
        "Doc_title":" Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.",
        "_version_":1606188971853873152},
      {
        "Meeting_name":" Genomic classification of cutaneous melanoma",
        "Background":"['We describe here the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 resected primary and/or metastatic melanomas from 331 patients. We establish a framework for genomic classification based on the pattern of the most prevalent significantly mutated genes into one of four subtypes', ' mutant BRAF, RAS, NF1, and Triple-WT (wild-type). Integrative analysis reveals enrichment of mutations in KIT, focal amplifications and complex structural rearrangements as a feature of the Triple-WT subtype. We find no significant outcome correlation with genomic classification, but samples assigned to a transcriptomic subclass enriched for immune gene expression are significantly associated with improved patient survival. That favorable prognosis of the immune transcriptomic subclass is associated with high LCK protein expression, a T-cell marker, and presence of lymphocyte infiltrate on pathology review. This clinicopathological and multi-dimensional analysis suggests prognosis of melanoma patients with nodal metastases is influenced by immunobiology of the tumor stroma, offering insights to further personalize therapeutic decision-making.']",
        "Doc_id":"AACR_2015-2972",
        "Doc_title":" Genomic classification of cutaneous melanoma",
        "_version_":1606189022381604864},
      {
        "Meeting_name":" Rewiring the cytokine network in melanoma",
        "Background":"['Malignant melanoma is one of the most aggressive types of malignancies in humans resulting in 50,000 deaths worldwide annually. Fortuitously, malignant melanoma is highly immunogenic and it is now well established that the host immune system can detect and kill melanoma. T helper type-1 lymphocytes (TH1) play a pivotal role in inducing and maintaining anti-tumour immune responses. In melanoma patients, it has been observed that higher number of TH1 cells in the tumour micro-environment lead to better prognosis. In this study, using an autochthonous zebrafish melanoma model, when we forced the expression of interferon gamma (IFNg) locally in the tumour microenvironment, thereby potentially enhancing TH1 differentiation, we observed an inflammatory response against melanoma that eventually lead to complete tumour regression.Using transposon mediated BAC transgenesis, we have generated a Tg(cd4', 'mcherry) reporter line labelling CD4+ cells in zebrafish. By driving Human NRASQ61L in zebrafish melanocytes we have modelled melanoma in zebrafish and later when these fish developed tumours we forced the expression of IFNg in melanoma cells using a tamoxifen inducible LSL/CreERT2 system driven by mitfa minimal promoter. Experiments were performed using animals with and without CreERT2. Following tamoxifen administration, we observed a loss of pigmentation in all the IFNg induced tumours (n = 12) by 2 weeks post induction which gradually increased over the study period. Whereas no loss of pigmentation was observed in control tumours (n = 12) throughout the study period. At 9 weeks post induction, the study was terminated and tumours were analysed using histology. In tumours were IFNg was induced, we observed that the tumour tissue was now replaced with fibrotic tissue accompanied by a marked lymphocyte infiltration and patches of necrosis. However, new tumour nodules were also observed to develop in the vicinity of regressing nodules which are unpigmented and potentially hypo-immunogenic. We observed no signs of tumour regression in control tumours.Although preliminary, our data is very exciting and promising as it will open new avenues for developing combinatorial therapies in melanoma. Using a high throughput in-vivo model system such as zebrafish, it is an exciting proposition to test the impact of combining anti-PD1/PDL1 inhibitors with various cytokines/chemokines in inducing effective and sustained tumour regression in melanoma.']",
        "Doc_id":"AACR_2016-4180",
        "Doc_title":" Rewiring the cytokine network in melanoma",
        "_version_":1606189035711102976},
      {
        "Meeting_name":" A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment.",
        "Background":"['Background', '    IMCgp100 is a novel biologic comprising a soluble T cell receptor (TCR) fused to an antibody fragment (scFv) being developed for the treatment of metastatic melanoma. The TCR component binds to the melanoma associated antigen (Ag) gp100 which is overexpressed and presented by HLA A2 on melanoma cells. The scFv component activates T cells in physical contact with the target via CD3. Thus, IMCgp100 is expected to bind melanoma cells and stimulate the immune system to attack the target tissue via cytotoxic lymphocyte killing and via stimulation of accessory immune mechanisms.The purpose of this trial is to assess the pharmacodynamic effects of a single intratumoral dose of IMCgp100 on the tumour microenvironment and to establish what local concentration of drug is required for optimal effect. Such data will aid in future trial design and facilitate clinical development.  Methods', '    This 2 stage exploratory study will assess the effects of 2 different doses of IMCgp100 in subjects with advanced unresectable melanoma not currently requiring systemic treatment and/or in a window between treatments. Eligible subjects must have completed other cancer therapies 14 days prior to injection, ECOG PS  2, no active, uncontrolled infection, no steroids within 2 weeks of injection. In the first stage, subjects will receive a single intratumoral injection of 0.00017mg of IMCgp100 into a target cutaneous or subcutaneous metastasis, 7-15mm in size. This should generate a local concentration of 1nM; shown to induce maximal tumour cell killing in vitro. One week later, biopsies of the target lesion and a designated reference lesion will be performed. Primary endpoints include', ' assessment of tumor and reference tissue for lymphocyte infiltration and Ag expression by IHC; molecular analysis of immune cell infiltration and activation status using Q-RT-PCR, flow cytometry, Luminex analysis. Secondary endpoints will measure markers of systemic immune activity and safety. The second stage will assess a 10 fold higher dose. Enrollment for the trial is now open. Up to 20 subjects may be enrolled to yield 6 evaluable, HLA 2+ subjects.']",
        "Doc_id":"ASCO_78852-102",
        "Doc_title":" A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment.",
        "_version_":1606189004558958592},
      {
        "Meeting_name":" Neutrophil-lymphocyte relationship and its association with overall survival in advanced melanoma.",
        "Background":"['Background', '  The neutrophil-lymphocyte relationship (NLR) has been associated with lower survival rate in many tumors. The mechanisms underlying this association are poorly understood. An NRL > 4 would modify the inflammatory response, in which neutrophils suppress cytolytic activity of immune cells such as lymphocytes, activated T cells and natural killer cells, which correlate with a good prognosis in other tumors. A high NRL ( > 4) has also been associated to peri tumor infiltration by macrophages, interleukins, various cytokines (IL1-6-7-8-9-12) and interferons. Platelets can release some growth factors such as platelet-derived growth factor, platelet factor 4 and thrombospondin; therefore, the ratio of Platelet-lymphocytes (PLR) > 194 would be associated with worse prognosis. Our primary objective is to determine if values > 4 of the NLR are associated with worse overall survival (OS), at diagnosis of Advanced Melanoma. The secondary objective is to determine if the PLR are associated with OS and to analyze the relationship of other clinical variables (such as age, sex, performance status, ulceration, mitosis, LDH value and location) with the value of NLR.  Methods', '  Retrospective and analytical study in which 71 patients diagnosed with Advanced Melanoma, in last 7 years were selected and whose NLR value (Low', ' < 4 or High > 4) and PLR value (Low < 194 or High > 194) was evaluated in relation to overall survival. Statistical analysis was performed using Kaplan-Meier test and univariate statistical analysis (Chi-square test).  Results', '   Median overall survival was 7,4 months. Patientes with NLR > 4 had an OS of 6,4 months, whereas in those with NLR < 4, it was 8,9 months (p = 0,027).  There were no significant differences in OS among patients according to PLR.  There was no association between clinical variables evaluated and NLR/PLR.   Conclusions', '  NLR > 4 levels at diagnosis of advanced skin melanoma were significantly associated with a lower survival. The PLR > 194 was not significantly associated with worse prognosis in this disease. NLR value could be a factor prognostic valuable.']",
        "Doc_id":"ASCO_148374-156",
        "Doc_title":" Neutrophil-lymphocyte relationship and its association with overall survival in advanced melanoma.",
        "_version_":1606189031867023360},
      {
        "Meeting_name":" Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA",
        "Background":"['Melanoma, the fastest rising cancer in the UK, is a major therapeutic challenge and effective treatments are urgently needed. The human high molecular weight melanoma associated antigen (HMW-MAA), a membrane-bound protein over-expressed in > 90% of melanomas, is thought to contribute to melanoma growth and metastasis. A number of studies indicate the merit of blocking these tumor-promoting functions by antibodies. Most antibodies for cancer therapy in clinical use belong to the IgG class, the most prevalent class in blood. IgE antibodies, characterised for their role in allergic responses and protection against parasites, function through high-affinity Fc receptors. IgE antibodies, naturally reside in tissues where they exert immunological surveillance, a different spectrum of effector cells, and offer a novel therapeutic approach by targeting solid tumors such as melanoma. Previous studies, suggest that IgE antibodies are more effective than the corresponding IgGs in eliciting anti-tumural immune responses, with our lead antibody candidate against the tumour antigen Folate Receptor alpha (FRa) presently in clinical development. We wished to elucidate whether this concept can be applied to the treatment of melanoma. To test this, we engineered IgG1, IgG4 and IgE antibodies of the same specificity against HMW-MAA and examined their functionality in activating immune effector cells against cancer cells. IgG1 and IgE antibodies induced significant tumor cell death by two mechanisms', ' antibody-dependent cell-mediated phagocytosis and antibody-dependent cell-mediated cytotoxicity in vitro, using patient-derived monocytes and monocytes from healthy volunteers. These results suggest different antibody classes may harbor complementary functional properties against cancer cells, by activating different families of Fc receptors on immune effector cells. Furthermore, we compared the therapeutic efficacy of these antibodies in tumor-bearing NOD/SCID/IL-2 receptor  chain-/- mice engrafted with human lymphocytes. We demonstrate, that IgE antibodies are superior compared to IgG1 (p<0.05) and non-specific antibody controls (p<0.001). Moreover, immunohistological and transcriptomic analyses revealed an increased lymphocyte infiltrate within the treatment groups. The data indicate, infiltrating immune cells interactions with the tumor microenviroment to reduce tumor growth. We are currently undertaking additional functional validation to identify the in vivo signaling mechanisms involved.']",
        "Doc_id":"AACR_2012-2524",
        "Doc_title":" Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA",
        "_version_":1606189022690934784},
      {
        "Meeting_name":" IFN- to improve immunotherapy for melanoma.",
        "Background":"['Background', '  Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) holds the promise to change the long-term prognosis of patients with metastatic melanoma. In this study we have explored strategies to improve the efficacy of cell products for infusion through tumor immune-sensitization.  Methods', '  We examined whether objective responses in our pilot ACT trial (NCT937625) were associated with the number of tumor-reactive T cells infused. Subsequently, we assessed the ability of immune-sensitizing agents to modulate the constitutive response of 12 clinical grade TIL products to matched autologous short-term cultured melanoma cell lines.  Results', '   Our data showed that a high absolute number of infused tumor-reactive T cells is critical to achieve an objective response. In addition, a defective population of tumor-specific CD8+ and CD4+ T cells unable to exert antitumor effector functions ex vivo was detected in most TIL products. However, an antitumor specific response could be restored by pretreatment of the autologous tumor cells with low dose IFN-. Of note, IFN- treatment was invariably associated with increased cancer immunogenicity as demonstrated by up-regulation of MHC molecules.  Conclusions', '  Combination strategies represent the next frontier of cancer immunotherapy. Although previous trials in melanoma showed that IFN- does not mediate clinical benefit when used as monotherapy, our findings show that its ability to increase tumor cell immunogenicity may enhance the efficacy of current immune-based therapies such as ACT through improved activation of pre-existing but unresponsive tumor specific lymphocytes. Therefore, additional studies on the possibility of a sequential combination of low dose IFN- and ACT are highly warranted.']",
        "Doc_id":"ASCO_94451-114",
        "Doc_title":" IFN- to improve immunotherapy for melanoma.",
        "_version_":1606189011960856576},
      {
        "Meeting_name":" Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade.",
        "Background":"['Background', ' Adoptive transfer of tumor infiltrating lymphocytes (TIL) can effect long-term durable regression in patients with metastatic melanoma but has not been widely tested in common epithelial cancers. Similar to metastatic melanoma, recent studies on epithelial GI cancers report that tumor regressions can be mediated by adoptively transferred TIL recognizing non-synonymous somatic mutations. Breast cancer metastatic tumors are infiltrated by TIL and reactivity against autologous somatic mutations can be identified.']",
        "Doc_id":"AACR_2017-4982",
        "Doc_title":" Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade.",
        "_version_":1606189003041669120},
      {
        "Meeting_name":" CTLA4 and CD47 combinational therapy to extend survival in melanoma.",
        "Background":"['Background', ' Irradiation (IR) combined with chemotherapy is the post-surgical standard of care treatment for melanoma, but metastasis still results in high mortality rates. Immune checkpoint inhibitors such as cytotoxic T-lymphocyte antigen-4 (CTLA4) have proven effective for immunotherapy of melanoma. CTLA-4 is up-regulated post-T cell activation and blockade enhances tumor responses in immunocompetent rodents and humans. Trials suggest that combinations of immune checkpoint inhibitors are more efficacious than single agents, but tumors remain resistant. We are investigating CD47 blockade for the treatment of cancer. CD47 is frequently elevated in cancers and serves as an inhibitory receptor for thrombospondin-1 on immune cells in the tumor stroma. CD47 blockade on CD8 T or tumor cells significantly enhances immune-targeted tumor cell killing post-IR compared to IR alone. Here we explore the potential for antisense CD47 and anti-CTLA4 therapy alone or in combination with IR using a syngeneic mouse melanoma model. Methods', ' C57BL/6 mice were inoculated with 1x106B16F10 melanoma cells in the hind limb and treated with 10 Gy IR combined with CTLA4 blocking antibody, CD47 translational blocking morpholino, or the combination of CTLA4/CD47 therapies. Granzyme B along with CD4/CD8 T cell infiltration were examined in tumors. Histology was evaluated for CD3 and necrosis. Results', ' The combination of CD47/CTLA4 with IR significantly increased survival by 25% compared to IR/CTLA4 alone at 50 days. Granzyme B expression was significantly increased in IR mice with CTLA4/CD47 combination, which correlated with infiltration of CD8+ T cells and a concomitant decrease in Gr1+CD11b suppressor cells compared to controls. In non-IR tumors, histology revealed minimal necrosis, while all IR groups showed increased necrosis. Tumor IR in combination with CTLA4 or CD47 increased immune cell infiltration. However, the combination of IR with CTLA4/CD47 showed widespread necrosis. All groups treated with the CD47 exhibited focal hemorrhage, which was more extensive when combined with CTLA4. Conclusions', ' Results herein suggest IR combined CTLA4/CD47 checkpoint blockade provides a survival benefit by activating a beneficial adaptive immune response.']",
        "Doc_id":"ASCO_183456-199",
        "Doc_title":" CTLA4 and CD47 combinational therapy to extend survival in melanoma.",
        "_version_":1606188992307396608},
      {
        "Meeting_name":" Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma.",
        "Background":"['Adoptive cell therapy with tumor infiltrating lymphocytes (TIL) is a promising immunotherapeutic approach and has resulted in durable response rates of 20-30% in patients with metastatic melanoma. However, several limitations exist to prevent the widespread implementation of adoptive cell therapy, including inadequate infiltration of tumor-specific T cells into tumors and anemic expansion of tumor-specific T cells in vitro. One such factor is PD-1 expression on T cells that plays an important role in T cell exhaustion. Agonistic co-stimulatory molecules such as 4-1BB which is transiently expressed on activated T cells can reverse T cell exhaustion and enhance anti-tumor immune response. In this study, we have examined two approaches to improve the frequency of tumor-specific T cells in tumors and TIL cultures. First, we examined whether blocking PD-L1/PD-1 signaling increased the infiltration of tumor-specific T cells in the murine B16 melanoma model. Mice bearing B16 tumors were treated with NrIgG or anti-PD-1 antibodies. T cells were isolated from B16 tumors on day 18 after tumor injection. Increased IFN- production following B16 restimulation was observed in TIL isolated from mice treated with anti-PD-1 antibody (1445  48 pg/ml) compared to TIL isolated from mice treated with control antibody (748  25 pg/ml, p<0.001). In addition, we examined whether the expansion of T cells during TIL culture in vitro could be augmented by targeting the co-stimulatory molecule, 4-1BB. T cells were isolated from B16 tumors and cultured in vitro with 10 mcg/mL anti-4-1BB antibody. After 5 days, increased B16-specific IFN- was measured in TIL cultured with anti-4-1BB antibody (1865  64 pg/ml, p<0.001 compared to TIL cultured with control antibody). Combination treatment with anti-PD-1 antibody therapy in vivo and anti-4-1BB antibody in vitro demonstrated synergistic effects, with increased levels of IFN- (4440  486 pg/ml) produced by B16-specific TIL. These findings suggest that anti-PD-1 antibody treatment in combination with in vitro 4-1BB antibody treatment can enhance the frequency of tumor-specific T cells isolated from B16 melanoma. This may represent a potential strategy to increase the effectiveness of TIL therapy in patients with melanoma.']",
        "Doc_id":"AACR_2013-3973",
        "Doc_title":" Effects of anti-PD-1 and anti-4-1BB antibody treatment on melanoma-specific T cells in a murine model of melanoma.",
        "_version_":1606189019615461376},
      {
        "Meeting_name":" The isoform 2 of FKBP51 is induced by PDL-1/PD1 interaction and marks peripheral blood mononuclear cells of melanoma patients",
        "Background":"['Melanoma delivers immune suppressive stimuli through PDL-1. FK506 binding protein 51 (FKBP51) is an immunophilin capable of immune suppression. We, previously, demonstrated a relevant role for this protein in melanoma biology and progression. Melanoma also expresses a splicing variant of FKBP51 (isoform 2 or ISO2), whose function is unknown. Aim of this study was to generate knowledge on the mechanism regulating PDL-1 expression in melanoma, and find biomarkers predictive of response to immunotherapy. We generated melanoma cells overexpressing the canonical FKBP51 or ISO2, and measured levels of PDL-1. Flow cytometry showed that expression of PDL1 in ISO2-melanoma (41.5+4.2%) was significantly higher than expression in control cells (15.5+4.7%) or melanoma overexpressing the canonical FKBP51 (23.2+5.7%). These results suggested a role for ISO2 in regulation of PDL-1 expression, that was confirmed in another tumor cell line, namely HeLa. Western blot assay showed different bands of PDL-1 (around 70kD, 50kD and 37kD). The band at 70kD was present in the tumor, but not in lymphocytes and, reasonably, corresponded to the form exposed on the membrane. This 70kD band was particularly upregulated in ISO2-melanoma. Tumor infiltrating lymphocytes (TIL) express a strong immunohistochemistry signal for FKBP51. Since a molecular mimicry suits melanoma and lymphocytes, we investigated whether PBMCs of melanoma patients, that are a good a source of TIL, expressed the two isoforms. We measured, by QPCR, isoforms levels in PBMCs of 70 healthy donors, 92 primary melanoma and 60 metastatic melanoma patients. Our results show that expression of ISO2, but not canonical FKBP51, was significantly higher in PBMCs of patients than in PBMCs of controls (Kruskal-Wallis test, p<0.0001). In addition, ISO2 expression in PBMCs from metastatic melanoma patients (range 7.0-36.0 au) was significantly higher than expression in PBMCs from primary melanoma (range 1.0-3.5 au)(p<0-007). Healthy donors PBMCs expressed ISO2 when cocultured with melanoma and such expression changed in accordance with PDL-1 expression on melanoma, as suggested by PDL-1 knockdown experiments. Moreover, ISO2 resulted increased in PBMCs cultured with PDL-1 recombinant protein, but not BSA. These findings suggested that the increased expression of ISO2 in PBMCs of melanoma patients was stimulated by the interaction between the tumor and PBMCs, through PDL-1/PD1. In conclusion, our results show that 1) ISO2, a splicing variant of FKBP51, upregulates expression of PDL1 in melanoma; 2) PDL1-PD1 interaction between tumor and lymphocytes induces ISO2 in lymphocytes; 3) increased ISO2 levels were measured in PBMCs of 152 melanoma patients; 4) ISO2 levels were especially high in PBMCs of advanced melanoma patients. Collectively, our results suggest ISO2 is a promising melanoma biomarker related to PDL-1.']",
        "Doc_id":"AACR_2014-2912",
        "Doc_title":" The isoform 2 of FKBP51 is induced by PDL-1/PD1 interaction and marks peripheral blood mononuclear cells of melanoma patients",
        "_version_":1606189022093246465},
      {
        "Meeting_name":" Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.",
        "Background":"['Background', ' Programmed death-ligand 1 (PD-L1) is expressed by various cells such as dendritic cells and tumor cells. In cancer, tumors evade the immune system by the interaction of PD-L1 with PD-1 receptor on activated T lymphocytes. This interaction forms the basis for the use of PD-1 inhibitors in cancer immunotherapy. The purpose of this study is to investigate differences in expression of PD-L1 on tumor cells and PD-1 receptor on tumor infiltrating lymphocytes (TILs) between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). Methods', ' Biopsy specimens of MUM and MCM patients were analyzed for PD-L1 and PD-1 expression at a CLIA-certified lab (Caris Life Sciences). PD-L1 expression on melanoma cells was confirmed using validated, immunohistochemical cell-surface staining with an anti-PD-L1 antibody (SP142, positivity  5% tumor cells). PD-1 expression on TILs was confirmed using the anti-PD-1 antibody (MRQ-22, positivity  1 TILs per high-power field). In total, 106 MCM and 18 MUM specimens were analyzed for PD-L1 expression, while 89 MCM and 17 MUM specimens were tested for PD-1 expression. Results', ' Overall, 22/106 (20.8%) MCM specimens expressed PD-L1 (Table). The highest rate of expression was seen in lung metastasis. Interestingly, all 6 of the metastatic liver lesions showed no PD-L1 expression. In comparison, none of the uveal melanoma specimens showed PD-L1 expression. PD-1 expression was seen in 68/89 (76.4%) and 9/17 (53%) of MCM and MUM specimens, respectively. Conclusions', ' While PD-1 expression was seen in both MUM and MCM, there was a stark difference in PD-L1 expression between them (20.8% vs. 0%; p = 0.04). A complete absence of PD-L1 expression by MUM tumor cells might explain the lack of therapeutic response to PD-1/PD-L1 inhibition and suggests an alternative mechanism via which it evades the immune system. Cutaneous MelanomaUveal MelanomaSite of metastasisNumber of patientsPD-L1 positiveSite of metastasisNumber of patientsPD-L1 positiveLymph node336/33 (18.2%)Liver140%Lung175/17 (29.4%)Other**40%CNS142/14 (14.3%)180/18Liver60%Other*369/36 (25%)10622/106 (20.8%)*Bone (n = 2), spleen (n = 2), skin, subcutaneous and soft tissue **Bone, mediastinum, lymph node and omentum']",
        "Doc_id":"ASCO_165858-176",
        "Doc_title":" Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.",
        "_version_":1606189024373899264},
      {
        "Meeting_name":" Impact of aging on immune response and survival in melanoma.",
        "Background":"['Background', ' Age is an independent predictor of worse survival in melanoma. Multiple factors may contribute to this observation including decline in host anti-tumor immune response with aging. However, the underlying immunologic pathways in which age impacts the anti-tumor immune response are unclear. Methods', ' We queried the U.S. Surveillance, Epidemiology, and End Results Program (SEER), NYUs prospective melanoma biorepository database, and the Cancer Genome Atlas (TCGA) to examine the association of patient age at time of diagnosis (young', ' < 45, middle', ' 46-65, and old', ' > 65) with clinicopathologic features and melanoma-specific survival (MSS). The prognostic value of tumor infiltrating lymphocytes (TIL) was evaluated in each age group. Differential expression of 579 immunoregulatory genes was assessed in a subset of the NYU cohort using an integrative pathway analysis. A mediation analysis tested whether gene expression levels transmitted an aging effect on decreased overall survival (OS). TCGA primary melanoma gene expression data served as independent validation. Results', ' We analyzed 304,476 (SEER), 1,241 (NYU), and 292 (TCGA) patients. Old age associated with shorter MSS in all cohorts (p < 0.001) independent of gender and stage and positively correlated with thickness, ulceration, stage, and mortality in the SEER and NYU cohorts (p < 0.001). Brisk TIL grade in old NYU patients and lymphocyte score 3-6 in middle age TCGA patients associated with prolonged MSS (p < 0.01). The NYU subset (n = 84) showed decreased lymphocyte migration, chemotaxis, and iCOS and CD28 signaling, which associated with decreased OS in the mediation analysis. IL-1B and IFN-g were predicted as inhibitory upstream regulators with aging, leading to downregulation of genes involved in dendritic cell function. The TCGA cohort (n = 41) pathway analysis validated IL-1B as an inhibitory upstream regulator with aging. Conclusions', ' Ages association with worse clinicopathologic features is dependent upon the specific study cohort. TIL as a read-out of the host immune response may have greater prognostic value in patients > age 45. Recognition of age-related factors negatively impacting host immune responses may provide new insights into therapeutic strategies for the elderly.']",
        "Doc_id":"ASCO_164493-176",
        "Doc_title":" Impact of aging on immune response and survival in melanoma.",
        "_version_":1606189037372047360},
      {
        "Meeting_name":" Locoregional treatment of immune escape' metastatic melanoma in the setting of immune checkpoint inhibition for widespread disease.",
        "Background":"['Background', ' Metastectomy confers a survival advantage in advanced melanoma in appropriately selected patients. Combining local therapies, e.g. surgery and electrochemotherapy (ECT) with immune checkpoint inhibitors is largely unexplored. No histopathology analysis has been previously reported on resected specimens from patients receiving pembrolizumab. Methods', ' In a cancer center in Ireland we collected data on patients with metastatic melanoma (MM) who received sequenced or combined surgery, ECT and pembrolizumab. Histolopathological analysis of the resected surgical specimens was performed. Results', ' Case1', ' A 36-year-old female with BRAF wild type(wt) widespread MM, following ipilimumab, was commenced on pembrolizumab due to progressive disease. Following 19 cycles of pembrolizumab, two growing FDG-avid lesions were resected in sequence from both lungs. Three months later, she continues pembrolizumab with stable metastatic disease. Case 2', ' A 65-year-old male with BRAF wt MM, after progression of disease on ipilimumab was commenced on pembrolizumab. Following 12 cycles of pembrolizumab, intracranial metastatic disease was found on neuroimaging. These areas were resected and whole brain RT was preformed. He recovered well, and continues pembrolizumab therapy. Case 3', ' A 33-year-old male with BRAFV600 mutated MM, after progression of disease on ipilimumab was commenced on pembrolizumab. During treatment, he received ECT to growing neck disease, and 2 growing lesions were resected from his back. He remains clinically well after 17 cycles of pembrolizumab. On histopathologic analysis, four resected specimens showed a non-brisk lymphocyte infiltration (from 3 patients). Conclusions', ' We found combining pembrolizumab and local measures to be safe and effective in highly selected MM patients. Histopathologic analysis showed a limited lymphocyte infiltration in specimens suggesting these deposits were sanctuary sites with mechanisms of immune escape and resistance to PD1 directed therapy, supporting the rationale for resection of the lesions. Further research and a longer follow up time is required to further evaluate this practice.']",
        "Doc_id":"ASCO_170098-176",
        "Doc_title":" Locoregional treatment of immune escape' metastatic melanoma in the setting of immune checkpoint inhibition for widespread disease.",
        "_version_":1606188981493432320},
      {
        "Meeting_name":" Hair depigmentation as an indicator of durable response to CTLA-4 therapy.",
        "Background":"['Background', ' Treatment with CTLA-4 monoclonal antibodies for metastatic melanoma has been known to induce immunologically related adverse events. It is unclear if these events correlate with clinical responses. We report here, for the first time, the occurrence of hair depigmentation following therapy with CTLA-4 monoclonal antibodies that correlate with durable clinical responses. No non-responders developed any hair depigmentation. Methods', ' Patients (pts) enrolled onto 2 clinical trials at NYU using either ipilimumab (ipi) or tremelimumab (treme) for metastatic melanoma were evaluated. 43 pts were accrued (33-ipi and 10-treme). 11 pts achieved long-term, durable responses (3 complete responses and 8 partial responses) lasting over a median of 24 months. 5F', '6M Age range', ' 37-78. All had normal baseline LDH levels. Results', ' Six pts developed sudden hair depigmentation starting with the eyebrows. Median time to depigmentation was 10 months. All 6 pts have continued to have either complete depigmentation of all body hair or the development of diffuse vitiligo. All of these pts have remained with stable disease or complete resolution of disease ranging from 24-36 months. Five of 6 had normal baseline total lymphocyte counts. One with low baseline lymphocyte counts normalized following therapy. All pts had prior therapies including biologics, immunotherapy and/or chemotherapy. All 6 pts also developed other immunologic-related toxicities including rash (6), pruritis (4), diarrhea (4), grade III hypophysitis (2). The remaining 5 pts without hair depigmentation remain with stable disease ranging from 24-48 months. Immune related toxicities in these include rash (4), pruritis (3), diarrhea (2) and myalgias (1). Tumor tissue from all 11 responders are being analyzed for tumor infiltration with CD3 T cells, infiltrating TILs, microRNA and SNPs. Blood samples drawn before and after response to therapy will be evaluated for anti-NY-ESO-1 antibodies. Conclusions', ' To our knowledge, this is the first report of immune related hair depigmentation in metastatic melanoma patients treated with CTLA-4 monoclonal antibodies who achieve durable responses. Scientific correlates being performed on blood and tissues and will be presented.']",
        "Doc_id":"ASCO_49147-74",
        "Doc_title":" Hair depigmentation as an indicator of durable response to CTLA-4 therapy.",
        "_version_":1606189017565495296},
      {
        "Meeting_name":" Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.",
        "Background":"['Background', ' Ipilimumab is a fully human monoclonal antibody to cytotoxic T-lymphocyte antigen-4. Identifying predictive markers may help select advanced melanoma pts most likely to benefit from ipilimumab therapy. Biomarkers in the tumor microenvironment are thought to be more relevant for predicting response than those in the peripheral blood. Methods', ' We examined tumor biopsy markers in a Phase II study CA184004 (ipilimumab 3 and 10 mg/kg). Ipilimumab was administered every 3 weeks (Q3W) x 4; eligible pts could receive ipilimumab Q12W starting Wk 24. Pre- and post-treatment (Wk 4) tumor biopsies were performed for hematoxylin and eosin analysis of tumor-infiltrating lymphocytes (TILs); immunohistochemistry of FOXP3 and indoleamine 2,3-dioxygenase (IDO); and mRNA expression profile analysis. Response was assessed with modified World Health Organization criteria. Associations between tumor biomarkers and clinical activity (complete response, partial response, or stable disease  24 wks) were assessed. Results', ' Ipilimumab 3 or 10 mg/kg was administered to 40 and 42 pts, respectively. In tumor biopsies, clinical activity was associated with high expression of FOXP3 (P = 0.014) and IDO (P = 0.012) at baseline and an increase from baseline in TILs (Wk 4) (P = 0.005) (Table). Tumor mRNA profiling identified genes with significant changes from baseline in expression, or with baseline expression levels that may be associated with clinical activity. These included various immune response genes and known melanoma antigens. Conclusions', ' Biomarkers in the tumor microenvironment have been demonstrated to be associated with clinical activity in pts treated with ipilimumab. Clinical ActivityWithout Clinical Activity TILs by Wk 4 (P = 0.005)*4/7 increase0/7 decrease3/7 no change2/20 increase3/20 decrease15/20 no changeBaseline FOXP3 expression (P = 0.014)*6/8 positive9/25 positiveBaseline IDO expression (P = 0.012)*3/8 positive3/27 positive*P values uncorrected for multiple testing']",
        "Doc_id":"ASCO_34554-65",
        "Doc_title":" Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.",
        "_version_":1606188980410253312},
      {
        "Meeting_name":" The HIF-1 hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy",
        "Background":"['The response to hypoxia modulates the expression of multiple genes. The tumor microenvironment of transplanted and spontaneous mouse tumors is profoundly deprived of oxygenation as confirmed by PET imaging. CD8 and CD4 tumor-infiltrating T lymphocytes (TILs) of transplanted colon carcinomas, melanomas and spontaneous breast adenocarcinomas are CD137 (4-1BB) positive, as opposed to their counterparts in tumor draining lymph nodes and spleen. Expression of CD137 on activated T lymphocytes is markedly enhanced by hypoxia and the prolyl-hydroxilase inhibitor DMOG. Importantly, hypoxia does not up-regulate CD137 in inducible HIF-1 knock-out T cells, and such HIF-1-deficient T cells remain CD137-negative even when becoming TILs, in clear contrast to co-infiltrating HIF-1-sufficient T cells. The fact that CD137 is selectively expressed on TILs was exploited to confine the effects of immunotherapy with agonist anti-CD137 monoclonal antibodies (mAb) to the tumor tissue, thereby avoiding liver inflammation, while still permitting synergistic therapeutic effects with PD-L1/B7-H1 blockade.']",
        "Doc_id":"AACR_2012-3538",
        "Doc_title":" The HIF-1 hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy",
        "_version_":1606189038895628288},
      {
        "Meeting_name":" Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.",
        "Background":"['Background', ' Development of biomarkers to evaluate prolonged systemic treatment response is crucial for optimizing individual checkpoint inhibitor therapies. Glucose consumption rates assessed by 18F-FDG PET/CT have been used to stage and monitor the response to therapy in patients with melanoma. We aim to explore whether local 18F-FDG uptake can predict systemic response and how it correlates with intratumoral infiltration measured by the proportion of exhausted antigen experienced T cells (TEx)/Total CD8+ cells. Methods', ' Following core biopsies or surgical excision, freshly isolated tumor samples were digested and tumor infiltrating lymphocytes (TILs) were extracted and stained with T cell myeloid and activation markers, and analyzed with 14 color FACS. Patients were treated with either Nivolumab 3 mg/kg q2 week or Pembrolizumab 2 mg/kg q3 week. TEx was calculated as % CD8+, PD-1+, CTLA-4+ cells divided by total CD8+ T cells in the tumor sample. Thirty-nine patients (23 males) with measurable advanced melanoma were included. The closest in time, (49  22 days), standard of care whole-body 18F-FDG PET/CT to the biopsy was used for analysis. Uptake was measured by maximum standardized uptake value (SUVmax) at the biopsied lesion. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), for a period of 149 months. Results', ' Of the 18 patients with high TEx (more than 24%), 11 were in CR or PR at follow-up with a SUVmax of 15.8 an, compared to an SUVmax of 10.7 for the 7 patients in PD or SD. Nine of the 21 patients with low TEX (less than 24%) were in PR or CR with an SUVmax of 4.9, significantly lower than the SUVmax of the 12 patients in PD or SD, 10.4. Conclusions', ' When associated with TEx, local glucose utilization measured by 18F-FDG may be of help for predicting systemic response to check inhibitor mono-therapy. Variations in local increased glucose consumption may reflect several pathophysiologic pathways including different concentrations of activated lymphocyte populations, non-homogenous melanocytic tumoral densities and local inflammatory cellular migrations.']",
        "Doc_id":"ASCO_171302-176",
        "Doc_title":" Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.",
        "_version_":1606188976200220672},
      {
        "Meeting_name":" Impact of obesity in melanoma outcomes",
        "Background":"['Introduction', ' In the United States and around the world, obesity rates have been rising. While rates of some cancers are higher in the obese population, the data related to melanoma incidence is conflicting. Furthermore, the impact of obesity on outcomes in melanoma is unknown. We aim to discern the impact of rising body mass index (BMI) on survival and surgical outcomes in melanoma.Methods', ' The first Multicenter Selective Lymphadenectomy Trial (MSLT-I) is a multinational randomized controlled trial evaluating the role of sentinel lymph node biopsy in melanoma. We queried this prospective trial database for all patients with height and weight data at the time of enrollment into the trial. Patients were stratified by BMI as obese (BMI 30) or not obese (BMI<30). Patient age, sex, Breslow thickness, and lymph node status were assessed for their impact on melanoma specific survival (MSS) and surgical complications. Pathologic data and primary site data were also analyzed with regards to obesity.Results', ' A total of 1,839 patients were included in the analysis, 741 from the observation group (OBS, no sentinel lymph node biopsy), and 1098 from the sentinel node group (SLN). 376 patients (20%) were obese and 1,463 (80%) were not. MSS at 5 years was 88.8% (1.7) for obese patients and 82.2% (1.0) for non-obese patients (p = 0.0512, univariate). A small minority of patients were underweight (n = 27, 1.5%, BMI < 18.5) and they experienced a trend towards worse survival than obese patients (5-yr MSS 79.0% 8.4). We assessed BMI in a multivariable analysis as a continuous and categorical variable and found a consistent direct association with MSS (for BMI 30', ' HR 0.69 [0.52-0.91], p = 0.010). Multivariable analysis identified decreased BMI, male sex, older age, thicker Breslow level, lymphatic spread, and ulceration as significant predictors of worse survival. Despite a trend towards increased local complications in the obese (23.1% vs. 20.5%, p = 0.267), there was no significant difference in rate of complications based on BMI. The distribution of primary melanoma sites was not different among obese and non-obese populations and there was no difference in pathologic variables (Breslow thickness, ulceration, regression, number of lymph nodes excised, or presence of tumor infiltrating lymphocytes). Conclusions', ' In this prospective trial database, obesity offers a protective effect on survival without a significantly increased rate of complications. Future studies may look for obesity-related factors and mechanisms to explain the improved outcomes.']",
        "Doc_id":"AACR_2015-859",
        "Doc_title":" Impact of obesity in melanoma outcomes",
        "_version_":1606188982496919552},
      {
        "Meeting_name":" Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types.",
        "Background":"['With the advent of immune therapies including inhibition of the PD-1/PD-L1 axis there is an urgent need to identify cancer patients that benefit from these therapies and to overcome mechanisms of resistance. Here, we analyzed the impact of tumor genetics on the composition of tumor microenvironment across 21 solid cancer types from the TCGA project. Using specific mRNA markers of 10 cell populations (MCPcounter), we estimated the content of T cells, CD8+ T cells, cytotoxic lymphocytes, B lineage cells, NK cells, monocytic lineage cells, myeloid dendritic cells, neutrophils, fibroblasts and endothelial cells in tumor tissues. Immune cell compositions were correlated with mutational load, the activity of 27 mutational signatures (MutSigs) and PD-L1 mRNA expression. Correlation strength was assessed using Spearmans rho statistics. Multiple testing was addressed using the Benjamini-Hochberg method and FDR control at 5%. MutSig 1 (clock-like, age-related) showed significant positive correlations with immune cell infiltrations in low-grade gliomas, negative correlations in breast cancer, melanoma, stomach cancer, lung and prostate adenocarcinoma, but no significant correlations in the remaining 15 cancer types. Of the two APOBEC-related signatures, MutSig 2 showed positive significant correlations with immune cell infiltrates in cervical cancer, bladder cancer, lung adenocarcinoma, head and neck cancer and thyroid cancer, MutSig 13 in breast and cervical cancer. In particular, correlation of MutSig 2 with cytotoxic lymphocytes was significant in cervical cancer, bladder cancer and lung adenocarcinoma (R = 0.29, R= 0.17 and R = 0.17), the corresponding correlation of MutSig 13 in breast cancer (R = 0.17). MutSig 4 (tobacco smoke-related) showed a positive significant correlation with CD8+ T cells and NK cells in lung adenocarcinoma (R = 0.15 and R = 0.14). In contrast, correlation of MutSig 4 with immune cell infiltrates was non-significant or negative in head and neck cancer. In colorectal cancer, MutSig 6 (defective mismatch repair) showed significant positive correlations with NK cells, cytotoxic lymphocytes, monocytic lineage cells and neutrophils infiltration (R = 0.45, R = 0.37, R = 0.23 and R = 0.19). PD-L1 mRNA expression and immune cell infiltrates correlated positively in all 21 cancer types. In particular, correlation with monocytic lineage cells was positive and significant in all cancer types and strong (R > 0.50) in 12 cancer types. Correlation with T cells was positive and significant in 18 cancer types and strong in 10 cancer types. In summary, pan-cancer analysis of DNA and RNAseq data showed that specific mutational signatures contribute to cancer cell immunogenicity, while the ubiquitous clock-like mutational process did not positively correlate with immune cell infiltrates in 20 of 21 cancer types. Moreover, PD-L1 mRNA expression strongly correlated with infiltrates of immune cells in the majority of cancer types.']",
        "Doc_id":"AACR_2017-3709",
        "Doc_title":" Deciphering the impact of tumor genetics on immune cell infiltration in major solid cancer types.",
        "_version_":1606188979933151232},
      {
        "Meeting_name":" Immune escape mechanisms associated with tumor recurrence after adoptive cell transfer immunotherapy.",
        "Background":"['Background', '  Adoptive cell transfer immunotherapy (ACT) with tumor infiltrating lymphocytes (TILs) results in unprecedented rates of durable clinical responses but some patients initially responding achieve only a temporary disease remission before tumor recurrence.  Methods', '  Disease relapse in a case of metastatic melanoma experiencing tumor recurrence after complete response to treatment with TILs was characterized at the cellular and molecular level using primary tumor cell lines and tumor infiltrating lymphocytes derived from metastatic lesions resected at different time points.  Results', '  Multiple mechanisms linked to tumor-intrinsic evolutional phenomena associated with tumor re-growth despite durable persistence of peripheral antitumor responses were identified. Tumor-cell intrinsic alterations led to both impaired immune sensitivity and universally reduced immune recognition associated with multiple defects in antigen processing machinery, but not to antigen loss or increased expression of immune suppressive molecules such as PD-L1. In addition, cell lines from tumor recurrence were characterized by increased in vivo malignancy independent of immune response sensitivity, in the absence of new known melanoma driver mutations.  Conclusions', '  Data from this study brings direct evidence that tumor cell evolutionary mechanisms responsible for immune escape, and associated with disease recurrence in human metastatic tumors after effective immunotherapies targeting multiple antigens, are extraordinarily complex and multifactorial. Future strategies to extend duration of responses to immunotherapy should consider targeting this complexity']",
        "Doc_id":"ASCO_129444-144",
        "Doc_title":" Immune escape mechanisms associated with tumor recurrence after adoptive cell transfer immunotherapy.",
        "_version_":1606189035278041089},
      {
        "Meeting_name":" Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.",
        "Background":"['Background', '  Density of tumor-infiltrating lymphocytes (TILs) has a prognostic impact in various extracranial solid tumors. We characterized TILs in patients with brain metastases (BM).  Methods', ' We immunostained neurosurgical specimens of patients with newly diagnosed single brain metastasis for CD3, CD8, CD45RO and FOXP3 and used previously published semiquantitative evaluation criteria.  Results', ' 118 BM specimens of patients with lung cancer (62/118; 52%), breast cancer (17/118; 14%), melanoma (6/118; 5%), kidney cancer (10/118; 8%) or another primary tumor (23/118; 19%) were available for this study. Dense infiltration with CD3+ TILs was observed in 64/118 (54%) specimens, with CD8+ TILs in 70/118 (59%), with CD45R0+ TILs in 72/118 (61%) and with FOXP3+ TILs in 26/118 (22%) specimens. Dense CD3+ TILs infiltration was more frequently observed in lung cancer, melanoma and kidney cancer BM than in breast cancer BM (p=0.024; Chi square test). Melanoma BM had more frequently dense infiltration with FOXP3+ TILs (p=0.003; Chi square test) than other BM subtypes. Density of CD3+, CD8+, CD45RO+, or FOXP3+ TILs did not correlate with preoperative steroid application (p>0.05; Chi Square test). Patients with dense infiltration of CD3+ TIL had significantly improved OS (27 vs. 12 months; p=0.002; log rank test). Further, dense infiltration with CD8+ TILs was associated with improved OS (16 vs. 12 months; p=0.048; log rank test) and large peritumoral edema on the preoperative MRI (p=0.03; Chi Square test). Dense infiltration with CD45RO+ TILs was correlated with improved survival prognosis (18 vs. 8 months; p=0.01; log rank test). Patients with dense infiltration of FOXP3+ TILs had an impaired survival prognosis (6 vs. 16 months; p=0.05; log rank test). A composite immuno score showed a strong association with median OS (27 months for cases CD8+/CD45RO+/FOXP3- infiltrates and 6 for cases with CD8-/CD45RO-/FOXP3+ infiltrates; p=0.001 log-rank test).  Conclusions', '  Dense TILs infiltrates are common in BM and correlate with the amount of peritumoral brain edema and improved survival prognosis. Further studies should investigate the therapeutic impact of immunomodulatory agents in patients with BM.']",
        "Doc_id":"ASCO_129576-144",
        "Doc_title":" Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.",
        "_version_":1606189028511580160},
      {
        "Meeting_name":" Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.",
        "Background":"['Background', ' Expression of inhibitory immune checkpoints (ICPs) within tumors has emerged as an important barrier for effective anti-tumor immunity. Antibody-mediated blockade of ICPs can lead to durable responses in patients. Interestingly, only a small subset of tumor infiltrating lymphocytes (TILs) express these checkpoints and there is a need to better understand the characteristics of this subset. We undertook this study to understand characteristics of TILs within melanoma. Methods', ' We used single cell mass cytometry, gene expression profiling of purified T cell subsets, T cell receptor (TCR) sequencing as well as functional studies to understand the characteristics of TILs in melanoma patients (n=50). We also performed exome sequencing of tumor cells in some patients. Results', ' We find that TILs are functionally and phenotypically distinct from circulating T cells. They express higher levels of inhibitory ICPs (PD-1, TIM-3) and secrete less IL2, IFNg and TNFa than T cells in circulation. Expression of vascular endothelial growth factor within tumors correlated with reduced T cell infiltration. Expression of ICPs (PD-1, TIM-3, PD-L1) were enriched in T cells with a phenotype and expression profile of tissue resident memory T (TRM) cells with most cells expressing multiple checkpoints. Within the myeloid compartment, ICPs were predominantly expressed on CD14+CD16+ subset. TCR sequencing revealed that individual melanoma metastases revealed that the top clones within each of the lesions have distinct TCRs. Concurrent TCR and tumor exome sequencing of individual metastases in the same patient revealed that inter-lesional diversity of TCRs exceeded differences in mutation/neoantigen load in tumor cells. Conclusions', ' Our findings suggest that TRM cells and CD16+ myeloid cells may be the major target of ICP blockade within tumors. The ability to activate, and retain TRM cells may be an important determinant of the T cell content of the tumor microenvironment and should be a goal for future vaccines. Importantly, our study illustrates inter-lesional diversity of TCRs within individual metastases which may differentially impact the outcome of immune therapy at each site.']",
        "Doc_id":"ASCO_178613-194",
        "Doc_title":" Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.",
        "_version_":1606189029644042240},
      {
        "Meeting_name":" Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model",
        "Background":"['Dasatinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia, has been shown to exert immunomodulatory effects in addition to direct oncokinase inhibition. Recently, we observed that dasatinib induces a rapid (within one hour after oral administration) and marked mobilization of lymphocytes (up to 8-fold increase in lymphocyte count), which closely follows the drug plasma concentration. In addition, in a subgroup of patients a clonal expansion of large granular lymphocytes occurs, which is correlated with good therapy response.As dasatinib-induced immunomodulatory effects are not leukemia specific, we aimed to exploit this activity to slow down or inhibit the growth of a syngeneic murine melanoma model and to characterize in detail the anti-tumor immune responses.Ovalbumin expressing murine melanoma cell line B16.OVA was grown under the skin of immunocompetent mice. The mice (n=6/group) were treated daily i.g. either with 30 mg/kg dasatinib or vehicle only. Blood was collected before tumor transplantation, before treatment, and on treatment days 4, 7 and 10. Tumor volumes were measured manually and specific growth rate was calculated based on the first and the last day of the treatment. In addition to white blood cell differential counts, immunophenotyping of blood and tumor homogenate was done by flow cytometry using antibodies against CD45.1, CD3, CD4, CD8b and NK1.1, and SIINFEKL-pentamer to detect B16.OVA-specific cells. To assess the functional properties of lymphocytes, we used antibodies against immune checkpoint inhibitors CTLA-4 and PD-1, and a degranulation marker CD107.On the 10th day of treatment, the tumor volumes were smaller in dasatinib group compared to control group, and there was a significant decrease in the tumor growth rate (0.06 vs. 0.18, p=0.01). Furthermore, dasatinib treated mice had increased proportion of CD8+ cells in the circulation (21% vs. 14%, p=0.04) and the CD4/CD8 ratio was significantly decreased (1.39 vs. 1.52, p= 0.04). During the tumor growth the mean CTLA-4 expression on CD8+ cells increased from 1.2% to 9% in the control group, whereas, in dasatinib group the increase was more modest (1.2% to 5.7%). Interestingly, 80% of tumor infiltrating CD8+ cells expressed PD1 antigen compared to <5% of PD1 positive CD8+ cells in the peripheral blood suggesting lymphocyte anergy or exhaustion induced by tumor cells.To conclude, dasatinib treatment slowed down the tumor growth in B16.OVA mouse model, which could be associated with the immunomodulatory effects of dasatinib. However, combinatorial treatment regimens may be needed as dasatinib is not able to fully break the immune cell anergy induced by tumor cells.']",
        "Doc_id":"AACR_2014-2587",
        "Doc_title":" Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model",
        "_version_":1606189027078176768},
      {
        "Meeting_name":" Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy",
        "Background":"['There have been significant advances in the treatment of metastatic melanoma through targeted and immunotherapy, however a significant proportion of patients still progress on these regimens with many experiencing mixed responses. Intense research efforts to better understand resistance are underway, and multiple molecular resistance mechanisms to targeted therapy have been identified. The appreciation of genetic heterogeneity as a contributor to resistance to therapy has grown, though immune heterogeneity has been poorly characterized. The goal of the present study is to better understand the molecular and immune heterogeneity in synchronous melanoma metastases at the time of disease progression. In this study, we prospectively evaluated 32 tumors from 15 patients who were treatment-nave (n = 4), or had received prior targeted (n = 4) or immunotherapy (n = 7). Whole exome sequencing demonstrated between 4-41% of non-synonymous exonic mutations (NSEM) were restricted to individual tumors within a patient. Deep profiling of infiltrating immune cell subsets by flow cytometry and immunohistochemistry analyses confirmed the immune infiltrate between synchronous metastases to be highly heterogeneous, specifically in regards to CD4 and CD8 T lymphocytes. In aggregate, 92% of these T cell clones were unique to distinct tumors within the same patient, with limited overlap with clones detected in the blood. NetMHC3.4 neoantigen prediction demonstrated a large fraction of predicted neoantigens were restricted to individual tumors, with over 10% of these presenting extremely high predicted affinity. Importantly, analysis of RECIST measurements of individual lesions within the same patient suggested this molecular and immune heterogeneity could contribute to differential tumor growth and response to therapy within the same patient. This has important clinical implications, and suggests a single tumor biopsy may not be sufficiently representative of the molecular and immune landscape of multiple tumors within the same individual.']",
        "Doc_id":"AACR_2016-2392",
        "Doc_title":" Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy",
        "_version_":1606188992898793472},
      {
        "Meeting_name":" Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy.",
        "Background":"['Background', ' Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) is a promising therapy for the treatment of metastatic melanoma. Trials at the NCI have shown a 50% response rate. However, outside of the NCI, ACT has been quite limited and little is known about how patient characteristics and prior treatment affect large-scale TIL expansion needed for treatment. Methods', \" As part of a phase II melanoma ACT clinical trial at M. D. Anderson Cancer Center, we evaluated how clinical characteristics such as age, gender, biopsy site, melanoma type, primary tumor location, and prior treatment of patients (N=134) affected TIL expansion rates. 159 isolated metastatic melanomas (19 patients having >1 tumor harvest) were analyzed for the ability to expand a minimum of 40 million TIL, considered a minimum number for the subsequent rapid expansion protocol (REP) needed for TIL infusion. Effects of these parameters on TIL anti-tumor reactivity and TIL/tumor fragment were also analyzed. Statistical analysis was done by either Fisher's Exact test, Wilcoxon Rank Sum test, or Kruskal-Wallis Test. Results\", ' 54.7% of the samples evaluated generated  40 million TIL, and 70% of 70 samples tested had anti-tumor reactive TIL. There was a significant relationship between age categories (p=0.0216) and gender (p=0.0164) on TIL expansion success. Younger patients did the best and females did better than males (odds 2.19, p=0.044). The site of the primary melanoma affected success of TIL expansion (p=0.0059), while no effect of tumor biopsy site and histological type was found. Prior chemotherapy (or biochemotherapy) greatly reduced TIL growth (odds 0.32, p=0.010) when compared to no prior therapy. Multivariate linear regression analyses showed that prior chemotherapy decreased TIL/tumor fragment yield by 6.19 million (p=0.0004) while immunotherapy increased it by 3.51 million (p=0.16) compared to no prior therapy. Total TIL yield or TIL/tumor fragment did not correlate with patient overall survival. Conclusions', ' Parameters such as age, sex, primary melanoma site, and prior therapy significantly affect TIL expansion and should be considered in selecting patients for melanoma ACT.']",
        "Doc_id":"ASCO_32543-65",
        "Doc_title":" Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy.",
        "_version_":1606189011166035968},
      {
        "Meeting_name":" Neutralization of IL-10 enhances antitumor efficacy of dendritic cell-targeting MIP-3-gp100 vaccine by way of type-I interferons in B16F10 mouse melanoma model.",
        "Background":"['The chemokine MIP-3 (CCL20) binds to CCR6 found on immature dendritic cells. Vaccines fusing MIP-3 to gp100 have been shown to be effective in therapeutically alleviating melanoma in mouse models. Other studies have provided evidence that IL-10 neutralizing antibodies enhance immunological melanoma therapies by modulating the tolerogenic tumor microenvironment. Here, we report that neutralizing IL-10 enhances the therapeutic anti-melanoma efficacy of a MIP-3-gp100 DNA vaccine. The current studies utilize the B16F10 syngeneic mouse melanoma model system. The MIP-3-gp100 DNA vaccine is administered intramuscularly (i.m.) into the tibialis muscle, followed immediately by i.m. electroporation. The standard therapeutic protocol was the following', ' challenge with lethal dose of B16F10 cells (5x104) on day 0; vaccinate with 50g vaccine plasmid on days 3, 10, and 17; and administer 150g of IL10 antibody intra-tumorally beginning on day 5, once every three days for up to six doses. Tumor sizes, growth, and survival were all assessed. Treatment responses were characterized by flow cytometric analysis of tumor infiltrate. Vaccine-specific T-cells were delineated by gp10025-33 stimulation followed by intracellular cytokine staining for IFN- and assessment by flow cytometry. The mechanism of IL-10 efficacy was explored by RT-PCR and confirmed with a knockout mouse model. With this therapeutic protocol, we demonstrate for the first time that a therapy neutralizing IL-10 additively enhances the anti-tumor efficacy of a MIP-3-gp100 vaccine, leading to significantly smaller tumors, slower growing tumors, and overall increases in mouse survival. Surprisingly, the additive effects of IL-10 were not shown to be directly mediated by any T-cell parameter tested, including vaccine-specific tumor infiltrating lymphocytes (TILs), total TILs of either CD4+ or CD8+ subset, regulatory T-cells, granzyme positive T-cells, and others. We discovered, however, that IFN-4 transcripts in the tumor were significantly upregulated in mice given vaccine and IL-10 compared to vaccine alone. Furthermore, infiltration into the tumor of plasmacytoid dendritic cells, known to be professional IFN-producing cells, were enhanced with the combination therapy. A mouse model with IFNR1 knocked out eliminated the protection provided by IL-10, demonstrating that the additional therapeutic value of IL-10 is primarily mediated by type-I interferons. In conclusion, efficient targeting of antigen to immature dendritic cells with a chemokine fusion vaccine offers a potential alternative approach to the ex vivo dendritic cell antigen loading protocols currently undergoing clinical investigation. Combining this approach with an IL-10 neutralizing antibody therapy that modulates the tolerogenic tumor microenvironment offers promise as a novel melanoma therapy.']",
        "Doc_id":"AACR_2017-1593",
        "Doc_title":" Neutralization of IL-10 enhances antitumor efficacy of dendritic cell-targeting MIP-3-gp100 vaccine by way of type-I interferons in B16F10 mouse melanoma model.",
        "_version_":1606189017523552256},
      {
        "Meeting_name":" Targeting TIGIT and PD-1 to increase the expansion and function of tumor antigen-specific CD8+ T cells in melanoma patients",
        "Background":"['T-cell Immunoglobulin and ITIM Domain (TIGIT) is an inhibitory receptor expressed by activated T cells, regulatory T cells and NK cells. Here, we show that tumor antigen (TA)-specific CD8+ T cells and CD8+ tumor-infiltrating lymphocytes (TILs) upregulate TIGIT and most often co-express TIGIT and PD-1 in melanoma patients. CD8+ TILs downregulate CD226, supporting an imbalance of TIGIT/CD226 expression in metastatic melanoma. TIGIT is a marker of early T cell activation, which is further upregulated by T cells upon PD-1 blockade and by dysfunctional PD-1+Tim-3+ TA-specific CD8+ T cells. PD-1+TIGIT+, PD-1TIGIT+ and PD-1+ TIGIT CD8+ TILs exhibit similar functional capacities ex vivo, suggesting that TIGIT upregulation alone or together with PD-1 is not a marker of T cell dysfunction. However, in the presence of TIGIT ligand-expressing cells, TIGIT blockade adds to PD-1 blockade to increase the proliferation, cytokine production and degranulation of TA-specific CD8+ T cells and CD8+ TILs. Collectively, our findings show that TIGIT together with PD-1 regulate the expansion and function of TA-specific CD8+ T cells and CD8+TILs in melanoma patients. They also support the use of dual TIGIT and PD-1 blockade to stimulate potent antitumor CD8+ T cells responses in patients with advanced melanoma.']",
        "Doc_id":"AACR_2015-459",
        "Doc_title":" Targeting TIGIT and PD-1 to increase the expansion and function of tumor antigen-specific CD8+ T cells in melanoma patients",
        "_version_":1606188972248137728},
      {
        "Meeting_name":" Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma",
        "Background":"['Background', ' Nivolumab, a fully human anti-programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has shown encouraging clinical activity in melanoma. We evaluated the pharmacodynamic effects of nivolumab on immune endpoints in patients (pts) with advanced melanoma in an exploratory phase 1 study (NCT01621490).Methods', ' 85 pts (41 and 44 anti-CTLA-4 therapy-nave and refractory, respectively) received nivolumab 3 mg/kg IV Q2W in 56-day cycles. Tumor biopsies were obtained at baseline (B/L) and on treatment during Cycle 1, Week 4 (C1Wk4). Response was assessed during the last week of each cycle. The primary objective was to evaluate the pharmacodynamic activity of nivolumab on immune biomarkers, including circulating T-cell subsets (by multiparametric flow cytometry), serum interferon (IFN) and IFN-induced factors (by multiplex immunoassay), and T-cell infiltration in the tumor microenvironment (by immunohistochemistry for CD3, CD4, CD8, PD-1 and FOXP3). Secondary objectives included safety, efficacy, and the association between tumor PD ligand-1 (PD-L1) expression and clinical responses.Results', ' Across all 85 pts, the objective response rate was 25%, with 2 pts having a confirmed complete response. The safety profile was consistent with prior nivolumab monotherapy trials. Of 85 pts, 34 had evaluable biopsies at B/L and C1Wk4. Increases in tumor infiltrating lymphocytes (TILs) at C1Wk4 relative to B/L were seen in most pts; 65% of pts had an increase in CD3+ T cells. Expression of other TIL markers CD4, CD8, FOXP3 and PD-1, correlated well with one another and CD3 after treatment (C1Wk4; r = 0.69-0.93, P<0.0001). Increased TIL, in particular CD3+ and CD8+, was associated with response; 100%/88% of responders had elevated CD3+/CD8+ TILs compared with 54%/58% of non-responders. PD-L1 expression was not consistently modulated between B/L and C1Wk4 (30 matched samples); however, highest PD-L1 expression (C1Wk4) was accompanied by highest TIL levels (C1Wk4). No consistent change in the frequency of activated peripheral T-cell subsets (HLA-DR+ or ICOS+, CD4 and CD8 T cells) was seen with nivolumab treatment, but peripheral increases in serum IFN--stimulated cytokines were observed. Mean concentrations of serum CXCL9 and CXCL10 increased 2.2- and 1.1-fold from B/L, respectively, 43 days after initial dose; no association was apparent between the increases and response.Conclusions', ' Nivolumab monotherapy is marked by increased TIL, inclusive of cytotoxic CD8 T cells, and FOXP3+ T regulatory cells and these increases are associated with response. Unlike ipilimumab, nivolumab treatment does not demonstrate consistent increases in circulating activated T cells. However, increases in peripheral IFN--stimulated cytokines, CXCL9 and CXCL10 are observed, presumably derived from the tumor microenvironment. Further characterization of the effects of nivolumab on the tumor microenvironment is ongoing.']",
        "Doc_id":"AACR_2015-2855",
        "Doc_title":" Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma",
        "_version_":1606189036229099520},
      {
        "Meeting_name":" Investigation of the immune infiltrate of melanoma metastases under immune checkpoint inhibition.",
        "Background":"['Background', ' Tumor infiltrating lymphocytes (TIL) play a crucial role in the therapeutic impact of immune checkpoint blockers. Methods', ' We investigated metastases from 56 melanoma patients before and during treatment with immune checkpoint blockers (i) immunohistochemically, (ii) with TCR repertoire profiling and (iii) analysis of the transcriptome. The patients were treated with ipilimumab (n = 25) or pembrolizumab (n = 23) or ipilimumab/nivolumab (n = 7); half of them had a disease control, the other half progressed as best response to treatment. Results', ' In contrast to previous reports immunohistochemical analysis of the immune infiltrate revealed no significant difference in the number of CD8+ TILs in pretreatment samples of responders and non-responders. Instead, the number of CD4 + TILs including regulatory T cells (Treg) and the number of PD-1 + cells was higher in responders especially when receiving pembrolizumab. Samples taken at least 6 weeks after start of the immune checkpoint blocker showed a significant higher number of immune cells in responders through all T cell subsets (CD3,4,8,FoxP3, PD-1), B cells (CD20) as well as macrophages (CD68, CD163). TCR repertoire profiling by deep TCR sequencing demonstrated that responders develop a more diverse repertoire under treatment (p = 0.05). Pretreatment samples as well as the size of the top 10 TCR clones posttreatment did not differ significantly in responders and non-responders. By RNA sequencing no differential expression profiles between responders and non-responders was found pretreatment. Posttreatment samples expressed different genes compared to pretreatment samples in responders including MHC molecules, CDK2/4, Myc, TNF family members and different apoptosis-inducing genes. There was no differential gene expression in non-responders pre- and posttreatment. Conclusions', ' Pretreatment metastases from responders and non-responders do not differ much. With treatment responding patients have significant higher numbers of immune cells including T- and B- cells as well as macrophages and develop a more diverse TCR repertoire. RNA sequencing revealed a differential expression pre- versus posttreatment only in responding patients.']",
        "Doc_id":"ASCO_191935-199",
        "Doc_title":" Investigation of the immune infiltrate of melanoma metastases under immune checkpoint inhibition.",
        "_version_":1606189006517698561},
      {
        "Meeting_name":" miR-126 reduces the tumorigenicity of melanoma cells in vitro and alters the melanoma microenvironment",
        "Background":"[\"The microRNA (miRNA) miR-126 is highly expressed in endothelial cells and often reported as down-regulated in cancer. The present study thoroughly examines the functional relevance of miR-126 in melanoma progression and suggests a central role of this miRNA as prognostic marker and modulator of the melanoma microenvironment. Initially, the expression of miR-126 was quantified in two independent, isogenic cell line model series of melanoma progression. To further explore its functional role, two stable over-expression cell lines were generated and subjected to an extensive series of in vitro assays. Subsequently, the prognostic relevance of miR-126 was assessed via in situ hybridization on a large melanoma tissue microarray cohort. In both melanoma cell line systems, miR-126 expression was inversely correlated with the level of tumorigenicity. Over-expression of miR-126 in vitro resulted in a significant decrease in colony formation, both in the presence and absence of anchorage, while cell viability remained unaffected. Using a three-dimensional spheroid invasion assay, over-expression of miR-126 significantly reduced cell invasiveness. In addition, a substantial reduction in tumor cell adhesion to VCAM-1 coated micro-channels was observed when the adhesive capacity of miR-126 over-expressing cells was examined under shear stress using the Cellix's Microfluidic Platform. Using in situ hybridization on tissue microarrays containing melanoma tissue, miR-126 expression was evident in the tumor vasculature whereas melanoma cells did not appear to express miR-126. Analysis of the degree of vascular staining revealed a significant association between lower vascular miR-126 expression and lower T-stage. In addition, high vascular miR-126 scores were significantly associated with prolonged overall survival, in particular in high grade tumors (T-stages 3 and 4). Overall, miR-126 over-expression was shown to trigger a less aggressive phenotype in melanoma cells in vitro. Nonetheless, its clinical relevance in melanoma may primarily be mediated by the tumor vasculature. Depletion of miR-126 has previously been linked to a number of tumor relevant phenotypes, including inflammation. Vascular up-regulation of the miR-126 target protein VCAM-1 may mediate increased tumor infiltration of lymphocytes and macrophages, which are known to play a crucial role in tumor development and prognosis. This renders miR-126 an exciting target for closer investigation with regard to its role in the melanoma microenvironment.\"]",
        "Doc_id":"AACR_2012-4366",
        "Doc_title":" miR-126 reduces the tumorigenicity of melanoma cells in vitro and alters the melanoma microenvironment",
        "_version_":1606188991699222528},
      {
        "Meeting_name":" Adoptive cell therapy for melanoma patients using tumor-infiltrating lymphocytes, lymphodepleting chemotherapy, and low-dose interleukin-2.",
        "Background":"['Background', '    Adoptive T cell therapy is based on isolation of tumor infiltrating lymphocytes (TIL) from autologous tumor, in vitro activation and expansion, and the reinfusion of these cells into a lymphodepleted patient. Together with high-dose interleukin (IL)-2 this treatment has in a few other countries successively been given to patients with advanced malignant melanoma and an impressive 50% response rate has been observed. Here we report the experience from a Danish Translational Research Center using low-dose subcutaneous IL-2 injections.  Methods', '    A pilot trial including patients with metastatic melanoma, PS 1, age <70, measurable and progressive disease, and no CNS involvement. Six patients were treated with lymphodepleting chemotherapy, TIL infusion, and 14 days of low-dose IL-2, 2 MIU/day.  Results', '    Low-dose IL-2 considerably decreased the toxicity of the treatment with no grade 3-4 events related to this drug. Two of the 6 treated patients have an ongoing complete response (30+ and 7+ months), 2 patients had stable disease (4.5 and 5 months) and 2 patients progressed shortly after treatment. Five patients went through surgery but were not treated because of rapid disease progression (2), development of brain metastases (2) or the inability to grow cells (1).  Tumor-reactivity of the infused cells and peripheral monocytes before and after therapy were analyzed. High tumor responses in the infusion products were correlated to clinical response and also an induction of tumor reactive T cells were seen in the peripheral blood for 1 patient in complete response.  Conclusions', '    Complete and durable responses are induced after treatment with adoptive cell transfer in combination with low-dose IL-2 questioning the need for high and toxic doses of IL-2.']",
        "Doc_id":"ASCO_97793-114",
        "Doc_title":" Adoptive cell therapy for melanoma patients using tumor-infiltrating lymphocytes, lymphodepleting chemotherapy, and low-dose interleukin-2.",
        "_version_":1606189031031308289},
      {
        "Meeting_name":" The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma",
        "Background":"['Background', ' Adoptive cell therapy (ACT) of autologous tumor-infiltrating lymphocytes (TIL) can produce long lasting treatment responses in patients (pts) with metastatic melanoma. In our initial report of 31 treated pts, we demonstrated overall response rate (ORR) of 48%. Due to the evolution of treatment options for metastatic melanoma with heavy reliance on immunomodulatory therapies, we sought to re-evaluate responses in the era of checkpoint blockade. Methods', ' Pts receive treatment consisting of 7 days of lymphodepleting chemotherapy consisting of cyclophosphamide and fludarabine. High dose interleukin-2 (720,000 IU/kg IV q 8 hrs up to 15 doses) was infused after TIL infusion. Responses were assessed by imaging per irRC. Results', ' A total of 74 pts have been treated in our initial TIL study with an updated ORR assessment of 43%. Stratification of pts according to their checkpoint blockade immune-modulator therapy prior to TIL ACT, demonstrated that prior Ipilimumab (Ipi) decreased ORR to 33% compared to 51% in checkpoint nave pts and decreased overall survival (OS) post-TIL therapy (median 7.7 vs 24.6 months respectively). There were too few pts to assess the impact of anti-PD1 as a single agent. A multiparametric analysis revealed that LDH levels at the time of therapy mainly influences OS and ORR to TIL but still could not invalidate the impact of Ipi prior to TIL ACT. The durability of the response was also found to be different between the 2 groups (30% for Ipi prior and 50% No Ipi prior). This new reality also impacted previously reported parameters that correlated with ORR to TIL ACT such as the expression of B-and-T lymphocyte attenuator (BTLA) on CD8+ TIL. Interestingly, assessment of mutation load (ML) of the tumors prior to TIL ACT showed that the check point nave group display a high ML ( > 100) within their tumor whereas some patients who had Ipi prior to TIL have a low ML ( < 100). Conclusions', ' Our preliminary analysis shows that pre-treatment with Ipi decreases ORR to TIL ACT. Understanding how prior ipi modifies TIL, the tumor and microenvironment will help to define the full extent of the impact and how to best treat Ipi refractory pts with TIL. Clinical trial information', ' NCT00338377']",
        "Doc_id":"ASCO_178181-194",
        "Doc_title":" The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma",
        "_version_":1606188978437881856},
      {
        "Meeting_name":" Dissecting the effect of age on immune response in melanoma patients.",
        "Background":"['Background', '  Older ageat diagnosis has been shown to be an independent negative prognostic factor in melanoma. Nevertheless, no biological basis for the impact of age on melanoma has been defined. In this study, we examined the impact of patient age on cellular immune response as well as response to immunotherapy treatment in the adjuvant setting in a well-studied cohort of melanoma patients.  Methods', '  A prospectively-enrolled cohort of patients presenting with stage III melanoma at NYU was studied. Associations between age at diagnosis and presence of tumor-infiltrating lymphocytes (TILs), response to immunotherapy, and stage IV progression-free survival (PFS) and overall survival (OS) were tested by log rank test. In addition, checkpoint PD-L1 expression was tested in pre-treatment tumor specimens in a subset of patients.  Results', '  316 patients (median follow-up for survivors', ' 45 months) were studied and categorized into two groups by age at diagnosis', ' 60 years (n=163) and >60 years (n=153). The two groups were well matched by clinical substage at presentation. Patients in the older group had significantly shorter OS compared to the younger group (P=0.039). TILs were absent in a significantly larger proportion of the older compared to younger group (35% versus 21%, respectively; P=0.017). Among patients who received adjuvant immunotherapies (n=86), patients in the older group had significantly shorter OS (P=0.048), with a similar trend for PFS (P=0.059). No significant survival differences were observed among patients who received non-immunotherapy treatments (n=57) or no adjuvant treatment (n=165). We reasoned that PD-L1 expression could explain the difference in response to immunotherapy treatment by age; however, no significant difference was observed in PD-L1 expression by age among 66 cases tested at the time of submission.  Conclusions', '  Data suggest that decreased immune response and a consequent lack of response to immunotherapy might be contributing, at least in part, to the worse prognosis of older melanoma patients. PD-L1, a key inhibitory receptor, does not seem to be responsible for the observed impaired immune response. Treatment strategies for melanoma patients may need to account for biological differences by patient age.']",
        "Doc_id":"ASCO_130004-144",
        "Doc_title":" Dissecting the effect of age on immune response in melanoma patients.",
        "_version_":1606188992239239168},
      {
        "Meeting_name":" Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.",
        "Background":"['Background', '    PD-1 activation by ligands (PD-L1 and PD-L2) inhibits T-cell activation and facilitates cancer progression. Trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types, but the complexity of PD-L1 expression and patterns of PD-1 tumor infiltrating lymphocytes (TIL) make development of the predictive biomarker challenging. We analyzed distribution of PD-1+ lymphocytes and PD-L1 expressing tumor cells in common cancer types and their association with other cancer characteristics.  Methods', '    339 carcinomas  (lung, breast, prostate, colon, ovary, endometrium, kidney, liver, bladder, pancreas) and 24 melanomas were profiled (Caris Life Sciences) using immunohistochemistry, in-situ hybridization and next generation sequencing (Illumina TruSeq panel).  Results', '  PD-1+ lymphocytes are consistently identified in reactive, peri-tumoral lymphoid follicles, but intra-tumoral PD-1+ lymphocytes in direct cell-to-cell contact with cancer cells were less common (e.g. 50% of breast cancers, 58% melanomas and 75% of NSCLC). PD-L1 was consistently detected in tumor microenvironment (endothelium, macrophages, myofibroblasts), but specific cancer cells expression of PD-L1 was less common (e.g. 43% BrCA, 52% NSCLC, 21% sporadic CRC), except in melanomas which were PD-L1+ in 92% of cases. Intra-tumoral PD-1+ TILs and PD-L1+ cancer cells were co-present in 58% melanomas, 44% NSCLC, 28% breast carcinomas and 8% CRC. Triple-negative breast cancers (TNBC) were frequently PD-L1 positive (59% all TNBC and 100% in metaplastic TNBC). In NSCLC, PD-1+/PD-L1+ tumors were mostly seen in the absence of targetable genetic abnormality (i.e. EGFR, ALK and ROS1 negative).  Conclusions', '  The study provides useful guidance for evaluation of PD-1 and PD-L1 as potential biomarkers for clinical trials as well as their frequency distribution in different types of malignancies. Not all patients respond to immunotherapy and intratumoral PD-1+ TILs and cancer specific PD-L1 expression may be required for the potential benefit to immune checkpoint inhibition therapy.']",
        "Doc_id":"ASCO_134456-144",
        "Doc_title":" Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.",
        "_version_":1606189016584028160},
      {
        "Meeting_name":" Characterizing the tumor microenvironment (TME) in primary melanomas using multiplex immunohistochemistry (mIHC).",
        "Background":"['Background', ' Biomarkers are needed in primary melanoma to risk stratify for adjuvant trials. High levels of infiltrating cytotoxic (CD8+) T lymphocytes (CTLs) and low levels of CD68+ macrophages (M) may correlate with prolonged survival but quantification methods are not standardized for clinical practice. HLA-DR is a marker of M activation not expressed by suppressor myeloid cells. A novel pathology technique using mIHC allows for quantitative and spatial analysis of immune cell subsets. Methods', ' In a pilot set of stage II/III primary melanomas from Columbia University Medical Center (n = 94), clinical follow up is available for 51 cases. 32 had no evidence of recurrence at last follow up (minimum 2 years) while 19 died of melanoma. 5m slides were stained using Opal multiplexed IHC (mIHC) for DAPI, CD3, CD8, CD68, SOX10, HLA-DR and Ki67. Tumor areas were pre-selected by a dermatopathologist, visualized using Mantra (Perkin Elmer) and analyzed using inForm (Perkin Elmer) and Spotfire (TIBCO). Results', ' In all patients (n = 94), CTLs are farther from tumor (SOX10+) cells when they are proliferating (Ki67+) (p < 0.0001***), while they are closer to M when they are activated (HLA-DR+) (p = 0.0002***). Next, we evaluated impact on prognosis using disease specific survival (DSS) as an outcome based on median value (n = 51). In this exploratory study no correction for multiple comparisons was made. We find that CTL density correlates with prolonged DSS in tumor (p = 0.0185*) but not in stroma (p = 0.1630 ns). Ratio of density of CD8/CD68+HLA-DR- correlates with DSS in both tumor (p = 0.027*) and stroma (p = 0.017*). Finally, distance from CTLs to HLA-DR- M was significantly greater in non-recurrent melanomas as compared to recurrent ones (p = 0.0167*). Conclusions', ' HLA-DR expression on M and Ki67 expression on tumor cells correlate with position of CTLs in TME in primary melanoma. CTL density is a favorable prognostic marker while HLA-DR non-expressing M may favor tumor progression. Quantitative mIHC allows for accurate spatial analysis of immune subsets within the TME and the development of novel, more accurate and potentially clinically relevant biomarkers.']",
        "Doc_id":"ASCO_194574-199",
        "Doc_title":" Characterizing the tumor microenvironment (TME) in primary melanomas using multiplex immunohistochemistry (mIHC).",
        "_version_":1606189040778870784},
      {
        "Meeting_name":" Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1.",
        "Background":"['Background', ' IL-10 has anti-inflammatory properties but stimulates the cytotoxicity and proliferation of CD8 T cells. The observation that T cell receptor mediated activation induces the expression of IL-10 receptors and PD1 on CD8 T cells, provides the mechanistic rationale for combining AM0010 and anti-PD1 in the clinic. Tolerability and anti-tumor activity of AM0010 alone was established in the ongoing phase 1 study. Objective responses were observed in pts with uveal melanoma, cutaneous T cell lymphoma and in 4 of 15 pts with RCC. Methods', ' Pts with advanced melanoma, RCC or NSCLC were treated with AM0010 (daily SC) and Pembrolizumab (q3wk IV). Tumor responses were monitored following irRC. Immune responses were measured by analysis of serum cytokines, activation of blood derived T cells, peripheral T cell clonality and immunohistochemistry of tumor infiltrating CD8 T cells. Results', ' In 19 pts, AM0010 10 mg/kg (n=13) or 20 mg/kg (n=6) in combination with anti-PD1 (2mg/kg) was well tolerated (observation period 10-15 months). All TrAEs were transient and DLTs or TrAEs leading to study discontinuation were not observed. There was no colitis, pneumonitis, or endocrine disruptions. G3/4 TrAEs were observed in 7 of 19 pts and included pruritus (1), anemia (3), thrombocytopenia (3) and malaise (1). Objective responses (PR/CR) were observed in 4 of 8 RCC pts, 2 of 5 NSCLC pts and 2 of 6 melanoma pts. 2 additional melanoma pts had tumor increase followed by decrease (pseudoprogression). AM0010 / anti-PD1 increased Th1 cytokines (IL-18, IFNg, IL-7) and the number and proliferation of PD1+ activated CD8 T cells while decreasing the proliferation of FoxP3+ Tregs and TGFb in the blood. AM0010 / anti-PD1 induced de-novo oligoclonal expansion of T cell clones in the blood without affecting total lymphocyte counts. AM0010 / anti-PD1 increased the number of tumor infiltrating Granzyme+ PD1+ CD8+ T cells in tumor biopsies of treated patients. Conclusions', ' AM0010 in combination with anti-PD1 is well-tolerated. The clinical activity and the observed CD8 T cell activation encourages the continued exploration of AM0010 in combination with anti-PD1. Clinical trial information', ' NCT02009449Best ResponseSDPRCRCBR(SD, PR, CR', ' > 24 weeks)RCC (n=8)4315NSCLC (n=5)32-4Melanoma (n=6)22-2 (NR)']",
        "Doc_id":"ASCO_169141-176",
        "Doc_title":" Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1.",
        "_version_":1606189003122409472},
      {
        "Meeting_name":" Effect of some cytokine combinations on growth and metastasis of experimental melanoma.",
        "Background":"['Background', ' The purpose of the study was development and experimental validation of new methods of melanoma immunotherapy involving cytokines. Methods', ' The study included 30 57Bl/6 mice with transplantable B16 melanoma. Dynamics of tumor growth, melanoma metastases to the lungs and spleen, morphology of melanoma, spleen and thymus and lymphocyte subsets in the blood and spleen after injected combinations of immunomodulators based on recombinant cytokines  IL-2 (Roncoleukin), IFN- (Ingaron) and TNF- with thymosin (Refnot)  were studied. Results', ' Roncoleukin+Ingaron was the most effective combination that inhibited tumor growth during the therapy and after it by 30-38% and had a marked antimetastatic effect, up to complete absence of metastases in all animals. Morphological study demonstrated that thymus was the most active in this group of mice (a well-developed cortex with densely packed thymocytes); apparently, it was the cause for the increased levels of T-cells in the blood and Th (CD3e+CD4+) in the spleen of tumor-bearing mice compared to controls. The spleen of the mice showed a well-developed white pulp with large follicles, and Th level was the maximal  47.91.5%, while in other groups it ranged from 15 to 35%. Morphological study of tumors revealed extensive necrosis (up to 2/3 of the tumor area), leukocyte infiltration, bleeds, blood clots in the vessel lumen and degenerative changes in tumor cells in all combinations of immunomodulators. Melanoma structure in the control group was typical, and most mice developed small and large metastases, sometimes multiple ones with extensive lung lesions; spleen metastases were observed in some mice. Conclusions', ' The study demonstrated the benefits of a search for optimal combinations of cytokine-based immune drugs to influence effectively an experimental transplantable tumor.']",
        "Doc_id":"ASCO_185552-199",
        "Doc_title":" Effect of some cytokine combinations on growth and metastasis of experimental melanoma.",
        "_version_":1606188990788009984},
      {
        "Meeting_name":" Relationship between liver metastases and PD-1 blockade in melanoma.",
        "Background":"['Background', ' WhilePD-1 blockade is effective in melanoma, durable responses remain elusive. We have previously reported that liver metastasis is associated with reduced response rates and that the fraction of CTLA4 hi/PD-1 hi CD8+ cells (activated-exhausted or T-ex cells) within the TIL is predictive of response to PD-1 blockade. Here, we explore the biology behind liver metastasis in human melanoma and in animal models. Methods', ' Patients with metastatic melanoma with or without liver metastasis were biopsied pre- PD-1 treatment and immune infiltrates were analyzed by FACS. The CD8 fraction was gated on CTLA4 and PD-1. C57BL/6 mice were implanted with a primary subcutaneous tumor and a metastatic tumor in the liver or the lungs (control), and given systemic PD-1 blockade therapy. Results', ' Patients with melanoma and liver metastasis (n = 25) had 15.2% T-ex cells while those without liver metastasis (n = 76) had 26.5 % T-ex cells, p = 0.0092. A T-ex fraction < 20% was significantly associated with lack of PD-1 response, p < 0.005. In C57BL/6 mice implanted with a B16 tumor (subQ & liver) treated with PD-1 antibody, 0/35 mice achieved subQ tumor rejection while in the SubQ only mice 9/30 mice (30%) rejected their tumors. The mean tumor size of mice with Sub Q+liver metastasis was 139.2 mm2 vs subQ only mice 23.4 mm2 at d 14, p = 0.002. Mice with liver metastasis showed a T-ex fraction 31.9% vs 67.3%without liver met, p = 0.0003. In contrast, in mice made lung metastatic, the subQ tumor rejection rate was 7/20 (35%), with T-ex infiltrate at 57.9%. The implantation of liver metastases from an unrelated MC38 tumor does not protect the subQ tumor from immune rejection. Conclusions', ' The presence of liver metastases is associated with reduced response to PD-1 blockade and reduced T-ex infiltrate in patients with stage IV melanoma. Mechanistic studies using a mouse model of syngeneic organ site specific metastasis confirms that the liver metastasis results in reduced antigen specific T cell at distant sites, resulting in reduced response. Site of metastasis may determine immune responsiveness in both mouse models and in humans with melanoma.']",
        "Doc_id":"ASCO_191526-199",
        "Doc_title":" Relationship between liver metastases and PD-1 blockade in melanoma.",
        "_version_":1606189035919769600},
      {
        "Meeting_name":" Immunohistochemical multiplex staining strategies with CD8, CD103, PD-1, FOXP3 and pan melanoma cocktail in tumor infiltrating lymphocytes in melanoma",
        "Background":"['IntroductionTumor-associated immune suppression can lead to defective T-cell mediated antitumor immunity. CD8 T-cells play a critical role in the host defense against cancers and infectious diseases. However, the presence of antigen-specific CD8 T-cells does not always imply that cancers and/or pathogens are efficiently eliminated in the body. In tumor infiltrating lymphocytes (TILS), other markers including CD103, PD-1 and FOXP3 are broadly expressed and have shown a wider range of immunoregulatory and important roles in T-cell activation, T- cell regulatory and programmed cell-death checkpoints. Existing methods can either deliver phenotypic information on homogenous samples such as flow cell cytometry or give immunohistochemical information on single biomarker. However, it would be of advantage to be able to visualize the distributions of multiple biomarkers in TILs that would discriminate stromal cells versus solid tumor. Therefore, a multiplex IHC stain utilizing a melanoma marker as a staining mask that separates the malignant tumor cells from stromal cells maybe a good strategy to facilitate better interpretation.Materials and MethodsMonoclonal mouse antibodies to CD8, FOXP3 and PD-1 and rabbit monoclonal antibodies CD8, CD103 and PD-1 were optimally tittered for single, double and triple stains and visualized with HRP DAB/Black chromogens and/or alkaline phosphatase fast red/blue chromogens. A mouse monoclonal pan melanoma cocktail was visualized with a fast red chromogen and was used as a staining mask for melanoma tumors cells, but not stromal cells.ResultsSingle, double and triple stains that included pan melanoma cocktail (mask) and CD8, CD103 FOXP3 and PD-1 were successfully established. All double and triple stains gave comparable results to single stains. The co-expression of TILs including CD8 and CD103 or CD8 or FOXP3 and PD-1 was easily identified with contrasting chromogens. TILs in stroma tissues and in malignant tumors cells were easily discriminated with the pan melanoma (mask) that stained only tumor cells with fast red chromogen, but did not stain TILS or stromal tissues.ConclusionThe evaluation of TILS in malignant melanoma was enhanced with multiplex stains. TILs in stromal tissues and melanoma tumors cells were easily distinguished with the Pan Melanoma staining mask. These finding may help facilitate important prognostic information and thus may support the rationale for using immunotherapy strategies.']",
        "Doc_id":"AACR_2016-467",
        "Doc_title":" Immunohistochemical multiplex staining strategies with CD8, CD103, PD-1, FOXP3 and pan melanoma cocktail in tumor infiltrating lymphocytes in melanoma",
        "_version_":1606188976622796800},
      {
        "Meeting_name":" Ki67 as a prognostic biomarker for patients with vertical growth phase (VGP) melanomas.",
        "Background":"['Background', ' In VGP melanomas proliferation is reflected in dermal mitotic figures (\"mitogenic\" VGP) and/or tumor cell nests larger than any epidermal nest. An alternative to mitotic rate (MR) to characterize cell proliferation is the expression of Ki67 protein. Since Ki67 is expressed in all phases of the cell cycle except G0, it is potentially a more robust biomarker for proliferation and prognosis than mitoses. Methods', ' To test the hypothesis that Ki67 would replace MR as a prognostic factor, we did a retrospective cohort study of 432 patients with Stage I/II primary VGP melanomas who had at least 10 years of follow up. Tissue sections were stained using the monoclonal antibody MIB-1 to Ki67 and the % of positive melanoma cells were evaluated by two readers. ROC curves for Ki67 and MR were computed. Predicted probabilities (PP) of 10-year melanoma-specific death were computed from 3 multivariate logistic regression models, one for each biomarker (Models 1 and 2) and one with both (Model 3), controlling for established melanoma prognostic factors (thickness, gender, anatomic site, ulceration, regression and tumor infiltrating lymphocytes), and compared. Cross-validation was used to assess differences between using Ki67 and using MR including the differences in PP, Brier scores and the misclassification rates. A decision curve analysis was done to assess the clinical net benefit of the two. Results', ' The areas under the ROC curve (AUCs) for Ki67 and MR, both continuous factors, were 0.69 and 0.79, respectively. In the multivariate analysis, Ki67 expression was significant in Model 1 (OR=1.03, 95% CI', ' 1.01-1.05), mitotic rate was not significant in Model 2 (1.05, 0.99-1.1), and only Ki67 was significant in Model 3 (1.03, 1.01-1.05). The AUCs for the three models were 0.84, 0.84, and 0.85, respectively. Based on cross-validation, there was no difference between the two biomarkers in PP, Brier scores, or misclassification rates. The decision cost analysis demonstrated the same net benefit for the two. Conclusions', ' A prospective study needs to be conducted to confirm that Ki67 and MR are equivalent.']",
        "Doc_id":"ASCO_35294-65",
        "Doc_title":" Ki67 as a prognostic biomarker for patients with vertical growth phase (VGP) melanomas.",
        "_version_":1606189007829467136},
      {
        "Meeting_name":" Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI).",
        "Background":"['Background', ' Metastatic melanoma is associated with poor overall survival. IPI was recently approved to this scenario in first and more lines of treatment in many countries after two landmarks phase III studies. However, this drug benefits only few PTS and nowadays we dont have predictive factors of response. Objective', ' To evaluate clinical and pathological data of PTS treated with IPI and to associate with survival data.  Methods', '  Retrospective analysis of PTS treated with IPI during expanded access(EA) to this drug between 03/2011 and 10/2012.   Results', '   Seventy PTS were treated during EA. Gender (M/F)', ' 29/41, age (median)', ' 58y, ECOG (0/1)', ' 87.2%. Histology', ' 78.5% skin, 14.3% choroid, 4.3% mucosal melanoma, 2.9% others. Stage', ' 50.7% M1c, 34.8% M1a and 14.5% M1b. LDH was above the normal limit in 50% of PTS and 20% had brain metastasis. NSM', ' 81%  3 sites and 19% 4 or more sites. Fifty-six percent received 4 doses of IPI, (71.7% in second line). The main reason to discontinue therapy was progression of disease (PD)', ' 48.2%.  Response evaluation', ' 51.4% PD, 14.3% stable disease(SD), 1.4% partial response (PR) and 4.4% complete response (CR), 12.8% mixed response (MR) and 15.7% were not evaluated. In PTS with PD, 70% had weak lymphocytic infiltrate (LI) (non-brisk) and in PTS with PR or CR, 50% had strong LI (brisk). Median follow-up', ' 6.1months(m). The median PFS and overall survival of entire population was 3.9m and 11.5m, respectively. There was a better PFS in PTS with 3 or less sites of metastasis', ' 5.8m vs 2.7m (p=0.05) (figure 1) and in PTS who received 4 doses of IPI', ' 6.7m vs 2.0m (p=<0.01). There were no difference with respect to LDH and M1 status.  Conclusions', '   In our study, number of sites of metastatic disease and brisk infiltrate were associated with better outcome.']",
        "Doc_id":"ASCO_134211-144",
        "Doc_title":" Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI).",
        "_version_":1606189029788745728},
      {
        "Meeting_name":" Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens",
        "Background":"['Despite the impressive clinical efficacy of immunotherapy in some patients, many still do not respond or progress following an initial response. The molecular mechanisms underlying the tumor resistance in those non-responders remain largely undefined. To address this issue, we set out to perform high-throughput unbiased pooled shRNA screens to identify critical genes that confer immune resistance. Patient-derived melanoma cells were transduced with barcoded pooled lentiviral shRNA libraries that targeted the human kinome, followed by exposure to cytotoxicity mediated by autologous tumor infiltrating lymphocytes. Tumor cells were then subject to genomic deep sequencing and integrated analysis to identify depleted barcodes and corresponding genes. One identified candidate of particular interest is Aurora Kinase A (AURKA), a cell cycle regulator that has previously been shown to contribute to tumorigenesis and correlate with poor prognosis for cancer patients. Importantly, our independent screening with a bioactive compound library also implicated Aurora Kinase as an immune resistance candidate against T cell immunotherapy. Further studies showed that suppression of Aurora kinase activity with a pan inhibitor - AMG900, exhibited a synergistic cytotoxic effect with tumor infiltrating lymphocyte-mediated killing on autologous tumor cells from patients. Furthermore, our Nanostring analysis of tumor biopsies from patients that received adoptive T cell therapy revealed significantly increased expression of AURKA in tumors from non-responding patient when compared with responder counterparts. These results have substantiated the validity of our pooled shRNA screening platform. Further investigations are ongoing to elucidate the underpinnings of Aurora kinase-mediated tumor resistance to immunotherapy and to functionally and physiologically validate other putative targets we have identified.']",
        "Doc_id":"AACR_2016-1441",
        "Doc_title":" Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens",
        "_version_":1606189040689741824},
      {
        "Meeting_name":" Selective histone deacetylase inhibition augments melanoma immunotherapy.",
        "Background":"['Background', ' Histone deacetylases (HDACs) are epigenetic modulators and regulate gene expression. The impact of the HDAC6 selective inhibitor ACY1215 was explored on immune cell biology, with novel implications for the treatment of melanoma patient T cells ex vivo prior to adoptive transfer. Methods', ' T cells were obtained from peripheral blood mononuclear cells of healthy donors and melanoma patients. Tumor infiltrating lymphocytes (TILs) were isolated from surgical biopsies. Cells were treated ex vivo with ACY1215 or DMSO control. Viability was addressed by MTS colorimetric assay. Cytokine levels were evaluated by Luminex. Expression of T cell markers and IFN/CD107a production were assessed by flow cytometry. T cell cytotoxicity was determined by co-culture of TILs and melanoma and analysis of annexin V and propidium iodide. Affymetrix based microarray was performed on TILs for gene expression analysis. Statistical significance of DMSO vs ACY1215 treated T cells was based on paired, two-tailed, students t-test. Results', ' ACY1215 was unique among pan and selective HDAC inhibitors in modulating T cell function, with minimal impact on viability. Treatment of melanoma patient-derived T cells reduced Th2 cytokine production (IL-4, IL-6, IL-10; p < 0.01) and maintained Th1 effector cytokine levels (IFN, IL-2). ACY1215 increased expression of the activation/costimulatory markers CD69 and ICOS (p < 0.05), and enhanced a central memory phenotype expressed by healthy and melanoma patient CD4 and CD8 T cells during ex vivo expansion (p < 0.05), as determined by expression of CD45RO, CD45RA, CD62L and CCR7. In fact, ACY1215 increased central memory TILs derived from multiple cell preparations (e.g. pre and post rapid in vitro expansion; p < 0.05). ACY1215 treated TILs exhibited higher levels of IFN/CD107a expressing CD8 T cells (50% vs 35%, p < 0.05), and enhanced cytotoxicity (50% vs 70% killing of HLA matched targets with DMSO vs ACY1215 treated TILs). Microarray analysis revealed increased expression of genes associated with an inflammatory response and T cell memory in ACY1215 treated TILs. Conclusions', ' ACY1215 augmented T cell proliferation and function during ex vivo expansion, with possible translatable clinical implications.']",
        "Doc_id":"ASCO_170144-176",
        "Doc_title":" Selective histone deacetylase inhibition augments melanoma immunotherapy.",
        "_version_":1606188989002285056},
      {
        "Meeting_name":" Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes.",
        "Background":"['Background', ' As like rising of PD-1 antibody, targeting therapy to tumor immunosuppression have been shown dramatic cure responses in melanoma and other malignancies. However there are still problems that the responders of those checkpoint inhibitors are limited. Recently, it is considered that tumor immunosuppression may be caused by not only cancer cells but also tumor microenvironments (TME). Cancer-associated fibroblasts (CAFs) are one of the major components and have a central role for tumor progression in TME. It has been hypothesized that they can also play an essential role in tumor immunosuppression. In this study, we evaluated the correlation between CAFs and tumor immunity system, especially tumor-infiltrating lymphocytes (TILs) in clinical samples and further in vivo study.']",
        "Doc_id":"AACR_2017-5934",
        "Doc_title":" Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes.",
        "_version_":1606189037884801024},
      {
        "Meeting_name":" Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.",
        "Background":"[\"Interleukin 15 (IL-15) effects on CD8 T and NK lymphocytes hold promise to treat cancer. Fusion proteins have been engineered to provide IL-15 receptor alpha (IL-15R) mediated trans-presentation to lymphocytes and extend the plasma half-life of the cytokine. In this study, we report on a triple fusion protein combining apolipoprotein A-I, IL-15 and IL-15Rs sushi domain. Apolipoprotein A-I conveys IL-15 to high-density lipoproteins (HDL), from which the cytokine is trans-presented by the IL-15R's sushi domain. Such a construction was tested by hydrodynamic gene transfer to the liver of mice. Lethal toxicity was observed upon injection of 10g of the expression plasmid. Mice died from an acute lymphocytic pneumonitis in which T and NK cells dominate a severe inflammatory infiltrate. Importantly, mice devoid of NK cells were not susceptible to such toxicity and mice lacking granzymes A and B also survived the otherwise lethal gene transfer. Lower plasmid doses (<2.5g) were tolerated and dramatically increased the numbers of NK and memory CD8 T lymphocytes in the liver, spleen and lungs, to the point of rescuing the deficiency of such lymphocyte subsets in IL-15R-/- mice. Doses of plasmid within the therapeutic window successfully treated metastatic tumor models, including B16OVA lung metastasis of melanoma and MC38 colon cancer liver metastasis. Sushi-IL15-Apo as a recombinant protein was also bioactive in vivo, became conjugated to HDL and displayed immuno-therapeutic effects against metastatic disease.\"]",
        "Doc_id":"AACR_2013-1223",
        "Doc_title":" Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.",
        "_version_":1606188976193929216},
      {
        "Meeting_name":" Combination immunotherapy with PD-L1 blockade and Poly I",
        "Background":"['Background', ' Programmed death ligand 1 (PDL1) is commonly expressed on the surface of many tumor cells, including breast cancer. The activity of tumor infiltrating lymphocytes (TIL) is inhibited by PDL1. Blocking PDL1 with monoclonal antibodies can prevent this immune suppression and enhance anti-tumor activity. Polyinosinic-polycytidylic acid (Poly I', 'C) is a Toll like receptor 3 (TLR3) agonist which was shown to synergize with anti-PDL1 antibodies in a B16 melanoma model (Celis et. al, Blood 2010). We sought to investigate if synergy could be demonstrated in a murine breast cancer model.Methods', ' Five week old female BALB/c mice were injected with 3x106 4T1 cells in a mammary fat pad and divided into 4 groups with ten mice/group (PBS control, 200g anti-PDL1 antibody (10F.9G2 Bioxcell) D1,5 IP, 50g Poly I', 'C (Invivogen) D1,6,11,16 IV, anti-PDL1+Poly I', 'C). Treatment started when tumors were palpable and measured twice weekly. The mice were sacrificed 20 days later with tumors, spleens, and lymph nodes harvested. Tumors were measured twice weekly. All experiments were carried out under approved IACUC #4277R per institutional guidelines. Statistical analysis performed using Prism Graphpad.Results', ' Mean tumor measurements (mm2) at day 20 for control=207.5, anti-PDL1=188.5, Poly I', 'C=182.6, anti-PDL1+Poly I', 'C=149.4. Two way ANOVA was statistically significant at p<.0001. Mean tumor weight (gm) at day 20 of anti-PDL1+Poly I', 'C=.99 vs control=1.23 p=.002 using t test.Conclusions', ' The combination of anti-PDL1 and Poly I', 'C TLR3 agonist demonstrates improved anti-tumor activity against established 4T1 orthotopic murine breast tumors compared to control or either agent alone. Characterization of TIL infiltrates in tumor specimens and immune activation in harvested lymphocytes is ongoing and will be presented. This data provides preliminary evidence supporting continued investigation of the combination of PDL1 and Poly I', 'C immunotherapy for breast cancer.']",
        "Doc_id":"AACR_2014-5018",
        "Doc_title":" Combination immunotherapy with PD-L1 blockade and Poly I",
        "_version_":1606189008702930945},
      {
        "Meeting_name":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "Background":"['Background', ' Predictive biomarkers for response and resistance to immune checkpoint blockade targeting programmed death 1 (PD-1) are incompletely characterized, and the utility of anti-PD-1 therapy for uterine leiomyosarcoma (ULMS) is unknown. Methods', ' A 49 yo woman with ULMS developed rapidly progressive metastatic disease 4 months after R1-resection of the primary tumor and was enrolled on a phase 1b study of pembrolizumab (10 mg/kg every 2 wks) (KEYNOTE-028). Tumor regression at multiple metastatic sites occurred within 2 months. A single pre-existing metastasis increased in size and was resected at 9 months. IHC, whole exome/transcriptome sequencing, and neoantigen analysis was performed on primary pretreatment (preRx) and treatment-resistant tumors (postRx). Results', ' Responsive tumor sites revealed complete pathologic response at time of surgery. Progressive tumor demonstrated viable ULMS. IHC showed tumor cells negative for PD-L1 and positive for PD-L2 both preRx and postRx. Degree of PD-1+ lymphocyte infiltration decreased significantly postRx compared to preRx. PreRx harbored exomic focal MYC amplification, TP53 nonsense mutation, and heterozygous PTEN deletion. PostRx maintained these genomic alterations and acquired a loss-of-function mutation in PTEN that resulted in biallelic PTEN inactivation. PreRx tumor expressed tumor-specific neoantigens (TSNs) that were immunogenic to patient-derived peripheral blood mononuclear cells; expression of TSNs decreased postRx. Conclusions', ' This patient exhibited complete pathologic response to pembrolizumab at all but one metastatic ULMS site. Genomic analysis of the resistant tumor revealed acquired bialllelic PTEN loss - recently implicated in resistance to PD-1 inhibition in melanoma and glioblastoma  reduced infiltration of PD-1+ lymphocytes, and diminished expression of neoantigens. To our knowledge, this is the first report of exceptional response to PD-1 inhibition in ULMS, and highlights biallelic PTEN loss and neoantigen downregulation as potential mechanisms of acquired resistance to immune checkpoint blockade across cancer types.']",
        "Doc_id":"ASCO_166429-176",
        "Doc_title":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "_version_":1606189008174448640},
      {
        "Meeting_name":" Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma",
        "Background":"['The mutational load in melanoma is high relative to that in most other human malignancies, resulting in the possible expression of large numbers of patient-specific mutated antigens. This may, in part, explain the immunogenicity of this disease and the high rate of responsiveness to immunotherapeutic strategies such as tumor-infiltrating lymphocyte (TIL) therapy. Indeed, recent data have shown that cytotoxic T-cell reactivity targeting neo antigens may be common in human melanoma TILs. Importantly though, the clinical relevance of neo-antigen specific T cell populations remains uncertain.To directly address the tumoricidal potential of defined neo-antigen specific T cell populations, we first identified two neo-antigen specific T-cell populations within a bulk melanoma TIL culture by the combination of exome sequencing and MHC multimer-based T cell screens. Subsequently, we generated TIL products that are highly enriched for these neo-antigen reactivities and we compared the anti-tumor activity of these neo-antigen enriched TIL with that of standard bulk TIL in NSG mice bearing the autologous tumor. We observed outgrowth of the tumors in mice treated with standard TIL. In contrast, tumors in mice treated with enriched TILs were controlled long-term. Additional experiments showed that this superior activity of neo-antigen enriched TIL was caused by the increased numbers of T cells with a high anti-tumor activity, rather than the depletion of cell populations with inhibitory activity. Furthermore, once tumors eventually recurred these were still recognized in vitro by cells from the initially infused TIL culture.Together, these preclinical data demonstrate that neo-antigen reactive T cells within bulk TIL cultures form a critical component of anti-tumor reactivity and provide a further basis to target mutated antigens with cancer immunotherapy.']",
        "Doc_id":"AACR_2015-4704",
        "Doc_title":" Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma",
        "_version_":1606188989323149312},
      {
        "Meeting_name":" A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas.",
        "Background":"['Background', ' The rate of positive sentinel lymph node (SLN) biopsy among T1 melanoma patients is 5%-8%. Identifying which T1 patients are at increased risk for lymph node metastasis remains unclear. Methods', \" Retrospective analysis of 484 patients with T1 melanoma who underwent SLN biopsy. Clinical and histological factors were evaluated including Breslow's depth, ulceration status, tumor-infiltrating lymphocytes (TIL), age, sex, and anatomic site. The incidence of positive SLN biopsy was calculated and then factors predicting positive SLN biopsy were identified. Results\", ' Of the 484 patients, 52.1% were T1a and 40.7% T1b. Seven percent had a positive SLN biopsy. The mean age of the cohort was 52.2 years with mean follow-up of 4.53 years. The majority of primary tumors were on the trunk (43.8%), followed by the lower extremity (19.8%), head and neck (19.6%), upper extremity (16.7%). Ulceration was present in 10.7% of primaries. Univariate logistic regression analysis showed the following 4 factors to be predictive of positive SLN biopsy', ' decreasing age, tumor 0.8 mm or greater, tumors on the lower extremity and trunk, and absent to few TIL. None of the patients with moderate to many TIL had a positive SLN biopsy. In a multivariate analysis, only decreasing age independently predicted SLN positivity. A predictive model was developed using these 4 factors. If 0-2 factors were present, the rate of positive SLN was 3%; if 3 factors were present this increased to 15% and if all 4 factors were present, the rate of positive SLN biopsy was 30%. Conclusions', ' A predictive model determining the risk of positive SLN biopsy in patients with T1 melanoma may be constructed using current clinical and histological parameters and may better identify those patients in the T1 cohort to undergo SLN biopsy.']",
        "Doc_id":"ASCO_43100-74",
        "Doc_title":" A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas.",
        "_version_":1606189019149893632},
      {
        "Meeting_name":" Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy",
        "Background":"['Adoptive T-cell therapy is an effective treatment for metastatic melanoma, achieving objective clinical responses in half of patients undergoing tumor infiltration lymphocyte (TIL) therapy. Epigenetic modifications are key players in regulating gene expression. Modulation of histone deacetylases (HDACs) has received attention for its implications in altering gene regulation. While HDAC pan-inhibition directly affects tumor growth, the immune system may be negatively impacted. Novel HDAC-selective inhibitors can ameliorate these undesirable effects. HDAC6 is unique in containing two catalytic domains, allowing for the development of isotype-selective inhibitors. Here a novel role of HDAC6 in T-cell immunity with important implications for adoptive cell therapy was explored. Initially a delay in B16 melanoma growth was observed in HDAC6KO mice (p<0.001 at day 19). Furthermore, tumor-free HDAC6KO mice vaccinated with melanoma antigen peptides displayed a mean of 30% antigen-specific circulating CD8+ T-cells versus 12% in WT mice. Moreover, HDAC6 expression was reduced over three fold in T-cells activated in vitro. To further investigate the role(s) of HDAC6 in anti-tumor T-cell responses, the HDAC6 selective inhibitor rocilinostat was utilized. Adoptive transfer of rocilinostat-treated T-cells conferred an increased anti-melanoma response in a B16 model (day 25 mean tumor volume 800 vs. 2200 cubic mm), characterized by accumulation of central memory T-cells in the lymph nodes. To directly address the clinical potential of targeting HDAC6, T-cells from healthy human donors and melanoma patient-derived TILs were treated with rocilinostat. A modest but consistent 5% increase in central memory phenotype in healthy CD4+ and CD8+ T-cells was observed. While a decrease in the nave, effector and effector memory subsets occurred, no differences in cell viability were seen. Rocilinostat treatment of TILs derived from different cell preparations (e.g. tumor digest, pre- and post-rapid expansion in vitro) displayed up to a three-fold increase in central memory in three patients analyzed. Impressively, repeated in vitro treatment with rocilinostat further increased the proportion of central memory CD4+ and CD8+ T-cells. Intriguingly, initial results show that the transcription factor T-BET, involved in T-cell function, was upregulated in TILs after rocilinostat treatment and in vitro expansion. Functionally, activation of rocilinosat-treated TILs resulted in increased IFNg+CD107a+ T-cells. Ultimately, rocilinostat pre-treatment of TILs or concomitantly with tumor resulted in 70% killing of HLA matched melanoma cells, compared to 50% killing by control-treated TILs, both relative to melanoma only control. These preliminary data provide a rationale for targeting HDAC6 in T-cells to improve cancer immunotherapy.']",
        "Doc_id":"AACR_2015-1338",
        "Doc_title":" Novel implications of histone deacetylase 6 selective inhibition in melanoma T-cell immunotherapy",
        "_version_":1606189028702420992},
      {
        "Meeting_name":" Acquisition of P- and E- selectin binding capacity by effector T cells is required for the abscopal response following experimental high dose radiation therapy.",
        "Background":"['High dose radiation therapy generates systemic adaptive immunity that limits distal tumor progression and synergizes with immune checkpoint blockade. Preclinical data demonstrate that ionizing radiation may sensitize otherwise refractory tumors to immunotherapy through mechanisms of lymphocyte activation and intratumoral recruitment, however, the molecular mechanisms that govern this response remain poorly understood. Selectins are critical regulators of leukocyte trafficking and migration, and facilitate the compartmentalization of nave, effector and memory T cells to their respective organ sites. Importantly, inflamed vascular endothelium expresses P- and E-selectin, which facilitate peripheral tissue infiltration of effector and memory lymphocytes. Therefore, both the acquisition of functional selectin ligands expressed by T cells, as well as endothelial activation coordinates peripheral tissue infiltration following infection or tissue injury. In this work we test the hypothesis that the immunogenic potential of high dose radiation therapy is sufficient to stimulate synthesis of selectin ligands on T cells, which is required for their subsequent infiltration into distal tumors and the abscopal response. We have established a mouse model of the abscopal effect, where radiotherapy-induced immune mediated-tumor regression is observed at sites distal to the primary, irradiated tumor. B16 F10 murine melanomas expressing model and endogenous antigens are implanted intradermal on opposing flanks. One day prior to radiation, nave TCR-transgenic CD8+ T cells are transferred into tumor bearing mice and 20Gy is delivered to a single tumor by half beam block. Using this model, we demonstrate that local high dose radiation therapy is sufficient to activate and expand nave tumor-specific CD8+ T cells in the tumor draining lymph node. Following a single high dose of radiation, tumor-specific CD8+ T cells become activated and subsequently traffic to and accumulate in distal, contralateral tumors where they limit tumor growth, thus recapitulating the clinical observation of the immune-mediated abscopal effect. Importantly, we demonstrate that high dose radiation is sufficient to upregulate selectin family of oligosaccharide binding adhesion molecules on newly activated antigen-specific CD8+ T cells. The acquisition of P- and E-selectin binding capacity by effector CD8+ T cells is required for the abscopal response as administration of selectin blocking antibodies reduced intratumoral CD8+ T cell infiltration and failed to mediate regression of distal tumors post radiation. Our data demonstrate that the acquisition of P- and E-selectin ligands requires prior antigenic stimulation and as such, these T cells represent a completely novel population of tumor-specific, homing competent CD8+ T cells that may predict response to therapy in patients.']",
        "Doc_id":"AACR_2017-5620",
        "Doc_title":" Acquisition of P- and E- selectin binding capacity by effector T cells is required for the abscopal response following experimental high dose radiation therapy.",
        "_version_":1606189014142943232},
      {
        "Meeting_name":" Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy",
        "Background":"['Background', ' Unique to modern immune therapy for cancer is that early in the course of treatment, patients frequently exhibit transient tumor enlargement (pseudo-progression, pPROG) due to tumor infiltration by lymphocytes (TIL). Currently, pPROG cannot be reliably distinguished from true tumor progression (PROG). There is a need for biomarker techniques to discriminate pPROG (effect of therapy) and PROG (therapy failure). Nuclear medicine offers radiopharmaceuticals capable of imaging immune cells; images can be fused to evaluate functional and anatomic characteristics of tumors, and potentially discriminate pPROG from PROG. Methods', ' In our study of metastatic melanoma patients, SPECT/CT imaging with 99mTc-interleukin-2 (99mTc-IL2) was performed to visualize TIL. Images were collected before/after 12 weeks of ipilimumab (IPI) or pembrolizomab (PEMBRO) therapy. The 99mTc-IL2 tracer was synthesized by conjugating succinimidyl-6-hydrazinopyridine-3-carboxylate (HYNIC-NHS) with commercial interleukin-2 (Aldesleukin). HYNIC-IL2 was incubated with tricine, 99mTcO4- (370-740 MBq) and SnCl2. After labelling 99mTc-IL2 was purified by reverse-phase chromatography and diluted in 5% glucose with 0.1% human albumin before injection. Five patients were enrolled in this study. Two patients failed to complete the 12 week 99mTc-IL2 scan due to discontinuation of IPI after', ' 1) grade 3 colitis and 2) patient refusal for adverse events attributed to IPI. No adverse events attributable to the tracer infusion were reported. Results', ' Metastatic lesions could be visualized by the tracer. Some lesions decreased in size, while others increased. A positive correlation was found between size and 99mTc-IL2 uptake, before and after therapy, suggesting the potential discrimination of tumor PROG (no 99mTc-IL2 uptake) from pPROG (high 99mTc-IL2 uptake). Immunohistochemical staining for TIL of 99mTc-IL2 positive and negative lesions are illustrated. Conclusions', ' The results demonstrate feasibility of 99mTc-IL2 imaging as a clinically useful tool capable of discriminating tumor PROG from pPROG. A clinical validation study is in progress. Clinical trial information', ' NCT01789827']",
        "Doc_id":"ASCO_192786-199",
        "Doc_title":" Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy",
        "_version_":1606189020308570112},
      {
        "Meeting_name":" Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity.",
        "Background":"['Background', ' Blockade of co-inhibitory immune receptors has become a promising approach for cancer immunotherapy. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a recently characterized immune checkpoint. Expression of CEACAM1 on tumors induces a co-inhibitory signal to CEACAM1-positive T and NK cells through homophilic interactions. Methods', ' CM-24 (MK-6018) is a humanized anti-CEACAM1 IgG4 antibody with high affinity and selectivity for CEACAM1. The effect of CM-24 alone or in combination was examined in vitro using tumor-infiltrating lymphocytes (TIL) and peripheral blood mononuclear cells. The anti-tumor efficacy of CM-24 was studied in vivo in subcutaneous xenograft and lung metastasis models of melanoma treated with IV injection of mlanoma-reactive TIL. Gene expression analysis of CEACAM1 and other genes of potential relevance to patient response to CEACAM1 were examined in a large cohort of human tumor samples. Results', ' CM-24 was demonstrated to be a potent blocker of intercellular CEACAM1-CEACAM1 interactions and reversed the inhibition of activated lymphocytes by restoring the phosphorylation of ZAP70. In addition, CM-24 enhanced the anti-tumor activity of TIL in the melanoma xenograft and lung metastasis models. CM-24 also showed synergistic activity with immune checkpoint blockers targeting PD-1 or PD-L1. The gene expression analysis of CEACAM1 and other genes in 18,000+ solid tumor samples allowed us to identify tumor types which represent potential indications for CM-24 therapy and to identify gene expression profiles as candidate biomarkers of response to CM-24 as monotherapy or in combination with a PD-1 or PD-L1 antagonist. Conclusions', ' CM-24 increases the cytotoxic activity of lymphocytes against malignant cells and has shown effective anti-tumor activity in various in vitro and in vivo models. Treatment with CM-24 either as monotherapy or in combination with anti-PD-1 treatment such as pembrolizumab may be beneficial. First-in-man clinical trial with CM-24 is ongoing.']",
        "Doc_id":"ASCO_164319-176",
        "Doc_title":" Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity.",
        "_version_":1606189035754094592},
      {
        "Meeting_name":" Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).",
        "Background":"['Background', '  The brain is considered as an immuno-privileged organ and little is known about the inflammatory response to melanoma BM.  Methods', '  Patients with neurosurgical resected and histologically verified melanoma BM were identified. Investigation of PD1, PD-L1, CD3, CD8, CD45RO and BRAF V600E were performed by immunohistochemistry and analyzed using previously published semiquantitative evaluation criteria.    Results', '  Forty-six specimens (28/46; 60.9% BRAF V600E positive) were available. Forty-one/46 (89.1%) specimens presented with TIL infiltration. CD3+ TILs were evident in 35/46 (76.1%), CD8+ TILs in 28/46 (60.9%), CD45RO+ TILs in 32/46 (69.6%) and PD1+ TILs in 28/46 (60.9%) specimens. The Table lists details of TIL infiltration density. PD-L1 expression on melanoma BM tumor cells was observed in 21/46 (45.7%) specimens. Median H-score for PD-L1 was 3 (range 190). Eight/21 (38.1%) PD-L1 positive specimens presented with an H score over 5 %. PD-L1 expression on tumor cells was associated with higher density of PD1+ (p=0.002), CD3+ (p=0.024) and CD8+ (p=0.050) TIL infiltration. Furthermore, density of CD3+ TILs was associated with density of CD8+ (p<0.001), PD1+ (p<0.001) and CD45RO+ (p<0.001) TILs, respectively. No association of previous systemic antineoplastic therapy (including chemotherapy and interferon) and expression of PD-L1, PD1, CD3 or CD45RO could be observed (p=n.s). Expression of PD-L1 on tumor cells or density of PD1+, CD3+, CD8+ or CD45RO+ TILs did not correlate with BRAF V600E status (p=n.s.) or survival from first diagnosis of BM (p=n.s.).  Conclusions', '  Melanoma BM show considerable inflammatory infiltrates and expression of PD1 and PD-L1. Clinical studies should investigate the value of checkpoint inhibitors in patients with melanoma brain metastases.']",
        "Doc_id":"ASCO_129569-144",
        "Doc_title":" Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM).",
        "_version_":1606189002463903744},
      {
        "Meeting_name":" Differential expression of the melanoma inhibitor of apoptosis protein (ML-IAP)/Livin in patients with ulcerated and non-ulcerated melanomas",
        "Background":"['Background', ' Cutaneous malignant melanoma is one of the most aggressive forms of skin cancer with an extremely poor prognosis for the patients diagnosed with metastatic disease. Ulceration has been correlated with an increased risk of death within a given thickness range, however, the biologic basis for the development of ulceration is poorly understood. Livin, an inhibitor of apoptosis protein (IAP), is overexpressed in various cancers and possesses both the ability to protect from cell death and to promote it once it is cleaved. It is unknown whether there is a differential cellular expression of livin in ulcerated versus non-ulcerated melanomas. Methods', ' To explore the role of livin in relation to ulceration, other clinicopathological factors and survival of melanoma patients, we have performed semiquantitative immunohistochemical analysis of livin expression as measured by percentage and intensity (levels) of cells immunoreactive for livin in tumor specimens having both ulcerated and non-ulcerated areas from 50 melanoma lesions. Results', ' Superficial as well as deep melanoma cells located in non-ulcerated areas of tumor had higher percentage of cytoplasmic immunopositivity for livin when compared with melanocytes in the ulcerated areas of the melanoma (p<0.0001). We also observed nuclear expression of livin protein in this subset of melanoma patients. Compared to the ulcerated areas, the superficially located melanoma cells from the non-ulcerated areas showed significantly higher intensity of livin immunoreactivity in their nuclei (p = 0.048) but not those from the deep non-ulcerated areas (p = 0.32). Ulcerated melanomas with low tumor stage (I/II) had higher percentage of tumor cells with nuclear livin expression than those from higher tumor stage (III/IV) (p = 0.002). Interestingly, we observed that patients with higher intensity of cytosolic expression of livin protein in the ulcerated area of tumor were more likely to have a brisk tumor-infiltrating lymphocytes (TILs) response (p = 0.001). Patients with higher intensity of cytoplasmic livin protein of tumor cells in ulcerated areas had higher risk of death compared to those with lower levels (p = 0.005). On the other hand, patients with higher intensity of cytoplasmic expression of livin in melanoma cells located superficially in the non-ulcerated areas of tumor had better prognosis (p = 0.045). Conclusion', ' Our data indicate that there is a decrease of nuclear as well as cytoplasmic expression of livin protein in melanoma cells from ulcerated when compared to non-ulcerated areas. Also, cytoplasmic livin expression is an indicator of poor prognosis, but apparently only in patients with ulcerated lesions. Although IAPs regulate caspases, they also regulate signaling pathways that activate NF-B modulating immunity. The prominent TILs response in livin-positive tumors suggests a possible involvement in tumor immunity in melanoma.']",
        "Doc_id":"AACR_2016-3570",
        "Doc_title":" Differential expression of the melanoma inhibitor of apoptosis protein (ML-IAP)/Livin in patients with ulcerated and non-ulcerated melanomas",
        "_version_":1606189005051789312},
      {
        "Meeting_name":" BRAF inhibition is associated with increased clonality of tumor infiltrating lymphocytes.",
        "Background":"['There have been significant advances in the past few years with regard to BRAF-targeted therapy for metastatic melanoma, however the majority of patients have disease progression within 6 to 7 months. We have previously shown that BRAF inhibition in melanoma in vitro is associated with an increase in melanoma antigens and increased reactivity to antigen specific T cells. More recently, we corroborated these findings in vivo in patients with melanoma undergoing treatment with BRAF inhibitors, demonstrating an increase in melanoma antigens and a significant increase in CD8+ T cells following treatment. However, the nature of this immune response to BRAF inhibition is poorly understood. The goal of the present studies is to better define the T cell infiltrate, so that we can develop a therapeutic strategy to leverage their presence.To do this, we performed tumor biopsies in patients with metastatic melanoma undergoing treatment with BRAF inhibitors at two time-points', ' pre-treatment (day 0), and on-treatment (day 10-14). Biopsies were also taken at time of progression when applicable. DNA was isolated and the CDR3 regions of rearranged TCR beta chain genes within the tumor were sequenced and analyzed using the immunoSEQ platform by Adaptive Biotechnologies. Results demonstrated a significant increase in the clonality in the tumor infiltrating lymphocytes in 7 of the 8 patients in on-treatment vs. pre-treatment samples, suggesting that treatment with a BRAF inhibitor may induce an antigen-specific T cell response. We also sought to determine if the increase in T cells associated with BRAF inhibition is related to an infiltration of new T cell clones or a proliferation of existing clones within the tumor. To study this, we analyzed the total T cell clones in these patient samples with regard to their presence or absence in the pre-treatment compared to on-treatment samples. Results demonstrate that over 80% of the individual clones detected after initiation of BRAF-targeted therapy are new clones, suggesting that this therapy is associated with an influx of TIL into the tumors. However, if attention is focused only on the most prevalent clones rather than the total clones, there is a dichotomous relationship between change in clonal populations and magnitude of tumor regression. Namely, those who have persistence of the same dominant clones had a good treatment response, whereas those who had a change in the dominant clonal populations had a poor response. Taken together, this data suggest that though BRAF inhibition in melanoma results in infiltration of new TIL, response to treatment is dependent on a pre-existing population of TIL clones. This data has important clinical implications, and may ultimately help predict who is likely to derive the greatest benefit from BRAF-targeted therapy. A better understanding of this response may also guide us in developing rational combination therapy in the treatment of melanoma.']",
        "Doc_id":"AACR_2013-2338",
        "Doc_title":" BRAF inhibition is associated with increased clonality of tumor infiltrating lymphocytes.",
        "_version_":1606188979765379072},
      {
        "Meeting_name":" Oral SHP-1 inhibitor TPI-1a4 increases TILs in melanoma tumors and interacts positively with CTLA4 antibody for melanoma cure in mice",
        "Background":"['SHP-1 phosphatase is a promising target for developing inhibitors as novel cancer immune therapeutics given its key role in negative regulation of immune cells. TPI-1a4 is a small molecule SHP-1 inhibitor identified recently and demonstrated activity for melanoma and colon cancer tumors in mice as a tolerated single oral agent. TPI-1a4 has been further evaluated herein for mechanism of action and potential clinical translation. Oral TPI-1a4 increased (up to 8x) in TILs in K1735 melanoma tumors in syngeneic mice in a dose-dependent manner and in correlation with tumor growth inhibition. The growth of 4-day established K1735 tumors (s.c.) in syngeneic C3H/HeJ mice was inhibited 44% (p < 0.05) by TPI-1a4 at 0.4 mg/kg (5 d/wk, gavage) or 90% (p < 0.01) at 0.8 mg/kg (5 d/wk, gavage) during a treatment period of 4 wks. Evaluation of tumor histology (H.E.) revealed increases (2x and 4x for the two treatments) of tumor-infiltrating lymphocytes (TIL). Immunohistochemistry analyses of the tumor samples demonstrate increases (3 and 6x) of CD45+ cells (pan-leukocytes), CD3+ cells (T lineage), B220+ cells (B/NK lineages), and Mac3+ cells (myeloid lineages). Oral TPI-1a4 interacted positively with CTLA4 antibody for survival extension and cure in K1735 melanoma tumor mice. TPI-1a4 (1 mg/kg, 5d/wk, gavage) or CTLA4 antibody (9H10, 100 ug x3, ip) as individual agents delayed tumor growth for 1-4 wks in C3H/HeJ mice with 4-day established K1735 tumors (s.c.). Their combination delayed tumor growth for 4-14 wks (4/5 mice) or completely blocked tumor growth (1/5 mice) by 20th wk in association with resistance to re-challenging with the melanoma tumor (s.c.). The combination was more effective in C3H/HeJ mice with 1-day established K1735 tumors, blocked tumor growth in most mice (4/5) comparing to mostly delayed tumor growth for several wks by the individual agents. TPI-1a4 in drinking water ad lib with weekly renewal was effective against the melanoma tumors in mice, suggesting chemical stability. Indeed, mass spectrometry verified structural integrity of TPI-1a4 stored as solid compound or in solvent at room temperature for 2 months. These data provide further evidences designate TPI-1a4 as a novel anti-cancer immune agent and a promising candidate for clinical translation. Our studies demonstrate for the first time the potential of TPI-1a4 to improve the clinical efficacy of CTLA4 antibody and other related cancer therapeutics. Future studies of TPI-1a4 analogs and derivatives are warranted and may lead to more refined and effective SHP-1 inhibitors and immune cell activators.']",
        "Doc_id":"AACR_2012-868",
        "Doc_title":" Oral SHP-1 inhibitor TPI-1a4 increases TILs in melanoma tumors and interacts positively with CTLA4 antibody for melanoma cure in mice",
        "_version_":1606189023287574528},
      {
        "Meeting_name":" Extending T-cell transfer therapy to melanoma and oral squamous carcinoma.",
        "Background":"['Background', ' T-cell based immune therapy in melanoma has shown markedly objective clinical responses in a single-center study at the NIH. In order to extend the treatment to other centers and investigate application to other histologies, we compare the characteristics of tumor infiltrating lymphocytes (TIL) expanded from two groups of cancer patients', ' malignant melanoma (MM) and squamous cell carcinoma (SCC) of the oral cavity. Methods', ' Expanded TIL cultures were examined for T-cell phenotype subsets using FACS and clonality by TCRBV gene segment semi quantification with PCR. Tumor reactivity was assessed by INF Elispot, CD107a expression by FACS and Cr51 release assay. To identify possible Tumor Associated Antigen (TAA) specific populations TIL were screened for a panel of epitopes from the known TAA Survivin, Telomerase, Bcl-x, Bcl-2, Ny-ESO 1, MART-1, and IDO. Results', ' Preclinical part', ' In both patient cohorts TIL were expanded within 5 weeks in 80% of the patients. Cultures comprised an oligoclonal repertoire of T effector memory cells (TEM). Tumor activity against HLA-A matched cell lines showed varying responses regarding frequency and magnitude; activity directed against autologous tumor cells were characterized by a strikingly high frequency of INFg producing cells and/or distinct CD107a+ populations with tumorlytic capacity. Peptide screening revealed that specific TIL cultures were not correlated with tumor activity although the TAA mRNA were identified in the tumor cell lines. Clinical part', ' TIL were expanded in 5 of 5 (100%) MM patients included. Kinetics, phenotypes, and preliminary activity data resemble preclinical results. Three patients have completed treatment and two have been evaluated by CT scan (1 SD and 1 PR). Immune monitoring is pending. Conclusions', ' Results on ex vivo expanding TEM from both MM and SCC show comparable outcome and demonstrates shared activity against several common TAA. A clinical pilot trial is ongoing in MM patients with metastatic disease and a pilot trial in patients with primary SCC stage T3/T4 will start in 2010.']",
        "Doc_id":"ASCO_52284-74",
        "Doc_title":" Extending T-cell transfer therapy to melanoma and oral squamous carcinoma.",
        "_version_":1606188974158643200},
      {
        "Meeting_name":" Improving antitumor effects of a BRAF inhibitor with a colony stimulating factor 1 receptor (CSF-1R) inhibitor, PLX3397",
        "Background":"['BRAF inhibitor targeted therapies such as vemurafenib (PLX4032) or dabrafenib, block BRAFV600 driver oncogenic mutations and result in high initial response rates and improve survival in patients with melanoma. Although response rate is over 50%, resistance eventually develops. A possible explanation is established tumors escape supported by the immune suppressive tumor-infiltrating myeloid cells (TIMs) including M2 type macrophages and myeloid derived suppressor cells (MDSC).Our murine melanoma SM1 model that harbors BRAFV600 mutation is an aggressive model, where mice with established tumors have to be sacrificed within two-three weeks. Treatment with PLX4032 has significant anti-tumor effect, but it cannot fully eradicate the tumor. In addition, our prior results show that SM1 is infiltrated by M2-polarized macrophages. By depleting TIMs with the CSF-1R inhibitor, PLX3397, the tumor infiltrating lymphocytes (TILs) is increased. To determine if combined therapy with PLX3397 and PLX4032 improved anti-tumor responses against SM1 tumors, C57BL/6 mice with established subcutaneous SM1 tumors received oral gavage daily with PLX3397 (50mg/kg) and i.p. daily with PLX4032 (100mg/kg). Combined treatment demonstrated superior effects compared to either of single treatment (tumor size on day 12_vehicle', ' 862.017.0 mm2, PLX3397', ' 439.36.9 mm2, PLX4032', ' 113.72.6 mm2, PLX3397+PLX4032', ' 12.94.6 mm2, p<0.05). When SM1 tumors were implanted in immunodeficient NSG mice treated with PLX3397 and PLX4032, the superior anti-tumor effect of the combined group disappeared and its tumor growth overlapped with PLX4032 treated group (tumor size on day 15_vehicle', ' 1432.946.2 mm2, PLX3397', ' 1374.641.4 mm2, PLX4032', ' 1080.030.0 mm2, PLX3397+PLX4032', ' 1028.349.0 mm2, p>0.05). To further confirm that combined treatment effect is mediated by CD8+ T-cells, SM1 tumors were implanted in immunocompetent C57BL/6 mice and treated with PLX3397, PLX4032, and anti-CD8 neutralizing antibody. The anti-tumor response in PLX3397, PLX4032, and anti-CD8 antibody group was greatly diminished (tumor size on day 16_vehicle', ' 751.612.2 mm2, PLX4032', ' 232.48.8 mm2, anti-CD8', ' 722.812.5 mm2, PLX3397+PLX4032', ' 101.07.6 mm2; PLX3397+PLX4032+anti-CD8', ' 442.05.7 mm2, p>0.05).In conclusion, our data from SM1 in vivo model combining CSF-1R blockade and BRAF oncogenic blockade supports the rationale for testing this combination in patients with advanced melanoma, and suggest that the benefit is mediated by anti-tumor T cells. This combination is now in clinical testing (NCT01826448).']",
        "Doc_id":"AACR_2014-147",
        "Doc_title":" Improving antitumor effects of a BRAF inhibitor with a colony stimulating factor 1 receptor (CSF-1R) inhibitor, PLX3397",
        "_version_":1606189025415135232},
      {
        "Meeting_name":" The relationship between fractional lymphocyte counts and survival in malignant melanoma.",
        "Background":"['Background', '    While strong evidence supports a relationship between acquired immune deficiency states and virus-associated malignancy, the relationship between immune function and epithelial malignancy in the setting of immunocompetence is less clear. In malignant melanoma, the success of lymphocyte-targeted immunotherapies suggest that lymphocyte immunity may play a role disease outcomes. Separate evidence suggests that immunosenescence in old age is associated with impaired lymphocyte immunity. We hypothesized that fractional lymphocyte counts are associated with survival in melanoma, and that this relationship is likely to be stronger in younger as compared to older individuals.  Methods', '    We retrospectively examined the relationship between peripheral blood immune indices and survival in malignant melanoma. We identified individuals who had died from malignant melanoma in our unit over the past 2 years. We recorded pre-treatment neutrophil, lymphocyte, and total white cell counts. Survival time from diagnosis of metastatic melanomawas calculated. The principal endpoint was the assessment of correlation between lymphocyte-neutrophil ratio or fractional lymphocyte count and survival in individuals younger or older than 65 years of age. The Pearson product-moment correlation coefficient was used to assess the degree of linear dependence between these variables.  Results', '    In total, 21 patients were identified; 11 patients aged less than 65, and 10 patients older than 65. In those aged under 65, the fractional lymphocyte count correlated positively with survival (r = 0.703; p < 0.02), and a negative correlation was observed between the fractional neutrophil count and survival (r = 0.705, p < 0.02). Approximately 70% of the variation in survival is explained by the baseline fractional lymphocyte count. In contrast to previous studies, the neutrophil-lymphocyte ratio did not correlate with survival. In the over 65 group, no significant correlations were identified.  Conclusions', '    Pre-treatment fractional lymphocyte counts correlate positively with survival in individuals with malignant melanoma aged under 65. These results suggest further prospective studies in larger populations are warranted.']",
        "Doc_id":"ASCO_152309-156",
        "Doc_title":" The relationship between fractional lymphocyte counts and survival in malignant melanoma.",
        "_version_":1606189013745532928},
      {
        "Meeting_name":" Regulation of PD-L1 expression in human melanoma by NF-kB",
        "Background":"['Background ', ' Antibodies targeting the immune check point inhibitor programmed death receptor 1 (PD-1) and its ligand (PD-L1) have been associated with relatively high response rates that appear durable in most patients. Past studies have shown the percentage of melanoma expressing the ligand for PD1, PD-L1 varies from 38 to 53% depending on the cutoff used to determine positivity and the antibodies used. In the majority of melanoma, expression of PD-L1 was associated with tumor infiltrating lymphocytes (TIL) and was believed to be induced by IFN gamma from T cells. Relatively few melanomas had (constitutive) PD-L1 expression in the absence of TILs.Study and Results', ' In the present study we examined the signal pathways involved in inducible and constitutive expression of PD-L1 expression on cultured melanoma cells, including those derived from patients pre and post vemurafenib treatment. Our results suggest that nuclear factor kappa B (NF-kB) has a role in IFN-gamma inducible expression as shown by inhibition of PD-L1 expression with the inhibitor, BMS 345541 which blocks phosphorylation of the inhibitory IkB kinase, resulting in cytoplasmic retention of NF-kB p65 and p50 subunits. Luciferase based promoter reporter assays confirmed an association between NF-kB activity and PD-L1 expression levels. Targeting NF-kB was more effective in reducing inducible PD-L1 levels than targeting either the MAPK pathway or the P13Kinase/AKT pathway. Transfections with the super repressor, Inhibitor of kappa B alpha, mutated at S32 and S36, to correlate with PD-L1 levels are being carried out. In addition, si RNA mediated knockdown of the p50 and p65 subunits to confirm the involvement of NF-kB in PD-L1 expression will be studied. We are also currently dissecting the signaling pathways involved in constitutive expression of PD-L1.NF-kB is an important protein complex involved in adaptive and innate immune response and regulates cytokine and chemokine production in melanoma. It also contributes to induction of proteins involved in cell proliferation and survival, playing a role in resistance to targeted therapy. The present results highlight another important function of this crucial transcription factor which our recent studies show may be targetable by inhibitors of the bromo domain and terminal repeat (BET) reader proteins.']",
        "Doc_id":"AACR_2014-2947",
        "Doc_title":" Regulation of PD-L1 expression in human melanoma by NF-kB",
        "_version_":1606189013127921665},
      {
        "Meeting_name":" Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.",
        "Background":"['Background', '  Immunotherapy with checkpoint blockade has shown encouraging activity in squamous cell carcinomas including a case report in tongue cancer (Herbst 2013). PD-L1 expression is common in HNC (Lyford-Pike 2013). In melanoma a T cell-infiltrated phenotype is common and correlates with immune inhibitory pathways. We interrogated the immune microenvironment in a large cohort of HNC in order to identify molecular correlates of an inflamed tumor microenvironment that may predict benefit from checkpoint blockade.  Methods', '  We evaluated the presence of a T cell-inflamed tumor microenvironment in a cohort of 134 (Chicago HNC Genomics (CHGC)) and 424 TCGA HNC samples using a melanoma expression signature (Harlin/Gajewksi 2009). We evaluated multiple immune-related markers by IHC in a subset of CHGC tumors including CD8 tumor infiltrating lymphocytes (TIL)(N=73) and PD-L1 (N=55). Results were correlated with genetic and clinical information.  Results', '  47% of CHGC and 33% of TCGA tumors showed a T cell-inflamed phenotype (TCIP) similar to melanoma based on a gene expression signature (Harlin 2009).  75% of HPV(+) tumors showed a TCIP compared to 23% of HPV(-) tumors in both cohorts. Mesenchymal subtype (Keck 2014) strongly correlated with TCIP (p<2.2x1016), and 90% of mesenchymal tumors showed TCIP including roughly equal numbers of HPV(+) and HPV(-) tumors in both cohorts. Basal and HPV-negative classical HNC tumors were TCIP negative. Based on IHC, 38% of CHCG tumors showed PD-L1 expression and 64% showed CD8+ TILs, both correlating with TCIP. Additional checkpoint molecules were universally co-expressed in the same TCIP tumors including CTLA4, LAG3, PDL-2, and IDO. Molecular processes enriched in non-TCIP tumors included EGFR/erbB signaling (p=0.09) characteristic of basal HNC, while multiple T-cell related signatures and the JAK/STAT pathway (p<0.05) characteristic of mesenchymal HNC were enriched in the TCIP tumors.  Conclusions', '  33-47% of HNC show a T cell-inflamed phenotype similar to melanoma. PD-L1 expression and TIL presence is common and strongly correlated with mesenchymal HNC in both HPV(+) and HPV(-) HNC and may benefit from immunotherapy.']",
        "Doc_id":"ASCO_130011-144",
        "Doc_title":" Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.",
        "_version_":1606188999581368320},
      {
        "Meeting_name":" Association of the immune checkpoint molecule expression with neutrophil-lymphocyte ratio in patients with gastric cancer",
        "Background":"['Background', '  Programmed cell death (PD) -1, one of immune checkpoint molecules, expresses on T cells and induces immune tolerances in tumor microenvironment by binding to the ligand PDL-1 on the cancer cells. The clinical effect of immune checkpoint inhibitors such as anti-PD-1/PDL-1 antibody was demonstrated in various cancer including malignant melanoma, lung cancer and gastric cancer. The development of biomarkers for case selection that these inhibitors are effective will be in urgent need. We previously showed that neutrophil-lymphocyte ratio (NLR), a marker for general immune response, was related with postoperative recurrence and advanced stage of gastric cancer. In this study, we report the association of pretreatment NLR with PD-1/PDL-1 expression in the primary tumor of gastric cancer.   Methods', '  Using immunohistochemistry, we retrospectively examined the expression of PDL-1 and infiltration of PD-1+ cells in primary tumor from 180 patients who had undergone surgery for gastric cancer between 2007 and 2010 at the Department of Surgical Oncology of Osaka City University.  Results', '  Positive expression of PDL-1 was observed in 78 (43%) patients. PDL-1 expression was correlated with tumor infiltrated PD-1+ cells and related poor prognosis of the patients with Stage II/III. NLR was correlated with pathological stage and lymph node metastasis. In the positive PDL-1 group, NLR was significantly increased compared with negative group. However, the number of infiltrated PD-1+ cells was not correlated with NLR. Conclusions', '  PDL-1 expression in gastric cancer tissues was associated with pretreatment NLR, indicating that local immune suppression could be reflected in the systemic immune responses. Our data also suggested that NLR might be one of surrogate marker for PD-1/PDL-1 blockade therapy for gastric cancer.']",
        "Doc_id":"ASCO_159361-173",
        "Doc_title":" Association of the immune checkpoint molecule expression with neutrophil-lymphocyte ratio in patients with gastric cancer",
        "_version_":1606188970540007424},
      {
        "Meeting_name":" Discovery, development and characterization of a new class of therapeutic anti-PD-1 antibody",
        "Background":"[\"Blockade of immune checkpoint (IC), such as PD-1, confers durable clinical benefit to a minority of melanoma and lung cancer patients. Challengingly, the 5-year survival rate is still below 30% in those patients, and most other solid tumors are not particularly responsive to immunotherapy. Therefore, more IC blocking mAbs are under development to meet clinical needs. Using Enumeral's unique single cell immunoprofiling platform, we developed a novel class of anti-PD-1 antibodies, named 244C8, with distinct epitope binding site than currently marketed anti-PD-1 antibodies. To evaluate the function of 244C8 on anti-tumor immunity, we employed ex vivo methods to determine responsiveness of tumor infiltrating lymphocytes (TILs), isolated from human lung cancer biopsies, to various anti-PD-1 antibodies, including our lead anti-PD1 therapeutic candidate 244C8. The results show that all anti-PD-1 antibodies tested reversed T cell exhaustion in tumor microenvironment. Further, 244C8-treated cells produced increased IFN-y compared to nivolumab, indicating a stronger anti-tumor immunity. In the settings of mixed lymphocyte reaction (MLR) and CMV antigen-recall assays, 244C8 treatment also led to higher levels of T cell activation compared to conventional anti-PD-1 antibodies. Interestingly, in both ex vivo and in vitro models, we observed a pattern of cytokine production in 244C8-treated cells that is consistently distinct from that produced by conventional/marketed anti-PD-1 antibodies, suggesting a differentiated mechanism of action.\"]",
        "Doc_id":"AACR_2016-2224",
        "Doc_title":" Discovery, development and characterization of a new class of therapeutic anti-PD-1 antibody",
        "_version_":1606189010663768064},
      {
        "Meeting_name":" Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs.",
        "Background":"['IMCgp100, a first in class immunotherapy, is a T cell redirecting bispecific biologic comprising an affinity enhanced T-cell receptor specific for gp100 and an anti-CD3 scFV. Phase I/IIa data has provided evidence of a favourable safety profile, and durable responses in both cutaneous and uveal melanoma have been observed. To complement the clinical studies we have developed a comprehensive biomarker strategy to aid our understanding of pharmacodynamics, patient response and potential mechanisms of resistance which includes analysis of markers in both the tumour and periphery. The data obtained to date provide evidence of the pharmacodynamic effects of the molecule including chemokine/cytokine release, in both the tumor and periphery, and lymphocyte infiltration into tumors. In addition, changes in the levels of certain chemokines following the first dose of IMCgp100 were associated with tumor shrinkage. The biomarker strategy we have developed forms the basis for the support of the on-going Ph II development of IMCgp100 in both cutaneous and uveal melanoma and for other ImmTAC molecules, as single agents and in combination, for the treatment of solid tumours.']",
        "Doc_id":"AACR_2017-3655",
        "Doc_title":" Biomarker strategy to guide the clinical development of ImmTACTM molecules, a novel class of bispecific T cell engaging biologic drugs.",
        "_version_":1606189013368045568},
      {
        "Meeting_name":" Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory TH2 cells via an IL-12 and OX40L dependent pathway.",
        "Background":"['Background', ' Antigens expressed by melanoma cells (MAA) and recognized by T lymphocytes have been used in various immunization strategies to treat cancer patients. However, the therapeutic efficacy of these approaches remains limited. Because MMP-2 (matrix metalloproteinase-2) activity is critical for melanoma progression, this protein represents a unique antigen for vaccine therapy. Methods', ' CD4+ T cells were stimulated with overlapping MMP-2 peptides. After 12 days, MMP-2-specific responses were determined by intracellular staining of cytokines. Specific T cells from positive samples were enriched and cloned using limiting dilution. Cytokine production was assessed by ELISA, intracellular staining, or cytometric bead array method. Results', ' We identified 11 novel CD4 MMP-2-derived epitopes, and showed that the corresponding T cells, detected in the CD45RO+/CD62L- memory fraction, displayed an inflammatory TH2 profile, i.e. mainly secreting TNF, IL-4 and IL-13 and expressing the TH2-specific transcription factor GATA-3. In contrast, CD4+ T cells that recognize other associated MAAs were typically TH1. Interestingly, nave T cells primed with active MMP-2 gave rise to TH2 specific cells, while nave T cells primed with peptides generated IFNg-secreting specific cells, consistent with a TH1 profile. Accordingly, we showed that the MMP-2 enzyme inhibited IL-12p35 production and induced OX40L expression by DCs. Both events were responsible for the TH2 skewing of MMP-2-specific T cells and other MAA-specific T cells. Furthermore, MMP-2 specific TH2 cells were found in 13 tumor-infiltrating lymphocyte populations out of the 31 melanoma patients tested. Conclusions', ' The protease activity of MMP-2 influences DC phenotype, more precisely IL-12 production and OX40L expression, which are responsible for the observed TH2 lineage commitment of MMP-2-specific T cells and other MAA-specific T cells. These findings open the way to therapeutic strategies skewing these already frequent and diverse MMP-2-specific responses towards a more efficient anti-tumor TH1 phenotype to treat melanoma patients.']",
        "Doc_id":"ASCO_40322-74",
        "Doc_title":" Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory TH2 cells via an IL-12 and OX40L dependent pathway.",
        "_version_":1606189039060254720},
      {
        "Meeting_name":" Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients.",
        "Background":"['Background', ' Although it is well-established that melanomas can elicit immune responses, they more often produce factors that adversely impact or block antitumor immunity. Suppressive immune cells such as Foxp3+ regulatory T cells (Treg) and tumor-infiltrating macrophages have been implicated as poor prognostic indicators in other cancer etiologies, but their prognostic value in melanoma has remained unclear. Methods', ' We performed an immunohistochemical (IHC) analysis of 62 melanoma tumors comprising a spectra of disease stages to assess tumor infiltration by T cells (CD3+, CD4+, CD8+ and Foxp3+ subsets), B cells (CD19+), and macrophages (CD68+). To assess the potential negative impact of tumors on regional immunity, we also analyzed a set of uninvolved regional lymph nodes (LN) harvested from sentinel node positive basins of 28 stage III melanoma patients. All immune markers were correlated with overall survival by univariate Cox regression analyses. Results', ' Overall, relatively few Foxp3+ T cells or B cells infiltrated melanoma tumors. In contrast, CD68+ macrophages were found to be abundant at all disease stages, typically comprising 5% to 20% of all cells within the tumor parenchyma. Although no significant associations were found with any immune markers in melanoma tumors, Cox regression analysis demonstrated a significant adverse association between the percentage of CD68+ macrophages in uninvolved regional LNs and overall survival (HR=1.93 per 5% increase in CD68+ cells, 95% CI (1.17, 3.18), p=0.01). Kaplan-Meier analyses revealed that stage III patients harboring >15% CD68+ cells in uninvolved regional LNs had a median survival of 2.6 yr vs. 7.7 yr for patients with <15% CD68+ cells. Conclusions', ' These results suggest that melanoma involvement of regional LNs can adversely impact the immune microenvironment of adjacent uninvolved regional LNs, possibly by facilitating regional immune suppression mediated by CD68+ cells. Pharmacological targeting of tumor-associated CD68+ macrophages may favorably impact survival outcomes for patients with stage III melanoma.']",
        "Doc_id":"ASCO_53041-74",
        "Doc_title":" Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients.",
        "_version_":1606189021725196288},
      {
        "Meeting_name":" Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly population.",
        "Background":"['Background', '  Non-Hodgkin lymphoma (NHL) survivors have increased risk of developing melanoma compared with the general population. Although immune dysfunction may play a role, no previous study has investigated immune-related factors and melanoma risk after NHL.  Methods', '  We used the SEER-Medicare linkage to identify a cohort of 44,875 individuals who were diagnosed with first primary NHL during 1992-2009 at ages 65-84 years and survived 1 year. Cox regression quantified melanoma risk associated with NHL treatments as well as autoimmune conditions and infections occurring at age 65.  Results', '  A total of 202 second primary melanomas occurred during 248,917 person-years, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes.  Melanoma risk after CLL/SLL was significantly increased among patients who received fludarabine- and rituximab-containing chemotherapy (hazard ratio [HR]=2.99, 95% confidence interval [CI]=1.68-5.33, versus no chemotherapy), whereas risk was not evident for  rituximab-containing therapy without fludarabine. Among non-CLL/SLL patients, melanoma risk was significantly elevated for patients receiving cyclophosphamide-containing chemotherapy without rituximab (HR=2.15, 95%CI=1.26-3.65) or rituximab and cyclophosphamide-containing chemotherapy (HR=1.66, 95%CI=1.00-2.75). Occurrence of autoimmune diseases after NHL diagnosis was associated with increased risk of melanoma (B-cell activating diseases', ' HR=1.43, 95% CI=1.02-2.01; T-cell activating diseases', ' HR=1.39, 95%CI=0.94-2.04), with particularly elevated risks for asthma occurring after CLL/SLL (HR=2.11, 95%CI=1.09-4.08). In contrast, localized scleroderma was associated with increased melanoma risk both prior to (HR=1.47, 95% CI=1.00-2.16) and after NHL (HR=1.44, 95%CI=0.87-2.39). Similarly, urinary tract infection was associated with increased melanoma risk prior to (HR=1.39, 95%CI=0.99-1.94) and after NHL (HR=1.59, 95%CI=1.05-2.41), but no significant associations were observed for other infections.  Conclusions', '  These findings support a role for immune perturbation in the development of melanoma after NHL.']",
        "Doc_id":"ASCO_132781-144",
        "Doc_title":" Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly population.",
        "_version_":1606189007299936256},
      {
        "Meeting_name":" Predicting response to immune checkpoint therapy using an mutation burden threshold",
        "Background":"['Treatment with antibodies to PD-1 or CTLA-4 leads to prolonged response in some cancer patients. Patients whose tumors have a high mutational burden have a better response to anti-CTLA-4 treatment with ipilimumab in melanoma5, and to anti-PD-1 treatment with pembrolizumab in non-small cell lung6 and colorectal cancer7. These results suggest that a sufficiently high non-synonymous somatic mutation burden in the tumor may lead to protein alterations that serve as neo-antigens to stimulate CD8 T-cell immune response. This immune response may be blocked by the tumor by engaging the immune checkpoint pathway, making such tumors especially vulnerable to immune checkpoint disruption. However, the specific criteria to identify patients likely to respond to immune checkpoint therapy have remained elusive so far.Using somatic mutation and RNA-Seq data from TCGA, we propose that there exists a mutational threshold, which we call the Activated Immune Mutational (AIM) Threshold, which can identify patients likely to respond to immune checkpoint therapy. Compared to AIM- patients (potential non-responders), AIM+ patients (potential responders) have tumors that meet four criteria', ' (1) a high non-synonymous mutation burden; (2) a high level of immune infiltration in the tumor; (3) a high CD8 T cell fraction in the leukocyte component of the immune infiltrate plus high expression of the T cell marker CD8A; and (4) a high expression of immune checkpoint genes PD-1, PD-L1, PD-L2, CTLA-4.We find that in melanoma, endometrial, colon, cervical and breast cancer, a clear AIM threshold satisfying all four criteria exists. The distribution of mutations in AIM- versus AIM+ tumors for these cancers is very different. In the former, there are high frequency somatic mutations in only a few genes, while in the latter, high frequency somatic mutations are found in many genes distributed over the whole genome.Pathological analysis of high-resolution images from 150 TCGA tumors (30 from each of the five tumor types) validated the presence of significantly higher lymphocytic infiltration in the AIM+ tumors compared to AIM- tumors. We show that AIM+ tumors can be identified using sequencing assays which are currently in clinical use. Finally, survival analysis in melanoma patients from TCGA treated with immunotherapy will be presented.']",
        "Doc_id":"AACR_2016-1424",
        "Doc_title":" Predicting response to immune checkpoint therapy using an mutation burden threshold",
        "_version_":1606189025386823680},
      {
        "Meeting_name":" Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.",
        "Background":"['Background', ' Checkpoint inhibitors (IT) have revolutionized treatment options for patients (pts) with advanced melanoma. Recently, we proposed a framework of 7 parameters (PM) describing requirements for a sufficient anti-tumor immune response (the cancer immunogram). In a first analysis we tested pts from our ipi cohort for outcome. Using this framework pts benefitting the most from treatment with ipi might be selected upfront, and in the future also from other checkpoint inhibitors. Methods', ' Using Kaplan-Meier- and Cox-regression-analysis correlations between 6 of these PM at baseline and overall survival (OS) were investigated in a single center cohort of pts treated with 3 mg/kg ipi for metastatic melanoma. Results of the 7thPM are currently being finalized. Results', ' PM assessed were', ' LDH (ULN vs > ULN), erythrocyte sedimentation rate (ESR,ULN vs > ULN), absolute lymphocyte count (ALC, < 1000/mm3 vs 1000/mm3) and IHC on tumor material for CD8+ T-cell infiltration ( < median vs median), PD-L1 expression ( < 1% vs 1% positive cells) and MHC-class I expression (loss vs weak/positive). We analyzed 179 pts treated with ipi between 2010 and 2013. Median age was 55 years (1988) and 61% of pts were male. Minimum follow-up of pts alive was 42 months(mo). Data were available as follows', '177 cases LDH, 159 ALC/ESR, 118 PD-L1, 99 CD8 and 68 MHC-class I. Median OS was 7.1 mo. In univariable analysis LDH (HR 2.5, 95%CI 1.8-3.5), ALC (HR 1.6, 95%CI 1.1-2.4), ESR (HR 2.4, 95%CI 1.5-3.8) and CD8 (HR 1.8 95%CI 1.2-2.8) were significant for OS (p< 0.01). Pts with all 4 favorable PM had a median OS of 25.1mo(95%NR), pts with 3 PM 15.8 mo(95%CI 7.0-24.7), 2 PM 8.1 mo(95%CI 1.0-15.3), 1 PM 4.8 mo(95%CI 3.3-6.3) and no favorable PM 1.7 mo(95%CI 04.9). In multivariable analysis LDH(HR 2.4,95%CI 1.5-4.0) and CD8(HR 1.7,95%CI 1.1-2.8) were the only independent PM. Pts with a normal LDH and high CD8 had a median OS of 15.8 mo(95%CI 9.5-22.2) vs 3.8 mo(95%CI 1.8-5.7) for pts that did not (p< 0.01). Conclusions', ' In conclusion, low values of baseline LDH and high values of CD8 are the strongest PM associated with a favorable outcome in pts with advanced melanoma, treated with ipi. The other PM added low effect on the pts outcome upon ipi.']",
        "Doc_id":"ASCO_192251-199",
        "Doc_title":" Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.",
        "_version_":1606189033737682944},
      {
        "Meeting_name":" Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity",
        "Background":"['Background', ' T cell-based bispecific agents have shown activity in hematologic cancers, but solid tumor efficacy remains elusive. IMCgp100 is a bispecific biologic comprising an affinityenhanced TCR specific for gp100 and an anti-CD3 scFV. In vitro, IMCgp100 binds gp100+ melanoma cells causing redirection of cytotoxicity and induction of potent immune effects. Methods', ' The Phase I was conducted in HLA-A2+ pts with advanced melanoma, using a 3+3 design to define the MTD. Pts were treated with IMCgp100 (iv) weekly (QW, Arm 1) or daily (4QD3W, Arm 2) to evaluate safety, PK and efficacy. The recommended phase 2 regimen (RP2D-QW) was defined. Results', ' In the Ph I dose escalation,31 pts received doses from 5ng/kg to 900ng/kg. In arm 1 dose-limiting toxicity of gr 3 or 4 hypotension was seen and associated with rapid trafficking of peripheral lymphocytes to skin and tumor. The MTD was determined to be 600ng/kg QW. IMCgp100 has an approximately dose-proportional profile with a plasma T1/2 of 5-6 hrs at the RP2D; pharmacodynamic effects of chemokine/cytokine release and lymphocyte infiltration into tumors was observed over 2 days post dose. Frequent related AEs (any grade) include rash (100%), pruritus (64%), pyrexia (50%), and periorbital edema (46%). Gr 3 or 4 related AE were observed in the first 3 weeks and include rash (23%), hypotension (6%) and lymphopenia (8%). Hypotension observed at the first doses was consistent with chemokine release (CXCL9, CXCL10) and movement of lymphocytes into tissues and, rarely associated with cytokine release syndrome (IL-6, IL-10, IFNg). To mitigate risk of severe hypotension, flat dosing and an intra-patient escalation regimen of IMCgp100 were implemented. At the RP2D, 26 pts were evaluable for efficacy; confirmed PR were seen in 4 pts (2 uveal (UM) and 2 cutaneous (CM), including patients refractory to checkpoint agents) and 12 pts had SD. Of the 12 pts with SD, minor responses (>10% shrinkage) were seen in 3 pts. Conclusions', ' IMCgp100 is a first in class TCR anti-CD3 bispecific T cell redirector with a favorable safety profile and durable responses in melanoma (CM and UM). Ph II development in CM and UM is ongoing. Clinical trial information', ' NCT01211262']",
        "Doc_id":"ASCO_170037-176",
        "Doc_title":" Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity",
        "_version_":1606188995063054336},
      {
        "Meeting_name":" T cell targeted peptides for monitoring immune response in melanoma",
        "Background":"['Melanoma develops the ability to evade immune recognition through multiple mechanisms, despite being highly immunogenic. This is demonstrated by the effective and additive response checkpoint blockade therapies have had during combination clinical trials in melanoma [1]. While the results of these trials have been promising, large portions of patients do not respond to treatment [1,2]. Additionally, many responders take months to show a response using standard criteria. In order to monitor patient response and understand the limitations of immunotherapy, we performed phage display to discover peptides targeted to tumor infiltrating lymphocytes (TILs) in melanoma tumors.To improve phage library characterization, we developed a method to deep sequence phage with the Ilumina MiSeq platform. Phage screens using PhD7 library (NEB) performed on HUVECS and on TILs, nave and effector T cells, and B cells harvested from mice. The phage libraries generated from these screens were deep sequenced using the Illumina MiSeq system. The sequencing data was analyzed with an efficient, custom MATLAB script, which arranges sequences by frequency determining peptide frequencies for each library. Peptide frequency was normalized to a reference library generated by amplifying an unscreened phage library. T cell screens were compared with B cell and endothelial cell screens in sequence frequency matrices. Top TIL targeting sequences were cloned into phage, and then fluorescently labeled along with insert-less control phage. Labeled phage were incubated with TILs, or effector T cells and analyzed for specificity using flow cytometry. Four phage clones were identified with at least four fold increased binding for TILs over effector T cells isolated from the spleen. Interestingly, only subsets of the TILs were bound by the targeted phage.We have identified and validated peptides that demonstrate specificity for CD8 TILs. These peptide sequences represent candidates for development into companion diagnostic imaging agents for use with checkpoint therapies. We are currently evaluating these peptides in an in vivo tumor model to further validate their specificity and to determine their biodistributions. Peptides that validate in vivo could be developed into useful imaging agents. After peptide sequences have been validated in vivo, we will determine the phage binding partner using a phage based pulldown. The peptide binding partners discovered through this approach will provide insight into the subset of TILs bound by the phage.[1] Wolchok, J. D. et al., N Engl J Med 2013; 369', '122-133.[2] Drake, CG. et al., Clin Cancer Res November 15, 201117.']",
        "Doc_id":"AACR_2016-4147",
        "Doc_title":" T cell targeted peptides for monitoring immune response in melanoma",
        "_version_":1606188993382187008},
      {
        "Meeting_name":" Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy",
        "Background":"['Radiotherapy is considered an efficacious local tool to erradicate or at least control cancer progression. However, recent lines of preclinical and clinical evidence indicate that proimmune effects of radiotherapy can be synergistically augmented with immunostimulatory monoclonal antibodies (mAb) to act both on irradiated tumor lessions and on distant, non-irradiated tumor sites. The combination of radiotherapy with immunostimulatory anti-PD1 and anti-CD137 mAbs was conducive to favourable effects on distant non-irradiated tumor lesions as observed on transplanted MC38 (colorectal cancer), B16OVA (melanoma) and 4T1 (breast cancer) models. Immunotherapy and radiotherapy synergized both when irradiation was given using external beams or provided with brachytherapy. The therapeutic activity was crucially performed by CD8 T cells, as found in selective depletion experiments. The irradiation regimen induced immune infiltrate changes in the irradiated and non-irradiated lesions featured by reductions in the content of effector T cells, Tregs, and myeloid-derived supresor cells (MDSC), while effector T cells were expressing more intracellular IFN gamma in both the irradiated and contralateral tumors. Importantly, 48h following irradiation CD8+ TILs showed brighter expression of CD137 and PD-1 thereby displaying more target molecules for the activity of the corresponding monoclonal antibodies. Likewise, PD-1 and CD137 were induced on tumor infiltrating lymphocytes from surgically excised of human carcinoma lessions that were irradiated ex-vivo. These findings advocate for clinical development of immunotherapy combinations with anti-PD1 plus anti-CD137 mAbs that can be synergistically accompained by radiotherapy strategies on treatable lesions, even if leaving disease outside the irradiation field.']",
        "Doc_id":"AACR_2016-4012",
        "Doc_title":" Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy",
        "_version_":1606188995178397696},
      {
        "Meeting_name":" Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance",
        "Background":"['Purpose', ' To evaluate the association between the immunoreactivity of the immune inhibitory ligand PD-L1 with tumour infiltrating lymphocytes (TILs) and known mechanisms of MAPK inhibitor (MAPKi) resistance in tumor biopsies resected at the time of MAPKi disease progression.Experimental Design', ' 23 patients with disease progression on MAPKi (vemurafenib, dabrafenib, and combination dabrafenib and trametinib) each had a progressing tumor biospied. All tumors underwent MAPKi resistance screening including RNA expression profiling. Morphological features, PD-L1 immunohistochemical immunoreactivity, and RNA expression profile were correlated with mechanisms of resistance (including mutations in NRAS and MEK, and amplification and aberrant splicing of BRAF).Results', ' PD-L1 immunoreactivity was significantly higher in tumors that harbored an aberrant BRAF splicing variant (n = 8) or MEK mutations (n = 5) than those with BRAF amplification (n = 4), NRAS mutations (n = 2) or those with unknown resistance mechanisms (n = 4) (mean 27% vs 1%, p = 0.049). Additionally, the PD-L1 immunoreactivity in tumors with known MAPK-reactivating mechanisms (n = 19) tended to be higher than those with unknown resistance mechanisms (n = 4) (mean 17% vs 0%, p = 0.283). The immunoreactivity of PDL1 in progressed lesions was independent of BRAFV600 genotype, RECIST response and type of MAPK inhibitor. Correlations with TIL subsets, RNA expression, and response to subsequent anti-PD-1 therapy are underway.Conclusions', ' The induction of PD-L1 immunoreactivity following MAPKi treatment in human melanoma is variable, however specific mechanisms of MAPKi resistance may confer increased expression of the inhibitory ligand. Further study is underway examining the association of the above with TIL infiltration, the RNA expression profile, and the response to subsequent anti-PD1 therapy.']",
        "Doc_id":"AACR_2015-5025",
        "Doc_title":" Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance",
        "_version_":1606189041574739968},
      {
        "Meeting_name":" Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations",
        "Background":"['Semaphorin 4D (SEMA4D, CD100) and its receptor plexin-B1 are broadly expressed in cancer; increased expression correlates with poor prognosis. SEMA4D normally functions to regulate the motility and differentiation of multiple cell types, including those of the immune, vascular, and nervous systems. In the tumor microenvironment (TME), SEMA4D is expressed strongly at the invasive margin and modulates the infiltration and spatial distribution of leukocytes, suppressing anti-tumor activity. Neutralization of SEMA4D was evaluated for effects on immune activity and tumor growth in preclinical models, incorporating single agent and combination treatments with other immunotherapies, including immune checkpoint blockade inhibitors. The safety and tolerability of humanized anti-SEMA4D antibody VX15/2503 was assessed in a Phase I clinical trial.RESULTS', 'SEMA4D restricts migration of myeloid cells expressing cognate PLXNB1/2 receptors, determined using trans-well migration assays and IHC of in vivo tumors. Antibody neutralization disrupted the SEMA4D gradient at the invasive margin, which correlated with recruitment of activated APCs and T lymphocytes into the TME, and significant shift toward increased Th1 cytokines (IFNg, TNFa) and CTL-recruiting CXCL9 chemokine, with concurrent reduction in Treg- and M2-macrophage promoting chemokines (CCL2, CXCL1, CCL17). Accordingly, an increase in Teff', 'Treg ratio (3x, p<0.005) and CTL activity (4x, p<0.0001) was observed. This orchestrated change in the tumoral immune context was associated with durable tumor rejection and immunologic memory in preclinical colon, breast, and melanoma models. Importantly, the immunomodulatory activity of anti-SEMA4D antibody can be further enhanced by combination with other immunotherapies, including immune checkpoint inhibitors and chemotherapy. Strikingly, the combination with antibody to CTLA-4 acts synergistically, with maximal increase in survival (110% tumor growth delay, p<0.01) and complete tumor regression in 100% of mice, as compared to 22% with monotherapy (p<0.01).SEMA4D antibody treatment was well tolerated in nonclinical and clinical studies; including a Phase I multiple ascending dose trial in patients with advanced refractory solid tumors. Patients with the longest duration of treatment, 48-55 weeks, included colorectal, breast, and a papillary thyroid patient, who had a partial response by RECIST. Progression free survival strongly correlated with elevated baseline lymphocyte counts (r = 0.6133), supporting an immune mediated mechanism of action for VX15/2503.CONCLUSION', 'Inhibition of SEMA4D represents a novel mechanism and therapeutic strategy to promote functional immune infiltration into the tumor and inhibit tumor progression. A phase 1b/2 trial of combination therapy with an immune checkpoint inhibitor is planned.']",
        "Doc_id":"AACR_2016-4888",
        "Doc_title":" Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations",
        "_version_":1606188987058225152},
      {
        "Meeting_name":" Blocking colony stimulating factor 1 receptor (CSF1R) improves anti-tumor effects of adoptive T cell transfer therapy.",
        "Background":"['Tumors can escape immune responses by creating an inflammatory milieu that supports and recruits tumor-infiltrating myeloid cells (TIMs) with immune suppressive functions, such as myeloid derived suppressor cells (MDSC) and M2-polarized macrophages. Therapies that block recruitment of suppressor TIMs have the potential to enhance adoptive cell transfer (ACT) of T cell based-immunotherapies.We originally established a BRAFV600E mutant murine melanoma cell line (SM1) for which ACT of melanoma-targeted T cells induced anti-tumor responses, but not complete eradication in vivo. By gene expression profiling and single-nucleotide polymorphism (SNP) arrays, we found that, out of 108 cytokines produced by SM1, colony stimulating factor 1 (CSF1) was highly expressed. CSF1 induces proliferation of immune suppressors Gr-1(+) CD11b(+) MDSC and F4/80(+) CD11b(+) macrophages. In order to block the recruitment of TIMs, we tested a potent CSF1R inhibitor, PLX3397. Cultured primary murine T cells exposed to PLX3397 with a broad range of concentrations (0.1 to 50 M) showed no evidence of cytotoxicity by MTS assay. We then tested the combination of PLX3397 and ACT in vivo using two models. In the first one, SM1 cells stably expressing the chicken ovalbumin (OVA) antigen were implanted in C57BL/6 mice. Daily oral gavage with PLX3397 (50mg/kg) combined with ACT of OVA-specific TCR transgenic cells (OT-1) demonstrated superior effects of the combined treatment (tumor size on day 14_vehicle', ' 1611.222.5 mm2, PLX3397', ' 1028.024.0 mm2, OT-1', ' 1112.535.7 mm2, combined PLX3397+OT-1', ' 347.315.5 mm2, p<0.001). We have observed a dramatic reduction of the number of macrophages in the tumor tissue (vehicle', ' 10.31.6%, PLX3397', ' 1.350.5%, OT-1', ' 12.00.6%, combined', ' 2.330.3%, p<0.001) and a skewing of type M2 to type M1 macrophages. In vivo real-time T cell tracking by luciferase bioluminescence imaging demonstrated an increased number of tumor infiltrating lymphocytes (TILs) in the combined therapy group (photon counts/pixel on day 5 post ACT', ' OT-1', ' 4424.5412, combined', ' 91761780, p<0.001). The second in vivo model was based on pmel-1 transgenic T cells, which targeted the endogenous melanoma antigen (gp100) expressed by SM1. The combined treatment of PLX3397 and ACT of pmel-1 also resulted in significant tumor shrinkage, reduction of M2 macrophages, and increased number of TILs. TILs were also collected and analyzed for function by intracellular staining of IFN. TILs from the combined treatment group released significantly higher levels of IFN (ACT', ' 48.28.7%, combined', ' 78.83.5%, p<0.001).In conclusion, our data derived from two independent in vivo models demonstrated dramatic potentiation of anti-tumor effects with the combination of CSF1R blockade and ACT immunotherapy, supporting the rationale for further testing in patients with metastatic melanoma.']",
        "Doc_id":"AACR_2013-3969",
        "Doc_title":" Blocking colony stimulating factor 1 receptor (CSF1R) improves anti-tumor effects of adoptive T cell transfer therapy.",
        "_version_":1606188994773647360},
      {
        "Meeting_name":" Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma.",
        "Background":"['Background', '    Patients with melanoma can be categorized based on the presence or absence of a T cell-inflamed tumor microenvironment. The presence of baseline CD8+T cells is associated with clinical benefit to immunotherapies, including anti-PD1 and anti-CTLA4. The molecular mechanism explaining lack of a T-cell infiltrate in a major subset are poorly understood, but differential expression of immunogenic antigens has been proposed as one explanation.  Methods', '    Using the TCGA data set for malignant melanoma, the T cell-inflamed gene expression signature was used to segregate patients by immune phenotype. Three categories of antigens were examined', ' cancer-testis (CT) antigens, differentiation antigens, and somatic mutational antigens.  Results', '    By transcriptional profiling, no difference was observed in levels of CT antigens or differentiation antigens. Using exome sequencing of tumor versus germline, a range of 18 to 3001 of non-synonymous mutations was observed in both cohorts. Using the syfpeithi algorithm for HLA-A*0201 patients, a median of 123 mutations having a high immunogenicity score were found in the T cell-inflamed cohort versus 176 in the non-T cell inflamed. To confirm actual immunogenicity, several synthesized peptides show positive HLA-A*0201 binding and can be recognized by human CD8+T cells in vitro.  Conclusions', '    Both the T cell-inflamed and non-T cell-inflamed subsets of melanoma show comparable expression of CT, differentiation, and mutational antigens. Lack of spontaneous immune infiltration in a major subset of tumors is unlikely to be due to lack of antigens. Strategies that improve spontaneous T-cell infiltration into tumors therefore could, in principle, render these patients response to immunotherapies once these antigens become recognized.']",
        "Doc_id":"ASCO_147244-156",
        "Doc_title":" Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma.",
        "_version_":1606189008392552448},
      {
        "Meeting_name":" Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.",
        "Background":"['Background', ' Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) is an effective approach for the treatment of metastatic melanoma, with objective response rates of approximately 50%. An increased understanding of the factors contributing to resistance to this promising therapy is needed. Methods', ' To determine the role of epigenetic mechanisms in TIL responses, cell infusion products from patients undergoing TIL ACT were separated by magnetic labeled antibodies into CD4 and CD8 populations, and assessed by an Illumina 450K DNA methylation array and chromatin immunoprecipitation of acetylated histone 3 with sequencing. Patient tumor samples were also assessed on a Nanostring platform for epigenetic gene and miR expression. The percentage of CD4 and CD8 T cells in TIL were assessed by flow cytometry. Results', ' Significant differences in DNA methylation of genes controlling CD4 lineage (CD4, CD8, RUNX3, XCL2, ZBTB7B) were found between responders (R) and non-responders (NR) (p < 0.05). Using a CD4/CD8 differentiation signature, principal component analysis (PCA) revealed clustering based on response, with NR CD8 T cells more closely resembling CD4 T cells (p < 0.05). PCA of acetylated histone 3 also showed differences between R vsNR (p < 0.05). Nanostring analysis of tumor fragments showed decreased expression in NR in several epigenetic regulatory genes including DNA methyltransferases (DNMT1, DNMT3A) and histone deacetylases (HDAC8, SIRT4)(p < 0.05). MiR-148 and miR-185, known regulators of DMNT1, were increased in accordance with the patterns seen for DNMT1, a known regulator of CD4/CD8 lineage commitment. Higher levels of CD4/CD8 double positive TILs were found in NR infusion products. Conclusions', ' These results demonstrate that resistance to TIL therapy is characterized by altered DNA methylation and histone acetylation patterns accompanied by differences in genes regulating these marks. It is hypothesized that epigenetic dysregulation of CD4/CD8 lineage impairs the therapeutic efficacy of TIL therapy. These data highlight an unexplored mechanism of T-cell dysfunction characterizing resistance to TIL ACT.']",
        "Doc_id":"ASCO_170003-176",
        "Doc_title":" Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.",
        "_version_":1606189010579881984},
      {
        "Meeting_name":" LTX-315, an oncolytic peptide, to convert immunogenically cold' tumors to hot' in patients with advanced or metastatic tumours",
        "Background":"['Background', ' Intratumoral LTX-315 disintegrates cytoplasmic organelles with release of tumor antigens in preclinical models accompanied by increase in tumor-infiltrating lymphocytes (TILs). LTX-315 induced complete regression in several rodent models, with systemic immune responses.  LTX-315 is strongly synergistic preclinically with immune checkpoint inhibitors (ICI). We are conducting a phase 1 trial to evaluate LTX-315 in combination therapy. Methods', ' Patients with advanced metastatic solid tumours received injections of LTX-315 into a single accessible tumour over 6 weeks. Additional injections could be administered thereafter every 2 weeks. Biopsies of injected lesions were taken at baseline, and on treatment. Results', ' 28 have been enrolled to date, median age is 58 (range 32-80) and median prior treatments 2 (range 1-14). LTX-315 monotherapy was administered at doses of 2-7mg to a median of 1.8 tumour lesions (range 1-6) for a median of 9 weeks (range 1-33). In 24 patients all LTX-315-related adverse events were CTC grade 1 or 2, most commonly local erythema, flushing, pruritis and hypotension, most resolving within minutes of injection. Related grade 3 (3 patients) or 4 (1) allergic/anaphylaxis adverse event occurred and resolved without sequelae. Best response in 44 injected lesions in 20 evaluable patients included 2 complete responses, > 50% reduction in 5 tumours, and 20 stable (injected ). Significant increases in TILs occurred in 67% (14 of 21) patients with biopsies of injected tumours available. Regression of distant non-injected tumour has been observed clinically on biopsy (abscopal effect). No irRC response in non-injected tumours has been observed in 16 evaluable patients. Stable disease (median duration 14 weeks) occurred in 50% of patients as best response (melanoma (4), sarcoma (3), breast (1)). Conclusions', ' This phase 1 study demonstrates that intratumoural LTX-315 has a manageable safety profile and induces increases in TILs in pre-treated patients. Partial and complete regression was seen in some injected tumours. Evaluation of LTX-315 in combination with ICIs in breast and melanoma is ongoing. Clinical trial information', ' NCT01986426']",
        "Doc_id":"ASCO_192334-199",
        "Doc_title":" LTX-315, an oncolytic peptide, to convert immunogenically cold' tumors to hot' in patients with advanced or metastatic tumours",
        "_version_":1606188991244140545},
      {
        "Meeting_name":" Recombinant protein MBP-NAP restricts tumor progression by triggering T-cell immunity in mouse metastatic melanoma model.",
        "Background":"['The pro-inflammatory and immunomodulatory properties of Helicobacter pylori neutrophil activating protein (Hp-NAP) not only make it play an important role in disease pathogenesis, but also make it a potential candidate for applications, including vaccine and drug development. Our previous work demonstrated that the recombinant Hp-NAP fused with the maltose-binding protein of Escherichia coli (rMBP-NAP) exert an important role in regulating the differentiation of Th1 cells. As a potential TLR2 ligand, it was reported to possess the ability to induce systemic antitumor immunity in murine hepatoma H22 and sarcoma S180 tumor models. To further understand the antitumor and immunomodulatory effect of rMBP-NAP, we elucidate the effect and mechanism of rMBP-NAP at the local immune response modulation in established mouse B16-F10 melanoma pulmonary metastasis model. Our results demonstrated that metastatic lung tumor growth was significantly arrested after rMBP-NAP treatment, along with marked reduction in the number of lung nodules and significant increase in survival. Flow cytometry immunophenotyping and Quantitative RT-PCR analyses demonstrated that rMBP-NAP could induce both local and systemic immune responses, which associated with higher influx of CD3+CD4+T cells, CD3+CD8+T cells and higher secretion of interferon (IFN)- and interleukin (IL)-27 cytokines. The intraperitoneal administration of rMBP-NAP in mice promoted infiltration of lymphocyte in the lungs and reduced the production of several proinflammatory cytokines, such as IL-6 and transforming growth factor beta (TGF) -, indicating an anti-inflammatory effect in local area. By comparing with control mice, mRNA expression of chemokines also revealed that rMBP-NAP treatment substantially decreased the expression of CCL2 and CCL20 in tumor tissues, which are central to recruit myeloid-derived suppressor cell (MDSC) and regulatory T cells (Treg) to tumor microenviroment and form immunosuppression. Moreover, we assess the expression of vascular marker CD34 in pulmonary section using immunohistochemical method, the results showed the vascularization was apparently inhibited in rMBP-NAP treated tumor bearing mouse. In conclusion, rMBP-NAP could induce the activation of effective Th1/Tc1 cells and the production of relevant inflammatory cytokines and chemokines, which are responsible for enhencing T cell immunity and reversing immunosuppression against metastatic cancer progression. Our findings strongly indicate that rMBP-NAP treatment might be a novel therapeutic approach against metastatic melanoma, and rMBP-NAP might be a potential template for the development of agents that could be used as immunomodulatory adjuvant in the therapy against melanoma.']",
        "Doc_id":"AACR_2017-166",
        "Doc_title":" Recombinant protein MBP-NAP restricts tumor progression by triggering T-cell immunity in mouse metastatic melanoma model.",
        "_version_":1606189005933641728},
      {
        "Meeting_name":" A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.",
        "Background":"['Background', ' JS001 blocks the interaction between PD-1 and its ligands and eradicates established tumor in human PD-1 Knock-in mouse model. Methods', ' A Phase I open-label study is designed to evaluate the safety and tolerability of JS001 in advanced solid tumor pts who are refractory to standard therapy. The study has a 3+3 dose escalation design with planned cohorts at 1, 3, and 10 mg/kg followed by a dose expansion. (Clinical Trial ID', ' NCT02836795). Results', ' As of January 27, 2017, pts enrollment has been completed with 36 pts from 3 indications (22 Melanoma; 9 Urothelial Carcinoma; 5 Renal Cell Carcinoma). The majority of melanomas are acral and mucosal origin. No DLT was observed and no MTD was reached in the study. The most common treatment-related AEs were grade 1/2, including hyper- or hypo-thyroidism (42%), rash (39%), fever (28%), leukopenia (22%), elevation of liver enzymes (19%), anorexia (17%), and fatigue (14%). Treatmentrelated grade 3 AEs include proteinuria (n = 1), and lipase increase (n = 2). The emergence of AEs is not dose related. JS001 PK shows dose-dependent exposure with the elimination half-life of 6 to 12 days. Among 32 evaluable pts, 1 pt have complete response (melanoma), 6 pts have partial response (3 melanoma, 2 RCC and 1 UC), and 10 pts achieve stable disease, for an ORR of 22% and a DCR of 53%. 6 out of 7 CR/PR pts still have ongoing response. Two groups of pts benefited most from JS001 treatment, pts with high tumor-infiltrating lymphocytes (TIL) (50% ORR) and pts with > 1% PD-L1 expression in tumor biopsy (46% ORR). Conclusions', ' JS001 exhibited a favorable safety profile in human. Treatment related AEs are in line with those from approved drugs in the same class. JS001 has demonstrated promising anti-tumor activity, especially in previously under-evaluated acral (20% ORR, 53% DCR) and mucosal (25% ORR, 50% DCR) melanomas. Clinical trial information', ' NCT02836795']",
        "Doc_id":"ASCO_189353-199",
        "Doc_title":" A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.",
        "_version_":1606189036303548416},
      {
        "Meeting_name":" Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.",
        "Background":"['Background', ' CAVATAK, an oncolytic immunotherapy, is a bio-selected oncolytic strain of Coxsackievirus A21 (CVA21). Intratumoral (IT) injection of CVA21 induces lytic tumor cell infection, up-regulation of immune checkpoint molecules and increased immune-cell infiltration. The Phase II CALM study investigated the efficacy and safety of IT CVA21 in 57 pts with advanced melanoma resulting in a confirmed ORR of 28.1% and DRR (continuously > 6 mths) of 21.1%. The CALM extension study (13 pts) investigated CVA21 induced changes in immune cell infiltrates within the tumor-microenvironment (TME). We describe factors regarding the nature of clinical responses in 70 pts with stage IIIC-IV melanoma given IT CVA21. Methods', ' The association of prior lines of therapy, tumor pseudo-progression, baseline tumor burden (BTB) and levels of immune cell infiltrates in the TME were examined with regard to clinical response. Results', ' Responders on the CALM study (16/57 pts, 28.1%) displayed reductions in both injected and non-injected lesions, suggesting the generation of significant host anti-tumor responses. A comparable ORR was observed in pts administered prior immunotherapy, 29.0% (9/31) vs other tx 27.0% (7/26). Interestingly, 26.7% (4/15) and 40% (2/5) of pts previously treated with ipilimumab and talimogene laherparepvec, respectively, developed confirmed responses. Three pts (18.8%) exhibited pseudo-progression (irRECIST criteria) prior to response. BTB of the 57 pts in the CALM study was 3.9 cm (95% CI 4.3, 6.5). A BTB less than median was associated with', ' superior ORR (39.3 vs 17.2 %), superior DRR (35.7 vs 6.9 %), and greater OS (p = 0.003). In the CALM extension study, CVA21 tx induced increases in immune cell infiltrates within the TME. In patients with responses, increases in CD8+ T-cells and PD-L1+ expression were observed in injected lesions. Reconstitution of immune cell infiltrates was observed in a number of CVA21 treated lesions from pts failing prior tx with immune-checkpoint blockade. Conclusions', ' IT administration of CVA21 can notably influence the dynamics of the TME and generate systemic anti-tumor immune responses as evidenced by increases in immune cell infiltrates and widespread non-injected lesion responses. Clinical trial information', ' NCT01227551']",
        "Doc_id":"ASCO_169144-176",
        "Doc_title":" Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.",
        "_version_":1606189010264260608},
      {
        "Meeting_name":" Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models",
        "Background":"['The PD-1/PD-L1 (programmed cell death protein 1; programmed death-ligand 1) pathway plays a key role in immunological tolerance and autoimmunity. PD-1 is primarily expressed on activated T and B cells while its receptor, PD-L1, is expressed in a variety of cell types including resting lymphocytes, DCs, and macrophages. Recently, multiple human solid tumor types (melanoma, NSCLC, RCC, ovarian, and colorectal cancer) have been found to overexpress PD-L1 within its tumor microenvironment. More importantly, PD-1/PD-L1 blocking agents (pembrolizumab, nivolumab, lambrolizumab, MPDL3280A) have been found active as a single agent or in combination with chemotherapy and some have produced durable clinical responses. On the other hand, human epithelial tumors are also known to overexpress the high-affinity folate receptor (FR)-alpha that is capable of bringing folate-linked drugs into the cell cytosol via endocytosis. Using flow cytometry, we assessed PD-L1 expression in various FR-positive syngeneic mouse tumor models (M109, Renca, L1210A, 4T1-Cl2, ID8-Cl15). PD-L1 expression was found to vary significantly among different tumor types and could be found not only on CD45- malignant cells but also on tumor stromal cells such as F4/80+CD11b+ tumor-associated macrophages. Using a rat anti-mouse PD-1 antibody (clone RMP1-14), we studied in-vivo efficacy of a folate-targeted chemotherapy in combination with PD-1/PD-L1 blockage in PD-L1-expressing tumor models. In syngeneic models with high PD-L1 expression and tumor-infiltrating lymphocytes, a synergistic and curable anti-tumor effect was observed and the animals developed tumor-protective immunity against rechallenge. Thus, our preliminary results suggest that folate-targeted chemotherapeutics may also be enhanced by PD-1/PD-L1 blockage by means of overcoming tumor-mediated immune suppression']",
        "Doc_id":"AACR_2016-262",
        "Doc_title":" Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models",
        "_version_":1606189020349464577},
      {
        "Meeting_name":" Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies.",
        "Background":"['Background Antibodies blocking the inhibitory checkpoint PD1, expressed by T lymphocytes, and kinase inhibitors of BRAF and MEK (MAPKi) are mainstays of current treatment for patients with metastatic melanoma. Mouse models point towards a synergistic antitumor activity of anti-PD1-antibodies and MAPKi, explaining the findings by an enhanced lymphocytic activity opposing tumor adaptive resistance. Recently PD1 was found expressed by a subpopulation of melanoma cells where it could mediate tumorigenic effects, but no data exist showing how MAPKi could modulate its expression. We hypothesized that MAPKi may upregulate PD1 expression and enhance the direct, immune-cell independent antitumor action of anti-PD1 antibodies. We first explore the exact prevalence and magnitude of PD1 expression in patients and cell lines. Then we test the effect of MAPKi on its expression and explore possible immune-independent synergisms with anti-PD1-antibodies.']",
        "Doc_id":"AACR_2017-5603",
        "Doc_title":" Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies.",
        "_version_":1606188998174179328},
      {
        "Meeting_name":" Complete regression of solid B16F1 melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore)",
        "Background":"['Background', \" Malignant melanoma is imposing an increasing threat to the world's population and new therapies are needed.Standard treatment involves surgery, chemotherapy, and radiation therapy and often leads to relapse after ended therapy. LTX-315 (Oncopore) is a chemically modified cationic cytolytic peptide which is equally active against drug-sensitive and drug-resistant cancer cells. Earlier animal studies have demonstrated that treatment of syngeneic murine A20 B-cell lymphomas and CT26WT colon carcinomas with intratumoral (i.t.) injection with LTX-315 resulted in complete tumor regression and long-term protective effect against re-inoculated tumor cells. The present study was undertaken to investigate whether LTX-315 induced an antitumor response in vivo in a highly aggressive murine melanoma tumor model. Methods\", ' Pre-cultured B16F1 melanoma cells (5 x 104) were subcutaneously inoculated into the abdomen of syngeneic C57BL/6N mice and established tumors treated i.t. with LTX-315. Animals were taken for analysis to elaborate the mechanism of action of LTX-315 and for potential immune modulatory effects following treatment. Blood plasma was analyzed for changes in cytokine content and tumor tissue was analyzed for infiltrating immune cells using immunohistochemistry and flow-cytometry. Results', ' Intratumoral treatment with LTX-315 resulted in a complete regression of tumor in the treated animals. Tumors treated with LTX-315 showed an increased infiltration of immune cells into the tumor compared to control tumors receiving vehicle. Conclusions', ' Our results suggest that LTX-315 treatment can induce complete regression in solid B16F1 melanoma tumors, thus leading to local tumor control. Intratumoral treatment with LTX-315 can lead to immune-modulatory effects such as an increase in the number of infiltrating immune cells, causing a shift in the balance between immune effector and immune suppressive cells in the tumor environment.']",
        "Doc_id":"AACR_2012-3543",
        "Doc_title":" Complete regression of solid B16F1 melanoma tumors obtained by intratumoral injection of LTX-315 (Oncopore)",
        "_version_":1606188986296958976},
      {
        "Meeting_name":" Association of activated B-cell infiltration in the tumor microenvironment with regulatory T-cell (Treg) infiltration, but not macrophages polarization in immunogenic human cancers.",
        "Background":"['Background', ' We reported an inverse association between tumor-infiltrating B and CD8 T cells in human cancers. Preclinical studies suggested that B cells regulate T cell activities via activation of Treg cells and alternative polarization of macrophages. In this study, we investigated the relationship between B cell infiltration, Treg cell infiltration, and macrophage polarization in five human cancers approved for the use of immune checkpoint inhibitors by the FDA. Methods', ' mRNA expression scores of 812 immune-related genes from the TCGA database were analyzed to calculate tumor infiltrating cells in 2951 patients with bladder urothelial carcinoma, renal cell carcinoma, skin melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma (Angelova et al., 2015). Expression patterns of Treg markers and M1/M2 phenotypic macrophage polarization markers were compared in relation to the presence of activated B cells (ActB) in human tumor tissues. Odds ratios (OR) of the numbers of tumors with versus without Treg cell infiltration by the presence of ActB cells were calculated. Results', ' Infiltration by ActB cells was significantly correlated with Treg cell infiltration in human cancers (OR=10.86, p<0.001). In lung adenocarcinoma, ActB cells also demonstrated a significant association with myeloid derived suppressor cells (MDSCs, p<0.05). Tumors infiltrated by ActB cells had significantly elevated expressions of Treg markers and suppressive cytokines (Table), but not macrophage polarization markers. No significant changes in survival outcomes were noted. Conclusions', ' We report for the first time an association between B cells and Treg cells in human immunogenic cancer tissues. ActB cell infiltration in the tumor microenvironment was positively correlated to Treg cell infiltration, but not macrophages polarization in immunogenic human cancers. ActB infiltration*P**(+)(-)Foxp31.17-0.18<0.01CD250.43-0.10<0.01CTLA-41.01-0.13<0.01CD390.56-0.20<0.01CD73-0.26-0.01<0.01IL-100.28-0.08<0.01IL-350.89-0.15<0.01TFG-beta0.04-0.070.20* mRNA expression z-score means.']",
        "Doc_id":"ASCO_181405-199",
        "Doc_title":" Association of activated B-cell infiltration in the tumor microenvironment with regulatory T-cell (Treg) infiltration, but not macrophages polarization in immunogenic human cancers.",
        "_version_":1606189018016382976},
      {
        "Meeting_name":" Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.",
        "Background":"['Background', ' Historically, patients with metastatic melanoma had an extremely poor prognosis with a median overall survival (OS) of 6 to 9 months. In 2010, the CTLA4 blocking antibody ipilimumab, showed for the first time, an improvement in median OS and was approved for this stage of disease. Yet, only around 20% of the treated patients benefit long-term. In addition, ipilimumab can cause serious, sometimes life-threatening side-effects and puts a high burden on health costs. Adoptive transfer of tumor-infiltrating lymphocytes (TIL) is another promising new treatment modality for patients with metastatic melanoma. Several independent phase II studies have shown comparable and consistent response rates of around 50%, with very durable responses in patients reaching a complete remission. TIL therapy consists of infusion of high numbers of ex vivo expanded TIL preceded by non-myeloablative (NMA) chemotherapy and followed by high dose interleukin-2 (HD IL-2). Methods', ' This is an international, open-label, multi-center, phase III study. Patients with irresectable stage IIIc or IV melanoma, between the ages of 18 and 70 years, with one or more resectable metastases summing up to at least 2-3 cm in diameter and adequate organ function, are randomized 1', '1 between TIL therapy and ipilimumab. Patients will be stratified according to BRAF V600 mutation status, line of treatment (1st or 2nd line) and treatment center. Patients randomized to TIL will receive NMA chemotherapy consisting of cyclophosphamide (60 mg/kg/day for 2 days i.v.) and fludarabine (50 mg/m2 for 5 days i.v.), intravenous adoptive transfer of > 5x109 TIL followed by HD IL-2 (600.000 IU/kg/dose every 8 hours, maximally 15 doses). Patients randomized to ipilimumab (3 mg/kg i.v.) will receive this once every three weeks, for up to 4 doses. The primary end-point is progression free survival at six months. Secondary endpoints are OS, complete response rate, ORR and safety profile. Enrollment began in September 2014. 168 randomized patients are required to show a 50% increase in PFS at 6 months. Clinical trial information', ' NCT02278887']",
        "Doc_id":"ASCO_164825-176",
        "Doc_title":" Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.",
        "_version_":1606188984581488640},
      {
        "Meeting_name":" Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer",
        "Background":"['Lung cancer remains a major cause of cancer mortality. Malignant lesions are normally endogenously corrected by the immune surveillance system. However, tumors evade this immunity by inducing immunosuppressive microenvironments during cancer progression. It has been thought that there are two critical components of tumors making them capable of maintaining the immunosuppressive microenvironment. One is the inhibition of cytotoxic T lymphocytes (CTL) activity against the tumor through immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1), which are negative regulators of CTL, and the other is by the induction of tumor infiltrating immune suppressive cells, which can deactivate the CTL. Recent studies demonstrate that multiple cancer types, including melanoma, lung, kidney, bladder, and stomach, respond to immune checkpoint inhibitors, such as PD-L1 and PD-1 with 11-30% response rates and durable responses. However, a substantial number of patients still fail to respond to immunotherapy and the refractory mechanisms are largely unknown. In this study, we focus on KRas-driven lung cancers, as there are no clinically effective targeted drugs available for treating this type of lung cancer. We demonstrate that during the progression of tumors in KRas mutation and p53 knockout-driven lung cancer mouse models; KRasG12D/+;p53-/- (KP), there is a gradual increase in the number of myeloid derived suppressor cells (MDSC) and that the combination of either anti-PD-1 or anti-PD-L1 antibody along with a MEK inhibitor, which targets downstream of KRas signaling, shows anticancer efficacy in these animal models. These combinations, in comparison to either single agent alone, effectively blocks the growth of subcutaneously (s.c.) injected syngeneic mouse lung cancer cells in immune competent transgenic KP mice, significantly increasing the survival rates', ' 37.5% (for anti-PD-1 antibody and MEK inhibitor), 62.5% (for anti-PD-L1 antibody and MEK inhibitor) vs. 0% single agents or control at the end of treatment. We find that the tumors in the control treated group harbor a substantial number of immune cells, including PD-L1 expressing MDSC. The combination treatment with either an anti-PD-1 or anti-PD-L1 antibody along with a MEK inhibitor dramatically modulates the composition and the activity of tumor infiltrated immune cells. Tumors in the combined treated group show a significant decrease in PD-L1 expressing MDSC in comparison with control tumors. Additionally, a combined treatment would block the PD-L1 activity of the infiltrated PD-L1 expressing MDSC in malignant tumors and thus lead to improved survival. These results point to a potential therapeutic opportunity for currently untargetable KRas-driven lung cancers.']",
        "Doc_id":"AACR_2016-2334",
        "Doc_title":" Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer",
        "_version_":1606188979400474624},
      {
        "Meeting_name":" Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.",
        "Background":"['Background', ' Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This expansion cohort in a phase I/II trial of MDX-1106, a fully human IgG4 antibody blocking PD-1, sought to further evaluate the safety and activity of the 10 mg/kg dose. Other objectives included evaluation of pharmacokinetics (PK) and immunological effects. Methods', ' Patients (pts) with treatment refractory metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colon cancer (CC), melanoma (MEL), or prostate cancer (CRPC), and no history of autoimmune disease received a single infusion of MDX-1106 at 10 mg/kg. Disease status was evaluated at week (wk) 8 by RECIST criteria. Pts with stable disease or lesional responses could receive additional MDX-1106 at wks 12 and 16. Those with PR/CR were observed without retreatment. Results', ' 21 pts (5 CC, 2 NSCLC, 8 MEL, 5 HRPC, 1 RCC) were treated from 10/07 to present, and 6 were retreated. No MDX-1106 related SAEs occurred. One pt developed arthritic symptoms requiring treatment, and 2 pts had asymptomatic TSH elevation. One pt with RCC had a PR after 3 doses, lasting 5+ months (mo). Lesional regressions (\"mixed response\") were seen in 2 MEL pts; to date, one has received 7 doses of MDX-1106 over 15 mo without serious toxicity. Biopsy of a regressing MEL lymph node metastasis showed a moderately increased and selective CD8+ T cell infiltrate post treatment. The median serum t 1/2 of MDX-1106 was 20.6 days, which was roughly 50% longer than observed for lower doses. There was no evidence of immunogenicity based on HAHA development. Interestingly, in contrast to PK results, flow cytometric analysis demonstrated sustained occupancy of 60-80% PD-1 molecules on T cells for at least 3 mo following a single dose. Analyses of circulating lymphocyte subsets and tumor B7-H1 expression are in progress. Conclusions', ' Intermittent dosing of MDX-1106 at 10 mg/kg demonstrated clinical activity against RCC and MEL without serious toxicity. Therapy with MDX-1106 to enhance endogenous antitumor immunity, either alone or combined with other immunological therapies, warrants further study.']",
        "Doc_id":"ASCO_34399-65",
        "Doc_title":" Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies.",
        "_version_":1606189021527015424},
      {
        "Meeting_name":" Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival.",
        "Background":"['Background', '    Despite the poor prognosis of patients (pts) with MBM several pts have prolonged survival. We hypothesized that the heterogeneity of BrMM is determined by differences in melanoma biology and its brain microenvironment.  Methods', '    We identified pts who have undergone craniotomy for MBMs. Evaluation entailed complete clinical information, acquisition of archived melanoma brain metastases, histopathologic analysis of hematoxylin and eosin-stained sections (n=101), whole genome expression profiling (WGEP, Illumina DASL) in 29 archived tissues. Results were validated by immunohistochemistry (IHC) or in situ hybridization (ISH).  Results', '    In univariate analysis (log-rank) factors significantly associated with prolonged survival were high immune infiltrate (HII) plus low hemorrhage (hazard ratio, HR, 2.71, p<0.001), present melanin (1.67, p=0.03), and recursive partitioning analysis (RPA) class 1 (0.37, p<0.0001). No association between HII and use of immunotherapy prior to craniotomy was noted. Only RPA class 1 (p=0.029) and HII plus low hemorrhage (p=0.002) remained significant in Cox proportional hazards model analysis. Gene set analysis of WGEP data confirmed that Encarta pathways related with T-cell activation and differentiation were significantly associated with prolonged survival whereas Y branching of actin filaments, presenilin action in Notch and Wnt signaling, G-protein signaling through tubby protein, lissencephaly gene in neuronal migration and development are among the gene categories associated with worse survival. IHC and ISH analysis of tumor sections for various markers (n=40) showed that high peritumoral CD3+ (3.31, p=0.009), high peritumoral CD4+ (4.41, p=0.014), and high peritumoral CD8+ (3.02, p=0.030) are associated with prolonged survival whereas neither CD14+ nor FoxP3+ infiltrate, nor high melanoma expression of antigen presentation molecules are associated with survival.  Conclusions', '    Our study is the first to document that high peritumoral T-cell infiltrates are associated with prolonged survival. High tumor hemorrhage, an adverse prognostic sign, reflects aggressive melanoma cells that migrate and invade in the brain.']",
        "Doc_id":"ASCO_93001-114",
        "Doc_title":" Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival.",
        "_version_":1606188994922545152},
      {
        "Meeting_name":" HVEM",
        "Background":"['Background', ' Herpes Virus Entry Mediator (HVEM) is a member of the TNF superfamily, its ligation of the immunoglobulin family member B-lymphocyte and T-lymphocyte attenuator (BTLA) activates inhibitory signaling in T-cells and could play a role in evading host anti-tumor immunity. Ectopic overexpression of HVEM is associated with poor survival in some solid tumors. Our objectives were', ' -to evaluate HVEM expression in melanoma (MM) -to explore potential link of its overexpression with clinical outcomes -to understand the mechanisms by which HVEM was ectopically expressed in MM, and how HVEM-BTLA may play a role in MM. Methods', ' HVEM expression was analyzed by IHC in formalin-fixed samples of mm metastases and was correlated with OS in 130 patients. To better understand how HVEM could interfere with prognosis, relation of HVEM with its ligand BTLA was studied in the tumor and tumor microenvironment on 15 fresh metastases by flow cytometry after tumor dissociation. Bioinformatic studies based on TCGA and CCLE data combined to targeting of candidate genes by siRNA were used to investigate HVEM regulation on MM. Results', ' Patients with high HVEM expression on mm cells in their metastases have a significantly (p = 0.0142) poorer overall survival than those with a low expression. TCGA transcriptomic data support these results. From the mechanistic point of view, we could show that 1-HVEM expressed at the tumor cell surface interacts with BTLA expressed by tumor-infiltrated lymphocytes. 2-HVEM expression is neither linked to the mm mutational status nor inducible by IFN 3-Genes co-regulated with HVEM are associated with an aggressive gene signature 4- HVEM strongly correlate with MITF expression, MITF binds HVEM promoter, and its downregulation by siRNA results in a decrease in HVEM expression. Conclusions', ' A high expression of HVEM by mm metastases seems to be a pejorative prognostic marker. HVEM-BTLA interaction is a co-signaling system similar to the PD1-PDL1 one, but seem to be constitutive rather than inducible. HVEM and its co-regulated genes may constitute a signature of aggressiveness associated to MITF. High HVEM expression on mm cells may dampen anti-tumor immune responses, making HVEM and BTLA potential new targets for checkpoint blockade therapy.']",
        "Doc_id":"ASCO_191686-199",
        "Doc_title":" HVEM",
        "_version_":1606189033206054912},
      {
        "Meeting_name":" -caryophyllene inhibits solid tumor growth and metastasis of B16F10 melanoma cells in C57BL/6 mice fed on a high-fat diet.",
        "Background":"['We previously observed that chronic consumption of a high-fat diet (HFD) increased the melanoma progression and lymph node metastasis in C57BL/6N mice injected with B16F10 melanoma cells. -caryophyllene (BCP) is a natural bicyclic sesquiterpene found in many essential oils especially clove and oregano oils. In the present study, we examined whether BCP inhibits HFD-induced melanoma growth and metastasis in the B16F10 allograft model. Four-week old, male C57BL/6 mice were fed on a HFD (60 kcal% fat) or control diet (CD, 10 kcal% fat) with or without BCP (0.15, 0.3% in diet) for a period of 21 weeks. Following 16 weeks of either CD or HFD in the absence or presence of BCP, B16F10 melanoma cells were subcutaneously injected into mice and all mice were continuously fed identical diets. Three weeks post-injection, tumors were resected and mice were sacrificed three weeks post-resection. The body weights and the growth of solid tumors were markedly increased in the HFD group as compared to the CD group, and these increases were suppressed by BCP treatment. The expression of proteins related to cell proliferation (Ki67, CDK4, cyclin A, and cyclin D1), angiogenesis (VEGF-A, VEGFR-2, and CD31) and lymphangiogenesis (VEGF-C, VEGF-D, VEGFR-3, and LYVE-1) was markedly increased in tumor tissues of the HFD group as compared to the CD group, and these increases were blocked by BCP treatment. HFD feeding increased the infiltration of CD45+ leukocytes and F4/80+ macrophages into tumor tissues. The administration of BCP significantly suppressed HFD-induced the infiltration of the immune cells into tumor tissues. HFD feeding reduced TUNEL-positive apoptotic cells in the tumor tissues, which was prevented by BCP treatment. Two weeks after tumor resection, the mice evidenced lung and lymph node metastasis. Lung and lymph node metastasis were increased in the mice fed on HFD, and these increases were markedly suppressed by BCP treatment. The present results demonstrate that BCP suppressed HFD-stimulated melanoma progression and metastasis, which may have been mediated via the suppression of cell cycle progression, angiogenesis and lymph angiogenesis, and induction of apoptosis in tumor tissues. These results suggest that BCP has potential as an anti-cancer agent for the prevention of obesity-stimulated melanoma progression.']",
        "Doc_id":"AACR_2013-4869",
        "Doc_title":" -caryophyllene inhibits solid tumor growth and metastasis of B16F10 melanoma cells in C57BL/6 mice fed on a high-fat diet.",
        "_version_":1606189041879875584}]
  }}
